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Abstract 
 
Influenza (‘flu) virus is a major health concern for humans and animals. The mode 
of transmission is predominantly by the respiratory route. 'Flu infection occurs 
seasonally and can cause global pandemics, with the most recent ‘flu pandemic, the 
2009 H1N1 Swine ‘flu, resulted in more than 18,000 deaths worldwide. ‘Flu poses 
major challenges, because the virus has an RNA genome, which has a high potential 
to recombine and produce new strains through a mechanism termed re-assortment. 
The constant appearance of new strains requires new vaccines; the time between 
virus identification and the deployment of the vaccine is an important challenge in 
‘flu control. Therefore, anti-influenza drugs, which can control the virus infection 
irrespective the virus strain are important. Such antivirals are usually cheaper 
compared to vaccination and can be self-administered. However, drug treatment is 
usually less effective over time due to the rapid evolution of the virus genome and 
the acquisition by the virus of drug resistance.  
The approval of the first peptide anti-viral, Enfuvirtidie, by the Food and Drug 
Administration (USA) illustrates the potential of peptides to combat infectious 
diseases. “Flupep”, a peptide originally identified as a mimic of the suppressor of 
cytokine signalling (SOCS) protein, was subsequently found to inhibit the 
infectivity of influenza A virus, including the H1N1 subtype. To understand how 
Flupep exerts its effects, it has been incorporated into the ligand shell of gold 
nanoparticles. The gold nanoparticles provide a very sensitive probe that can be 
detected optically, and are a model for a potential future nanoparticle formulations. 
The results demonstrate that the nanoparticle-Flupep conjugates have enhanced 
 ` 
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anti-‘flu virus activity compared to free peptide in a cell-based plaque assay. 
Nanoparticle-Flupep conjugates do not bind to influenza virus in vitro. However, 
the nanoparticle-Flupep conjugates bind to cells and, following binding, remain 
cell-associated and able to inhibit ‘flu virus infectivity. The cell bound nanoparticle-
Flupep conjugates may be removed by washing the cells with 1 M NaCl, indicating 
that ionic interactions are likely to underpin their binding to cells. Treatment of cells 
with heparinases I and II neuraminidases, but not chondroitinase ABC reduces 
binding of Flupep-nanoparticle conjugates, indicating that heparan sulfate and sialic 
acid are major cellular binding sites of the peptide. Since the Flupep sequence has 
a basic C-terminus likely to be involved in binding these polysaccharides, heparan 
sulfate binding sequences from growth factors were added to the FluPep sequence. 
These additions enhanced its anti-viral activity, showing that engineering 
extracellular matrix binding of peptides inhibiting ‘flu virus is a route to increasing 
their effective potency. 
Overall the thesis demonstrates that Flupep, contrary to published work, exerts its 
anti-viral effects by binding to cells, and FluPep binding sites include heparan 
sulfate and sialic acid. Other binding sites are likely involved, since the IC50 of 
Flupep and its derivatives is orders of magnitude lower than the likely affinity of 
the peptides for polysaccharide binding sites. Thus, the hypothesis is put forward 
that Flupep interacts with one of more dual receptor systems consisting of 
polysaccharide and protein(s) and that this underlies the efficacy and mode of action 
of the peptide 
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Chapter 1  
1 General introduction  
1.1 Pandemic Influenza virus  
1.1.1 Overview 
Influenza (‘flu) virus is is an infectious disease for humans, farm and wild animals 
(Chavas et al., 2010). The  ‘flu  virus is a member of the to the Orthomyxoviridae 
family, a negative-stranded RNA viruses with a segmented genome, which is nearly 
spherical, but somewhat pleomorphic with a particle size of around ~100 nm in 
diameter (Bouvier and Palese, 2008). The influenza A virion is embedded with 
spikes of haemagglutinin (HA) and neuraminidase (NA) glycoproteins that 
projecting from a host cell–derived lipid membrane (Fig. 1). Virus nomenclature is 
according to H number (for the type of haemagglutinin) and an N number (for the 
type of neuraminidase). There are 18 known H antigens (H1 to H18) and 11 
different N antigens (N1 to N11) (Gamblin and Skehel, 2010). Heamagglutinin HA 
is a trimeric glycoprotein, which is considered responsible for receptor binding and 
membrane fusion (Hamilton et al., 2012), while neuraminidase NA is a tetramer 
glycoprotein that cleaves sialic acids from cell surface N-glycans to aid the release 
of newly synthesised viruses (Fig. 1). The M2 protein is a tetrameric integral 
membrane protein that forms an ion channel that is responsible for the acidification 
of the interior of the viral particle during viral infection (Skalickova et al., 2015a). 
M1 is a matrix protein located under the viral lipid envelope associated with the 
viral ribonucleoprotein (vRNP) complex, from which it dissociates upon 
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acidification of  the interior environment of the viral particle due to the action of 
the ion channel formed by M2 (Fig. 1)  
 
Fig. 1.  Schematic of influenza virus structure. Derived from (Skalickova et al; 
2015) 
All eight vRNA segments inside the virion are bound to the nucleoprotein NP and 
to the influenza virus RNA polymerases to form ribonucleoprotein (RNP) 
complexes (Fig. 1) (Lamb and Choppin, 1983).  
There are three influenza viral types; A, B and C (Blumel et al., 2009). Influenza A 
viruses circulate in a wide range of avian and mammalian hosts, whereas influenza 
B and C are human viruses. Influenza A and B viruses are the predominant 
causative agent of the vast majority of human infections. Past epidemics and 
pandemics are mainly associated with type A, while type B is less frequently 
associated with epidemics. Type C causes a very mild respiratory influenza illness.  
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1.1.2 Seasonal ‘flu, epidemics and pandemics 
 
Influenza is a highly infectious viral disease which can occur as sporadic cases, an 
epidemic or a pandemic (Morens et al., 2009).  In temperate and cold climates, most 
common are seasonal outbreaks whereas in tropical climates outbreaks may occur 
throughout the year (Lowen and Palese, 2009). These forms of ‘flu have varying 
ranges of infection from severe illness to death, and those with chronic medical 
conditions, elderly people and pregnant women are usually the most vulnerable to 
infection (Barker, 1986, Barker and Mullooly, 1980). An epidemic is a seasonal 
outbreak, which infects many people and spreads to neighbouring countries, 
generally due to the re-emergence of the previous year’s virus strain. Slight changes 
in the virus’ surface binding proteins may result in it not being recognised by the 
host's immune system, enabling infection and spread. In contrast, pandemic ‘flu is 
a worldwide outbreak or a severe epidemic resulting from a introduced new 
influenza A virus strain (Saunders-Hastings and Krewski, 2016). This can spread 
quickly from person to person due to the lack of pre-existing immunity, so the pool 
of hosts is very large (Morens et al., 2009). Pandemic ‘flu occurs sporadically, and 
over the last 300 years there have been about three influenza pandemics in each 
century (Hill et al., 2017). The most recent ‘flu pandemic was the 2009 H1N1 Swine 
‘flu, which resulted in more than 18,000 deaths worldwide (Pasricha et al., 2013). 
The worst pandemic on record was the so-called 1918 Spanish ‘flu, which caused 
an estimated ~50 million  deaths worldwide (Taubenberger and Morens, 2006). 
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1.1.3 Virus transmission 
 
The three main routes of viral transmission among humans are (i) inhalation of 
virus-laden aerosols, (ii) contact with infected individuals, and (iii) contact with 
contaminated fomites. Which of these is  the most common mode of transmission 
still unknown (Mubareka et al., 2009). Speaking, singing and even normal breathing 
can produce sufficient aerosols for respiratory transmission. Coughing and sneezing 
produce heavier aerosols, which eventually fall to the ground within a few meters 
and infect only those in close proximity (Cowling et al., 2013). Transmission by 
direct contact occurs by physical contact with, for example, hands containing nasal 
secretions. Research has shown that up to 60% of objects in homes with infected 
individuals harbor influenza viral RNA, which can mediate virus transmission 
(Barker et al., 2001). Thus, hands often become contaminated with respiratory 
viruses. Thereafter the touching of the nasal mucosa or the conjunctivae enables the 
virus to infect the individual (Ansari et al., 1991) 
1.1.4 Virus replicative cycle  
The conventional view of the virus replication cycle is that it starts with attachment 
to the host epithelial cells of the respiratory tract via the surface glycoprotein 
haemagglutinin (HA) (Mair et al., 2014). This interaction with cell-surface 
molecules is followed by endocytosis and fusion of the viral and endosomal 
membranes, which then allows delivery of the viral genetic material to the 
nucleocytoplasmic space (Skehel and Wiley, 2000).  Haemagglutinin is a trimer 
that binds to sialic acids carried on the glycan portion of cell surface proteins (Das 
et al., 2010). This interaction triggers endocytosis of the virus. Endosomes are 
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acidified by the action of the vacuolar H+ATPase, which triggers a conformational 
change in HA (Guinea and Carrasco, 1995).  This exposes the N-terminus of 
haemagglutinin 2 (HA2), allowing its insertion into the endosomal membrane, 
which causes fusion of the viral and endosomal membranes. The ion channel 
formed by the M2 protein acidifies the interior environment of the viral particle 
(Skalickova et al., 2015a). The lower pH in the virus leads to the dissociation of 
viral matrix protein (M1) from viral ribonucleoprotein (vRNP) complex, which is 
then released into the host cytoplasm to be transported to the nucleus (Skalickova 
et al., 2015a). Here the viral RNA is replicated and transcribed, which is catalysed 
by RNA polymerase complex (Brunotte et al., 2014, Stubbs and te Velthuis, 2014). 
The host cell ribosomes translate the viral mRNA to produce new viral proteins. 
HA, neuraminidase (NA) and M2 proteins are transported to the plasma membrane  
where new viral particles will assemble and be released (Leser and Lamb, 2005). 
Neuraminidase, the second main surface glycoprotein is considered to facilitate the 
release of the new assembled virion particles from the cell surface, so allowing these 
to infect other cells (Takimoto et al., 2002, Rossman et al., 2010). 
1.2 Prevention and treatment 
1.2.1 The challenge  
The treatment of ‘flu infections is difficult, because the virus has RNA genome, 
which has a high potential to recombine and create new strains through re-
assortment (Treanor, 2004). From the host perspective, this results antigenic drift 
and shift, which result in antigenic mutants of the virus that alter the virus 
immunological and pharmacological identity periodically. Antigenic drift is when 
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small changes in the viral genome happen frequently over time, resulting in a series 
of minor changes in the surface antigens, which can occur in all three influenza 
types. In contrast, antigenic shift is the result of a large change in one or both surface 
antigens (HA or NA) and is a result of a genetic recombination between influenza 
A viruses, and is most common in those that affect humans and birds (Shao et al., 
2017).  
1.2.2 Prevention 
The most effective means to combat 'flu infection is by vaccination. Vaccines need 
to be administered annually before the season of influenza. No attempts at herd 
immunity levels of vaccination have been attempted. Instead, all those over 6 
months who are at risk of developing severe or complicated influenza, are targeted 
for vaccination. The prioritised groups are (Baek et al., 2014): 
 Elderly people aged 65 years or older 
 People with chronic diseases, such as diabetes, cardiovascular disorders 
(except controlled hypertension). 
 Those on immunosuppressive drugs 
 Women (within 2 weeks after delivery)  
 Healthcare workers (Baek et al., 2014).  
According to the Centers for Disease Control and Prevention (CDC), getting the 
seasonal flu vaccinate would reduce the risk of getting the ‘flu by at least between 
40% and 60% among the overall population when most circulating flu viruses are 
well-matched to the flu vaccine.  
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However, the efficacy of the vaccine is not guaranteed.  Vaccine efficacy depends 
on the degree of antigenic resemblance between the virus circulating wild strain and 
the immunizing strains (Santak et al., 2013), the antibody response to vaccine, 
which is lowest in aged and in immunosuppressed patients and greatest in younger, 
healthy adults. Other important factors are the number of doses administered (in 
terms of generating partial or local herd immunity within a community) and the 
viral strains vaccinated in past years, which will influence the immunogenicity and 
effectiveness of current-season vaccination (DiazGranados et al., 2016, Ruggiero 
and Utili, 1992). The appearance of new strains requires new vaccines. Thus, one 
disadvantage of using vaccination is the gap between virus identification and the 
time to deployment of the vaccine. Influenza vaccines must be updated annually 
due to changes in the virus (Section 1.2.1), which involves a prediction of the likely 
virus (es) circulating in the following year. After virus identification follow vaccine 
manufacture (usually in eggs), testing and distribution of the influenza vaccine. The 
entire process takes 6-9 months. 
There are several contributing factors that limit the efficacy of the virus. The long 
lead time of the production process means that the circulating strain(s) can change, 
and so partially (or wholly) escape the immune system’s priming by vaccination. 
An issue that has recently come to light is that production of vaccine in chicken 
resulted in partial masking by a glycan of a key antigenic determinant in the vaccine 
from 2016–2017(Zost et al., 2017).   
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1.2.3 Treatment 
1.2.3.1 Drug treatment overview 
Due to the partial coverage of the seasonal ‘flu vaccine and the possibility that one 
day the vaccine will not have much efficacy against a major outbreak, drugs that 
prevent or mitigate ‘flu infection are an important target.  Generally, there are two 
types of anti-influenza drugs, based on their mechanism of action. The first class 
are neuraminidase inhibitors such as Oseltamivir (Tamiflu) and Zanamivir. The 
second class are virus ion-channel blockers such as Amantadine and Rimantadine 
(Symetrel).  
The effectiveness of Tamiflu has been questioned by Cohen (Cohen, 2014). 
Moreover, due to the virus strains changing from one season to next or even in the 
same season, drug resistance occurs. For example influenza viruses resistant to 
neuraminidase inhibitors arise through mutations in NA which can change the 
catalytic site of NA and thus reducing inhibitor, but not substrate binding (Colman 
et al., 1993). ‘Flu virus resistance to adamantines such as amantadine and 
rimantadine  has increased substantially over the last few years (Bright et al., 2005). 
The frequency and distribution of M2 gene mutations in adamantane-resistant 
influenza variants circulated in the world between 1902 and 2013 and different HA 
-subtypes A viruses (H1– H17) was investigated. The results demonstrated that a 
high-level resistance to adamantanes was exhibited by H1, H3, H5, H7, H9, and 
H17 subtype influenza A viruses, associated with specific resistance-associated 
mutations in their M2 genes. However, a rarer resistance to adamantanes was found 
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in H2, H4, H6, H10, and H11 subtypes, whereas HA subtypes H8, H12–H16 didn’t 
show any resistance to this class of drugs (Dong et al., 2015).  
The resistance of virus to drugs and the questioned efficacy of Tamiflu (Sections 
1.2.3.2 and 1.2.3.3) mean that there is a need for the development of new drugs 
(Rodewald et al., 2006). One type of new drug, peptides, one of which is the focus 
of this thesis are described in (Section 1.5.2.3) 
1.2.3.2 Ion channel blocker and evidence for the lack of effectiveness 
Until 2003, adamantines were highly active against all community isolates of 
influenza A virus (Deyde et al., 2007). This might be result of the increased use of 
amantadine that accompanied the spread of influenza A subtype H5N1 (influenza 
A/H5N1) virus. Now the majority of the influenza A virus subtypes, especially the 
most common H1N1 and H3N2 that circulate globally are resistant to adamantanes 
and so these are largely ineffective anti-influenza A virus drugs.  The adamantanes 
mechanism of action is to inhibit the release of vRNP and so influenza A virus 
replication by binding to the M2 channel pore. This blocks proton conductance and 
so the pH decrease in the virus necessary for the dissociation of M1 protein from 
vRNP and the release of the latter into host cell cytoplasm does not occure (Ma et 
al., 2009). Influenza A virus resistant to adamantanes occurs either by amino acid 
mutations (L26F, V27A, A30T/V, S31N, G34E, and L38F) in M2 transmembrane 
domain that line the channel pore; mutation of V27, A30, and G34 lead to narrowing 
of the pore whereas the other three mutations (L26, S31, and L38), destabilize 
helix–helix assembly required for pore formation (Cady et al., 2010, AshaRani et 
al., 2009, Pielak et al., 2009). 
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1.2.3.3 Tamiflu and evidence of the lack of effectiveness 
In 1999, the US Food and Drug Administration approved Oseltamivir (Tamiflu), a 
neuraminidase inhibitor for seasonal flu. The efficacy of the drug was established 
by meta-analysis, systematic reviews of a number of randomized controlled trials, 
which were funded and marketed by Roche (Gupta et al., 2015). Tamiflu was 
recommended by many organisations, such as the World Health Organization 
(WHO), the Centers for Disease Control and Prevention and the European 
Medicines Agency, for its prophylaxis of influenza. Consequently,  it was 
stockpiled as a means to tide over ‘flu crises, especially after swine influenza 
pandemic of 2009 (Gupta et al., 2015). Thus, since the first cases of H1N1 ‘flu, the 
drug was widely prescribed, and U.S. government spent more than $1.5 billion 
stockpiling Tamiflu since 2005, as part of their protective plan against ‘flu 
pandemic (Lenzer, 2009).  
Roche claimed that their drug reduced hospital admissions by 61% complications 
such as bronchitis, pneumonia, and sinusitis by 67%, and lower respiratory tract 
infections requiring antibiotics by 55% (Lenzer, 2009). Then some discrepancies 
were found, published in a study led by Chris Del Mar from the Cochrane team at 
Bond University in Australia. They re-examined the previous studies and re-
analysed the data. They concluded that there was at best weak evidence that Tamiflu 
reduces complications, hospitalizations, or deaths, and any benefit offered by the 
drug was slight (Jefferson et al., 2014). There were asymptomatic reported cases of 
‘flu in a school in the UK at 2009, which led to 7 days prophylaxis of oseltamivir 
to all the children due to an order from the Health Protection Agency (HPA) (Gupta 
et al., 2015). The purpose was to reduce the risk of contact between the 
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asymptomatic patients and the rest of the children causing an outbreak. However, 
follow-up indicated that the drug didn’t reduce the risk of transmission and 
infection (Toovey et al., 2008, Gupta et al., 2015). A cohort study in children in 
Japan demonstrated that oseltamivir intake was associated with events of abnormal 
behaviour and disturbance of consciousness and instance of deaths (Jefferson et al., 
2012). Abnormal behaviour on the 1st day after drug intake were recognised in the 
studies by Roche. However, other data indicated that this was more serious, with 
over 50% increased risk of abnormal behaviour associated with oseltamivir and 
occurrence of unconsciousness in a number of patients on the 1st day after drug 
intake (Gupta et al., 2015). Therefore, Japan developed a package with a warning 
showing the dangerous effect of the drug to children and restricted the use of 
oseltamivir for adults (Muthuri et al., 2014). However, there was no evidence of 
increased risk of neuropsychiatric events in the Roche review of 2007 (Cohen, 
2014). Nevertheless, label warning against rare adverse events, e.g., hallucination, 
self-injury, abnormal behaviour were updated due to the global accumulation of 
adverse events overseas oseltamivir (Gupta et al., 2015).  
Thus, Tamiflu may not be effective and has serious side effects in children, one 
group who are particularly at risk from ‘flu (Rudavsky, 2018). In addition, 
resistance to NA and M2 channel inhibitors has arisen rapidly. Therefore, new anti-
influenza drugs remain a major priority.  
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1.3 Viral assays  
1.3.1 Plaque assay 
One of the most common viral assays, used to determine the virus titre or 
concentration of virus in a sample, is the plaque assay. Derived from work on 
bacteriophage, it was first adapted by Renato Dulbecco to make it suitable for 
animal virology in the late 1950s (Kevles, 1993). 
The principle of the assay is that a monolayer of cells is infected with virus. 
Following a set time to allow viruses to bind to the cells, the excess is removed and 
an overlay of a semi-solid medium such as agarose is applied, which prevent viruses 
from diffusing across the cell monolayer and resulting secondary plaques. Virus 
bound to the susceptible cell delivers its genetic material and viral replication takes 
place within the cell nucleus. The virus infected cell will lyse and spread the 
infection to adjacent cells, where the infection-to-lysis cycle is repeated. Over a 
period of a days (depending on virus and cell type used) the area of lysed cells 
enlarges and upon staining of the cells with toluidine blue it becomes visible to the 
naked eye (Fig.2). Plaques are counted manually, and the results are used to 
determine the plaque forming units per sample unit volume (pfu/mL), which is the 
combination of the dilution factor used to prepare the plate and the plaque number. 
Based on the assumption that each plaque is due to one original infective virus 
particle, the pfu/mL is considered to represent the number of infective virus 
particles within the sample (Baek et al., 2014). 
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Fig. 2.  Plaque forming mechanism in plaque assay 
The plaque-forming unit (PFU) refers to a virus or group of viruses which cause a 
plaque and is one measure of virus quantity. The multiplicity of infection or MOI 
is the ratio of the infectious agents to infection targets (e.g., cells) is another 
measure. For example, the MOI of a group of cells inoculated with virus particles 
is the ratio of the number of virus particles to the number of target cells present.  
The cell line used in this thesis, which is susceptible to influenza virus is MDCK 
(Madin-Darby canine kidney), which was derived in 1958 by Madin and Darby 
from a kidney of a normal cocker spaniel (Lugovtsev et al., 2013). The first 
evidence of the susceptibility of these cells to virus infection was published by 
Green (Green, 1962). Thereafter, the immunologic and cytogenetic properties of 
MDCK cells, as well as their susceptibility to several viruses were characterised by 
Gaush and co-workers (Gaush et al., 1966). Thus, the MDCK cell line is a widely 
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used in influenza virus research (Audsley and Tannock, 2004) and cell lines derived 
from upper respiratory tract are used less frequently. The reasons for this are not 
clear, but may relate to theneed to transform human primary cells to immortalise 
them, which is usually accomplished with retroviral genes. This may alter the 
antiviral response of the cells. In addition, changing established practice requires 
considerable benchmarking. Moreover, there other data demonstrating the utility of 
this cell line in influenza virus research. For example, MDCK cells have been used 
to select influenza vaccine strain candidates as a platform for vaccine development, 
since the original antigenic properties of a strain are maintained during the 
propagation process in MDCK cells (Katz et al., 1990, Saito et al., 2004). 
1.4 nanoparticles 
Nanoparticles are particles between 1 and 1000 nanometres in diameter, but as 
probes in biology diameters of 100 nm or less are usually considered, as this is in 
the size range of biological macromolecules (Kreuter, 2007). There are many 
nanomaterials, but for as labels in biology, the electronic and optical properties of 
noble metal and of semiconductor quantum dot nanoparticles make these the most 
appealing, because the optical techniques for their detection are standard in 
biological laboratories. 
1.4.1 Quantum dots (QDS)  
Quantum dots are usually between 2 - 10 nm in diameter and are fluorescent. Their 
emission can be easily tuned to cover from the blue to the red with increasing 
nanoparticle size. This is because quantum dots, semiconductor nanoparticles such 
as (CdSe),  show a strong restriction of excited electrons and holes, which leads to 
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significantly different optical and electronic properties compared to bulk CdSe (Qu 
and Peng, 2002). Quantum dots have other unique optical and electronic properties, 
giving them many advantages over conventional ﬂuorophores, such as organic 
dyes, ﬂuorescent proteins and lanthanide chelates (Wang et al., 2006). These 
properties include the width of the excitation spectrum, the width of the emission 
spectrum, photostability, and the decay lifetime. Normal dyes suffer from narrow 
excitation spectrum; therefore, they require excitation by light at a certain 
wavelength, which is variable among different dyes. Quantum dots have a wide 
absorption spectrum so they can be excited by a wide range of wavelengths, a 
characteristic which may be used to excite many different coloured QDs at the same 
time using a single wavelength (Han et al., 2001) 
Because of the small size of QDs, their electrons are restricted in a small space 
when the radius of the semiconductor nanocrystal is smaller than the exciton Bohr 
radius (this is the average distance between the electron in the conduction band and 
the hole it leaves behind in the valence band) (Shaalan et al., 2016). There is 
quantization of the energy levels according to Pauli’s exclusion principle, which is 
the principle that two identical fermions, e.g., electrons, cannot occupy 
the same quantum state in a body such as an atom (Reimann and Manninen, 2002, 
Bawendi et al., 1990). Overall, as the size of the crystal reduces, the difference in 
energy between the highest valence band and the lowest conduction band increases. 
Additional energy is then required to promote the electron to the conduction band, 
and so, additional energy is released when the crystal returns to its ground state, 
resulting in a colour shift from red to blue in the emitted light. As a result of this 
phenomenon, quantum dots can send out any colour of light from the same material 
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by changing the quantum dot. Thus, due to the high level of control possible over 
the size of the nanocrystals produced, quantum dots can be tuned during 
manufacturing to emit any colour of light (Yoffe, 2001). 
1.4.2 Gold nanoparticles AuNPs      
Gold is likely one of the first metals to have been discovered, since it exists as a 
metal rather than an oxide(Materials, 2012). Historically, Chinese, Arabian, and 
Indian cultures managed to produce colloidal gold and utilized it for medicinal 
purposes (Chinese “golden solution” and Indian “liquid gold”) (Dykman and 
Khlebtsov, 2011). Francisco Antonii, a philosopher and doctor of medicine, 
published what is considered to be the first book on colloidal gold in 1618 (Dykman 
and Khlebtsov, 2011). The use of gold nanoparticles in biology started in 1971 
when Faulk and Taylor described a method of antibody conjugation with colloidal 
gold for direct electron microscopy visualization of the surface antigens of 
salmonellae (Faulk and Taylor, 1971). This pioneering work led to the adoption of 
immunogold electron microscopy as a means to identify at molecular scale 
resolution the location of specific macromolecules in cells. Since, they have a large 
surface to volume ratio, AuNPs possess strong size-dependent properties. The 
electronic and optical properties of these metal nanoparticles give rise to local 
surface plasmon resonance (LSPR)((Crespilho et al., 2009), (Endo et al., 2007), 
surface-enhanced Raman scattering (SERS) (Zou et al., 2015), and surface-
enhanced fluorescence (SEF) (Rosi et al., 2006).  
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1.4.3 Optical properties of gold nanoparticles: scattering and absorption 
nanolabels 
Noble metal nanoparticles have historically been of great interest throughout the 
ages due to their optical properties (Heiligtag and Niederberger, 2013). These 
properties have made them useful for optical and plasmonic detection techniques, 
due to their strong interaction with light. Gold nanoparticles have been the subject 
of much research, and there is very good control of their size and shape during their 
manufacture (Robertson et al., 2016). The importance of such synthetic capabilities 
are that the diameter and shape of the nanoparticles affects greatly the optical 
properties they exhibit. For example, spherical gold nanoparticles of diameter ~ 10 
nm possess a clear single plasmon band at 520 nm (He et al., 2005).   
The surface plasmon resonance absorption peak moves towards the infra-red (IR) 
portion of the spectrum and most visible wavelengths are reflected, giving the 
nanoparticles clear or translucent color, as the particle size is increased toward the 
limit of bulk gold (Juve et al., 2013). In contrast, the optical properties of nanorods 
depend on both their size and aspect ratio (Smitha et al., 2013). This is because they 
possess two plasmon absorption bands; a longitudinal localized surface plasmon 
resonance (longitudinal LSPR) band located in a longer wavelength region, which 
can be tuned by varying the aspect ratio of the nanorods from the visible to the near-
IR region and a transverse localized surface plasmon resonance (transverse LSPR) 
band located in the visible region around 520 nm (Jayabal et al., 2015).  
When any object is exposed to light this may be absorbed or scattered.  With gold 
nanoparticles these processes are due to the interaction of their free electrons with 
photons. When gold nanoparticles are exposed to light, the electrical field of the 
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light causes the collective oscillation of the conduction electrons at the surface of 
the particle with respect to the core of the nanoparticle (Venkatesh and Prasad, 
1983). The oscillation of these electrons relative to atomic lattice is due to the 
displacement of the electron cloud relative to the nuclei and a restoring force from 
Coulomb attraction between electrons and nuclei. The consequence is the collective 
oscillation of the electrons. There are four factors that determine the oscillation 
frequency:  the electron mass, the density of electrons and the shape and size of the 
charge distribution i.e., the size and shape of the nanoparticle. This explains, for 
example, why gold nanorods have two plasmon resonances, one corresponding to 
oscillations along the long axis and the second to the oscillations along the short 
axis (Zhu et al., 2005, Jain et al., 2006, Sokolov et al., 2003).  
Early techniques for the optical detection of single particles relied on the scattering 
of light with labels such as plastic beads (μm in diameter) and then large (> 40 nm) 
gold nanoparticles (Kusumi et al., 1993).  The use of scattering labels in single 
molecule analysis resulted in new insights into the organisation and dynamics of 
molecular systems, particularly those at the cell surface, where labelling was easier. 
An example of early work is the tracking latex bead labelled alpha-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors - glutamate 
receptors in the central nervous system) on neurites of cultured neuronal cells 
(Borgdorff and Choquet, 2002). In the case of scattering nanoparticles, the 
interaction of the particles with light waves, known as Rayleigh scattering, occurs 
when the electromagnetic waves in light are scattered by particles with diameters 
much smaller than the wavelength of the light (Turzhitsky et al., 2014). With noble 
metals such as gold, the free electrons are called plasmons and so their oscillation 
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local surface plasmon resonance, The surface plasmon absorption, scattering and 
total extinction efficiencies are described by Mie theory (Haiss et al., 2007). For 
spherical nanoparticles, scattering scales to the sixth power of the radius ( r6)  while 
absorption scales to the volume (r3) (Madjet et al., 1995). When the diameter of 
gold nanoparticles is ≥40, the scattering starts to dominate. The absorption of light 
in the blue-green portion of the spectrum (~520 nm for ~10 nm diameter gold 
nanoparticles) and reflection of red light (~700 nm) produces  a rich red colour for 
nanoparticles of diameter ~ 10 nm (Fig. 4). There are factors other than nanoparticle 
size that affect the wavelength of which plasmon resonance occurs (Nehl and 
Hafner, 2008). One is the local environment, which includes the solvent and 
molecules adsorbed to the nanoparticle surface. 
 
Fig. 4. AuNPs maximum absorption peak before and after aggregation. Mix 
matrix AuNPs are gold nanoparticles of diameter 8.8 nm with a mix matrix ligand 
shell (Section 2.3.1). Mix matrix AuNPs + DTT are the same gold nanoparticles 
aggregated after prolonged treatment with DTT in the presence of electrolytes 
(Sections 2.6.1 and 2.9.1). 
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The wavelength of surface plasmon resonance related absorption shifts to longer, 
redder wavelengths as particle size increases. At the limit, when the nanoparticles 
aggregate, the spectrum become featureless (Fig. 4).  
Silver, a noble metal like gold has entirely analogous optical properties. However, 
silver nanoparticles have a stronger absorbance and scattering than gold 
nanoparticles, and they are also strong enhancers of Raman scattering. There is a 
long-standing use of silver and more recently silver nanoparticles in health fields, 
due to their antimicrobial properties. These they are drawing increasing attention 
for potential prevention of bacterial/fungal and viral infection, in part due to 
growing antibiotic resistance (Franci et al., 2015). 
1.4.4 Synthesis of gold nanoparticles: 
Gold nanoparticles are usually synthesised by the reduction of the metal salt for 
example by citrate (equations 1 and 2). Other common reductants include NaBH4, 
aldehydes, which include biological compounds such as glucose. It is known that 
HAuCl4 can be hydrolyzed to various gold complexes (Zhao et al., 2012) in a 
manner that is dependent on the pH of the reaction solution, as shown in equation 
(1).  After the addition of the reducing agent, both hydroxyl groups and chloride 
ions will be released upon reduction of the gold precursors, as shown in equation 
(2). Growth of nanoparticles is by nucleation of Au0 and accretion of further atoms 
on the nucleus. Binding of ligands such as citrate, the starting concentration of Au+ 
and reductant will determine the size of the nanoparticle product.  
 
HAuCl4 + n H2O                 AuCl4-n OH
- + (n + 1) H+ + n  Cl- …….(1) 
AuCl(4-n) OHn                      Au(particle)        + (4 - n) Cl
- + n OH-…….(2) 
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 For nanoparticles of diameter ≥ 20   nm small nanoparticles are synthesised and 
used as seeds in a subsequent reaction.  
 
1.4.5 Silver nanoparticles  
Silver is a noble metal and nanoparticles of silver (AgNPs) have similar properties 
to gold nanoparticles. Thus, their conduction electrons react to photons in much the 
same way.  However, they are stronger scatterers and absorbers of light than gold 
nanoparticles (Haiss et al., 2007),  (Paramelle et al., 2014). Silver nanoparticles of 
diameter ~10 nm with a mix matrix ligand shell (Section 2.3.1) have a plasmon 
peak at ~ 410 nm, which is narrower than that of gold (Fig. 5 for silver, Fig. 4 for 
gold).  The position of this peak is dependent on the nanoparticle size and shifts 
towards the red as the silver nanoparticles get larger; when they aggregate the 
nanoparticle become electronically coupled and the spectrum becomes featureless 
(Fig. 5). The plasmon absorption of silver nanoparticles is more sensitive to the 
immediate environment that corresponding gold ones. For example, without a 
ligand shell, the silver nanoparticles in Fig. 5 have a plasmon peak at ~395 nm, 
indicating that the self-assembled monolayer of the ligand shell shifts the plasmon 
band by ~ 15 nm. The corresponding shift for gold nanoparticles is less than 2 nm 
(Levy et al., 2004). 
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Fig. 5. AgNPs maximum absorption peak before and after aggregation. Mix 
matrix AgNPs are silver nanoparticles of diameter 8.8 nm with a mix matrix ligand 
shell (Section 2.3.1). Mix matrix AgNPs + DTT are the same silver nanoparticles 
aggregated after prolonged treatment with DTT (Sections 2.6.1 and 2.9.1). 
  
In contrast to gold, silver ions inhibit a range of microorganisms, including 
pathogenic ones. Indeed, silver nitrate has long been used clinically to prevent the 
infection of wounds, though more recently this has been questioned (Storm-
Versloot et al., 2010), and, as the authors of this Cochrane review point out, clinical 
data in the area is of poor quality. In any event, the historical association of silver 
ions and anti-microbial activity, which is experimentally demonstrable, has led to 
an interest in developing silver nanoparticles as slow release agents for silver ions 
at sites of infection (Wang et al., 2016). The increasing resistance of pathogenic 
microorganisms to drugs has fuelled this interest.  
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Silver ions have a strong bacteriostatic action; that is they halt bacterial growth 
(Slawson et al., 1992, Spadaro et al., 1974), and though there are documented cases 
of resistant bacterial strains, these remain rare (Pooley, 1982, Klaus et al., 1999).  
The slow release of silver ions by nanoparticles in the context of inhibition of 
bacterial growth was demonstrated with E. coli grown in Luria–Bertani (LB) 
medium on solid agar plates. Addition of different concentrations of silver 
nanoparticles and lysis of the bacteria was evidenced by scanning and transmission 
electron microscopy (SEM and TEM), which showed that the E. coli cells were 
damaged. This was due to the formation of “pits” in the cell wall of the bacteria, 
resulting in an increasing permeability of the cell wall and cell death. The silver 
nanoparticles were found to accumulate in the bacterial membrane. Such 
experiments have led to the idea that silver nanoparticles may be suitable for the 
formulation of new types of bactericidal nanomaterials (Sondi and Salopek-Sondi, 
2004).  
Silver nanoparticles, presumably through the release of silver ions have also been 
shown to exert showed potent anti-fungal activity against clinical isolates and 
ATCC strains of Trichophyton mentagrophytes and Candida species at 
concentrations of 1–7 μg/mL in vitro, which was comparable to that of 
amphotericin B, but superior to that of fluconazole (amphotericin B IC80, 1-5 
μg/ml; fluconazole IC80, 10- 30 μg/ml) (Kim et al., 2008). While high, such 
concentrations are attainable topically.  
Silver nanoparticle have also been shown to possess inhibitory activity towards a 
range of unrelated human viruses in a variety of model systems. AgNPs effectively 
inhibited  Herpesviridae and Paramyxoviridae viruses in Vero cells (Gaikwad et al., 
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2013). The antiviral activity of silver nanoparticles against hepatitis B virus was 
measured by incubating 5-50 µM ~10 nm AgNPs with hepatoblastoma cells, which  
secrete HBV-like particles containing hepatitis B virus   DNA into the medium 
(Ladner et al., 1997). After 48 h incubation, total DNA was extracted and HBV 
DNA was quantified by real-time PCR, and  the AgNPs were shown to the level of 
inhibit hepatitis B virus DNA in the medium by 38% at 5 µM and 80% at 50 µM 
(Lu et al., 2008). Similarly, in a model of HIV-1 infectivity using Hut/CCR5 cells 
AgNPs were shown, after 3 days infection, to reduce in a dose-dependent manner 
the in inhibiting HIV-1 replication with 50 µM AgNPs causing a 98% inhibition. 
(Sun et al., 2005).  
Silver nanoparticles have also been shown to inhibit the infectivity of H1N1 
influenza A virus (Li et al., 2016). To determine the inhibitory activity of silver 
nanoparticles on H1N1 influenza A virus, the embryo inoculation assay and MDCK 
cells were used as the infection model. Electron microscopy analysis and flow 
cytometry assays demonstrated that silver nanoparticles reduced H1N1 influenza A 
virus activity. (Xiang et al., 2011),  
1.4.6 Ligand shells 
Noble metal nanoparticles, as synthesised, are generally not useful in biology. 
These bare metal nanoparticles are not colloidally stable and will aggregate in 
physiological concentrations of electrolytes (Moore et al., 2015). Moreover, the 
surface of AuNPs and AgNPs bind groups found in biological molecules: thiols, 
amines and carbonyls (Sainsbury et al., 2007). Thus, though gold is considered to 
be relatively non-reactive, it will bind non-specifically to with proteins, 
polysaccharides and DNA/RNA and silver nanoparticles likewise. Consequently, 
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the surface of the noble metal nanoparticles needs to be protected. What follows is 
focussed on gold nanoparticles, since the most work has been done on these, though 
the same principles apply to silver nanoparticles.  
Stabilization of metal nanoparticles has different meanings, dependent on the 
context. Stability from a physical perspective means that the nanoparticle maintains 
its integrity as a nanoparticle colloidal solution and the material does not change 
chemically. From a biological point of view there are additional features, which are 
that the nanoparticles remain soluble and dispersed in physiological environments, 
having low to not detectable non-specific binding to biological macromolecules. 
This may be achieved by means of a passivating shell, which is the coating of the 
metal surface. There are different strategies for the passivation nanoparticles, which 
include (Kim et al., 2015, Li et al., 2013, Gajan et al., 2009, Nune et al., 2009): 
 Silica 
 Layer-by-layer (LBL) 
 Polymers 
 Self-assembled monolayer (SAM) 
 
Fig 6. Diagram to show the results of the four different passivation strategies.  
Nanoparticle and passivation layer roughly to scale for a ~10 nm diameter 
nanoparticle. A. silica shell, B. LBL shell .C. polymer. D. SAM. 
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1.4.6.1 Silica passivation of nanoparticles 
One approach to passivation is the deposition of a homogeneous shell of an 
inorganic material, such as silica. This achieves colloidal stabilization and 
generates what is called core–shell geometry (Liz-Marzan et al., 1996). Silica shells 
not only provides greatly enhanced colloidal stability in water, but also can be used 
to determine the distance between core particles within assemblies by controlling 
the shell thickness (Ung et al., 1998). Three steps have used in to make silica 
encapsulated nanoparticles: (1) By using silane coupling agents such as silicon 
alkoxides with an amino or thiol group as surface primer, modification of the metal 
nanoparticle surface to make it vitreophilic; (2) slow silica deposition in water from 
a sodium silicate solution, and (3) extensive growth of the silica shells through sol–
gel reaction using silicon alkoxide in ethanol/ammonia mixtures (Ung et al., 1998). 
One obvious drawback of the silica shell for biology is that it makes the nanoparticle 
a lot larger (Fig. 6A).  This goes against the idea of using a small nanoparticle in 
the first place and may cause problems due to the large hydrodynamic radius of the 
silica covered nanoparticle preventing this accessing all parts of the biological 
system. In addition, the silica shell does not impart stability that is suitable for the 
direct use in cell biology, because biological molecules bind silica and some means 
of functionalization is required, a layer of polymer is often attached to the silica 
shell. This will make the nanoparticle even larger. So silica core-shell nanoparticles 
have important drawbacks in terms of their use in biology. 
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1.4.6.2 The layer by layer (LBL) passivation of nanoparticles 
The LBL approach generates another kind of ligand shell to protect metal 
nanoparticles. This involves coating of nanoparticles with successive layers of 
polyelectrolytes of opposing charges, which assemble into a layered structure. The 
ability to control the deposition and achieve a uniform layer of polyelectrolytes with 
nanometre thick precision is one a feature of electrostatically driven LBL assembly. 
The LBL approach provides a general route to tailor the general characteristic of 
nanoparticles, because polyelectrolytes readily adsorb onto different surfaces and 
can be modified or reacted to incorporate different functional groups. Furthermore, 
the outer polyelectrolyte provides colloidal stability to the nanoparticles by giving 
well defined surface charge to the nanoparticles. However, this surface charge will 
attract biological molecules of the opposite charge, so leading to a specific binding. 
In addition, there will be several layers, so the nanoparticle hydrodynamic radius 
will be increased (Fig. 6B). Finally, the polyelectrolytes do not form a complete 
physical barrier, so biological molecules may penetrate to a greater or lesser extent 
into the layers. 
1.4.6.3 Polymer passivation of nanoparticles  
Polymers are another commonly used ligand shell. Generally polymers with one or 
more functional groups (particularly thiols) that bind to gold are used. These can 
displace existing ligands, which includes thiol ligands if the polymer is at high 
enough concentration and/or possesses multiple thiols (Lu et al., 2002). Polymers 
can also be used to attach biological molecules using other functional groups 
present, such as amines or carboxylic acids.  Polymers that have been used include 
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mercapto polyethylene glycol and mercapto dextans (Costanzo and Beyer, 2007),  
Polymer ligand shells have some disadvantages. As with the silica and LBL 
approaches, they increase the hydrodynamic radius of the nanoparticle considerably 
(Fig. 6C).  In addition, like the LBL system, the polymer shell is not a physical 
barrier that is biological molecules can penetrate it and either take up residence 
(changing the biological functionality of the nanoparticle) or access the underlying 
gold surface and exchange for the polymer. This could ultimately destroy the 
polymer ligand shell. 
1.4.6.4 Self-assembled monolayer (SAM) passivation of nanoparticles 
Self-assemble monolayers (SAMs) are another strategy used to protect AuNPs. 
SAMs ensure the passivation keeps the hydrodynamic radius of the nanoparticle to 
a minimum, since the ligands that make up the monolayer are short (Fig. 6D), There 
are many examples of self-assembling ligand shells, including PEGylated 
alkanethiols and peptides. All of them follow the same design principal, they start 
with a thiol group for bonding to the metal, a hydrophobic core, allowing packing 
of the monolayer, and a hydrophilic terminus exposed to solvent to enable solubility 
in physiological environments. They give excellent solubility to the metal 
nanoparticle. For example, PEGylated alkanethiols and peptides, such as CALNN, 
have been found to protect gold and silver nanoparticles from aggregation by 
electrolyte induced aggregation and also to protect silver from oxidation in water 
containing electrolytes (Levy et al., 2004a, Doty et al., 2005). Moreover, SAMs 
formed from peptides only impose a small increase in nanoparticles hydrodynamic 
radius (Octeau et al., 2009) 
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Functionalisation of SAM protected nanoparticles can be achieved through a group 
that is exposed to solvent or, in some systems, by the incorporation of a ligand with 
a functional group exposed to solvent. In addition, it is possible to control the 
valency of functionalisation. Thus, the CALNN pentapeptide  ligand system was 
shown to allow a simple means for producing nanoparticles carrying a single 
biomolecular recognition function (Levy, 2006).  In these experiments a ligand shell 
of the peptide CALNN was assembled on 6 nm diameter AuNPs. Functionalisation 
of the nanoparticles was achieved by incorporating into the initial ligand solution a 
a functional ligand (CALNNGHHHHHHGKbiotinG) as a mole % of the CALNN 
ligand. The functional ligand had the same initial five amino acids, to ensure it 
packed into the SAM similarly to the matrix CALNN peptides and towards its C-
terminus a hexahistidine sequence. The latter would allow separation of 
functionalised from non-functionalised nanoparticles by immobilised metal ion 
affinity chromatography, using a standard nitrilotriacetic acid-Ni2+ column. The C-
terminal biotin provided a further means of detection and separation. Following 
purification of the nanoparticles from excess ligand by size-exclusion 
chromatography (Levy et al., 2004b) the binding and elution of functionalised 
nanoparticles form the nickel affinity column was demonstrated. Moreover, it was 
shown that the fraction of bound, so functionalised nanoparticles, depended on the 
mole % of the peptide CALNNGHHHHHHGKbiotinG in the initial ligand mixture.  
Thus incorporation of the functional ligand was random, dependent only on its 
relative concentration. This allowed the analysis of populations of functionalised 
nanoparticles and the partial separation of ones bearing 1, 2 or more functional 
ligands. The relative proportions of nanoparticles in these different fractions 
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corresponded reasonably to that expected from random incorporation of ligands 
into the self-assembled monolayer. Thus, the assumption that the probability Pf of 
reaction of a functional peptide with a gold NP is simply equal to the molar ratio of 
functional versus matrix peptide present in solution and does not change during the 
capping process holds.  A consequence is that for small values of Pf, the proportion 
of labelled NPs tends to zero, but essentially all labelled NPs have exactly one label 
and in practical terms when 10 % of the nanoparticles are functionalised, so bind to 
the affinity column, ~95% of these will carry just one functional ligand, and the 
remaining 5% two or more (Levy at al 2005, Figure 2A). 
There are, however, drawbacks to both peptide and PEGylated alkane thiol ligands. 
The peptide SAMs carry a high negative charge, due to the C-terminal carboxylic 
acid group that is exposed to solvent.  This results in binding positively charged 
molecules (Duchesne et al., 2008a), which are abundant in biological systems, e.g., 
any protein with a basic isoelectric point or which possesses an uneven charge 
distribution on its surface. In addition, the peptide ligands are not stable when 
challenged by small thiol-containing molecules. That is, they undergo ligand 
exchange, where the thiol in solution replaces the peptides on the surface of the 
nanoparticle and this includes cysteine, which is present at ~ mM concentrations in 
cell culture medium (Chen et al., 2012, Duchesne et al., 2008a). Both the non 
speciﬁc interactions of the nanoparticles and ligand exchange must be prevented, 
because these can lead to a change and/or loss of the functionality of the 
nanoparticle. Whereas SAMSs formed from PEGylated alkane thiol ligands do not 
suffer from these disadvantages, they are more limited in their capacity for 
functionalisation. With peptide ligands, extension of the amino acid sequence at the 
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C-terminus and/or incorporation of particular functional groups such as biotin is 
part of the options available during commercial peptide synthesis. In contrast 
PEGylated alkane thiol ligands are available with a limited number of functional 
groups, generally requiring synthetic chemistry to attach a biological function. 
Moreover, it was found that addition of a very small mole % of peptide ligands did 
not give rise to the stoichiolmetric incorporation of these into a PEGylated alkane 
thiol ligand shell (Duchesne et al., 2008a). This may be due to the preference of the 
alkane for packing against alkanes, to the exclusion of the peptide ligand.  
1.4.6.5 The ‘mix matrix’ SAM ligand shell 
To overcome these drawbacks, a ligand shell of thiolated pentapeptidols and alkane 
thiol ethylene glycol, was designed and called a ‘mix matrix’, as it is composed of 
two different ligands, typically 70% (mole/mole) of the peptidol H-CVVVT-ol and 
30 % (mole/mole) of the ethylene glycol–terminated alkane thiol HS-C11-EG4 
(Duchesne et al., 2008) Fig. 7A.  
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Fig. 7. Diagram of gold nanoparticle passivation with the mix matrix ligands. 
The pentapeptidol (darker ligand) and alkane thiol ethylene glycol (lighter ligand) 
are shown. The organisation, if any, of the two ligands on the surface is unknown. 
 
The thiol groups (HS on the cysteine of the peptidol and –SH on the alkane thiol 
ethylene glycol) have a high affinity for gold and silver, and the N-terminal amino 
group of the cysteine provides for a further interaction. The central section of both 
ligands is hydrophobic and will, in aqueous solutions, pack together, which drives 
self-assembly. The C-terminal hydroxyl of the peptidol is hydrophilic and aids 
solubility, but is insufficient to prevent aggregation; the four terminal ethylene 
glycol units are highly mobile and they provide both hydrophilicity and steric 
repulsion, which prevents aggregation (Duchesne et al., 2008a)(Duchesne et al 
2008). Mix-matrix capping ligands have been shown to provide both gold and silver 
nanoparticles with excellent solubility, stability to electrolyte- induced aggregation, 
resistance to nonspecific binding to biological molecules, ligand exchange with 
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small thiols such as dithiothreitol (Duchesne et al., 2008a, Chen et al., 2012, 
Duchesne et al., 2012),  and to degradation by cyanide (Free et al., 2012). 
By having both the peptidol and alkane thiol ethyleneglycol ligands in the SAM, it 
is then possible to include one or both types of ligand carrying a functional group 
and these are now incorporated stoichiometrically into the ligand shell, that is 
according to their mole % in the initial ligand mixture (Section 1.4.6.4) (Fig 7 B).  
 
Fig. 7. Gold nanoparticles passivation and functionalisation. B Principle of 
functionalisation of gold nanoparticles using different mole% of the functional 
ligand (shown here is FluPep ligand, Section 2.3) to produce nanoparticles with 
different grafting densities of the functional ligand. 
 
Thus the mix matrix SAM ligand shell is easily functionalised by the incorporation 
of a ligand with an extension. Mix matrix ligand shells have been functionalised 
using ligands possessing affinity tags (Duchesne et al., 2008a), such as tris 
nitriloacetic acid to enable stoichiometric conjugation to proteins with a 
hexahistidine tag (Duchesne et al., 2012).  This approach has been used to increase 
the efficacy of loading nanoparticles into a protein cage containing hexahistidine 
tags (Paramelle et al., 2016). In addition, using the same principle, selective 
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chemical conjugation of proteins and oligosaccharides has been achieved by first 
functionalising the nanoparticles with an azide. This was then converted to a thiol 
to react with maleimide-functionalised oligosaccharides or to a maleimide to react 
with a single accessible cysteine side chain on the surface of a protein (Nieves et 
al., 2015).  
Thus, the SAM formed by the mix matrix allows good stabilisation of noble metal 
nanoparticles, only causes a small increase in the nanoparticle hydrodynamic 
volume. Importantly, for the purposes of this thesis, the mix matrix ligand shell can 
easily be functionalised with peptide ligands with some control over the 
stoichiometry of functionalisation. For these reasons, this will be the system that 
will be explored first to determine whether it may be functionalised with peptides 
that inhibit ‘flu virus infectivity.   
1.5 Antiviral peptides 
1.5.1 Examples of antiviral proteins and peptides 
Peptide-based drugs are becoming established as viable therapeutics after the 
successful use of Enfuvirtidie against HIV. This is the first peptide-based antiviral 
drug approved by the Food and Drug Administration (USA) (Cooper and Lange, 
2004). Peptide-based drugs potentially offer many advantages, as they are 
biologics, so can carry in their structure a lot of information relating to selectivity 
and specificity of their targets, so they might have fewer off target effects than small 
molecules. Production can be scaled and is cheaper than protein biologics. 
Moreover, aspects of their pharmacodynamics, to their lifetime in the body can be 
tuned. Thus, peptides will be  rapidly cleared from the circulation and degraded in 
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vivo to amino acids (a non-toxic end product), whereas the incorporation of D-
amino acids and/or alternative linkages to peptide bonds, e.g., isopeptide bond, will 
prolong their lifetime in vivo (Skalickova et al., 2015b). 
The antiviral peptides target different aspects of the virus replicative cycle: (i) entry 
blocker peptides, which inhibit viral attachment and virus-cell membrane fusion; 
(ii) viral envelope targeting peptides, which disrupt the viral envelope; (iii) viral 
polymerase peptides, which inhibit replication of influenza virus by interacting with 
viral polymerase (Skalickova et al., 2015b).  
Several viral diseases have been treated successfully with antiviral peptides 
including HIV. The infection with human immunodeficiency virus (HIV) results in 
CD4+ T cell depletion and the subsequent loss of immune function, which 
eventually leads to death from AIDS. It has been demonstrated that some peptides 
inhibit the fusion of the HIV virus. Thus, the membrane-associated and secreted 
C46 peptides efficiently block infection of cells by interfering with the function of 
HIV-1 gp41. Peptides derived from the heptad repeat 2 (HR2) region of the HIV 
fusogenic protein gp41 are also potent inhibitors of viral infection, and one of them, 
called enfuvirtide, is now used for the treatment of therapy-experienced AIDS 
patients. An understanding of the mechanism of these peptides, which interfere with 
the virus cell fusion pathway has allowed the design of more potent peptide 
inhibitors by means of increasing the affinity of the peptide for the intermediate 
form of the viral protein involved in fusion (Lee et al., 2014),(Pessi et al., 2009).  
It was shown that bovine and human lactoferrin (LF) specifically inhibited hepatitis 
C virus (HCV) infection in cultured non-neoplastic human hepatocyte-derived 
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PH5CH8 (Abe et al., 2007a). Moreover, it was also demonstrated that the main 
contributing factor to prevent of hepatitis C virus HCV infection, is the interaction 
of lactoferrin  (LF) and the envelop 2 (E2) protein. Only part of lactoferrin is 
required for this activity. (Abe et al., 2007b). LF and a peptide derived from it have 
been shown also to inhibit herpes simplex HSV. A different peptide, from the 
lactoferrin N-terminal domain, has a high potency anti HSV peptide, blocking viral 
entry and stimulating the immune system. Interestingly, Lf synergises with 
acyclovir (ACV), is a potent inhibitor of HSV replication and is an apparent 
inactivator of the HSV DNA polymerase. Other researchers have targeted the 
requirement of HYSV to bind to heparan sulfate. They introduced a protease 
resistant arginine-rich peptide, called DG2 containing D-amino acids. DG2 is stable 
with respect to proteases, inhibits HSV-1 entry into cells and blocks all aspects of 
infection (Jenssen, 2005),(Jaishankar et al., 2015).  
1.5.2 Peptides inhibiting influenza virus 
There are a number of macromolecules and peptides shown to inhibit influenza 
virus. Some have been discovered through a process of structure-led screening and 
design. Others have been fortuitous discoveries.  
1.5.2.1 Macromolecular inhibitors of influenza virus infectivity 
Because HA binding to sialic acid is the first step in virus entry, blocking this 
interaction is considered to be a promising therapeutic route (Guo et al., 2002, 
Matrosovich and Klenk, 2003). Indeed, studies since the late 1940s have 
demonstrated that a variety of sialic acid-containing molecules isolated from 
different natural sources, ranging from serum, urine and meconium to egg white 
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and edible bird nests are inhibitors of influenza viruses (Krizanova and Rathova, 
1969). Many sialic acid-containing polymers have been developed such as 
sialyloligosaccharides containing poly L-glutamic acid backbones, sialic acid-
conjugated dendritic polymers and sialyllactose-carrying polystyrene (Reuter et al., 
1999, Totani et al., 2003, Tsuchida et al., 1998). HA interaction with 
sialylglycoconjugates is also the target for a peptide identified by random library 
selection for sialic acid mimetics (Matsubara et al., 2010).  
LF (Section 1.5.1) interacts not only with the viral influenza viral envelope, but also 
with viral haemagglutinin and blocks viral attachment. The relation of this to 
lactoferrin heparin-binding properties is now known (Pietrantoni et al., 2003). 
 ‘Phage display libraries have been screened for peptides that bind HA competitive 
with sialic acid and so would block HA interacting with the cell surface.  Initial hits 
were improved by selection of expanded sublibraries. Analysis of the structure of 
the most effective peptide shows that it is a mimic of sialic acid. Other peptides 
have been derived from existing proteins, by analogy with, for example, the 
peptides derived from lactoferrin (Section 1.5.1). The Kα2-helix peptide from the 
viral FLICE-like inhibitor protein (vFLIP) of Kaposi’s sarcoma-associated 
herpesvirus (KSHV) when fused to the TAT peptide inhibits influenza A virus 
replication and transmission in vitro and in vivo. It protected mice challenged with 
lethal doses of highly pathogenic influenza A H5N1 or H1N1 viruses (Moon et al., 
2017). Moreover, the TAT-Kα2 peptide may have a broad antiviral activity 
spectrum as it is also effective vesicular Stomatitis Virus (VSV) and respiratory 
Syncytial Virus (RSV). The possible mechanism of action TAT-Kα2 peptide is the 
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destabilization of the viral membranes, depending on their lipid composition of the 
viral envelop (Matsubara et al., 2010, Moon et al., 2017). 
1.5.2.2 Peptides derived from natural sources 
There are a considerable number of peptides that inhibit influenza virus infectivity, 
at least in vitro. What follows is a brief summary of some of these.  
Cyanovirin-n (CV-N ) and related sequences showed highly potent antiviral activity 
against almost all strains of influenza A and B virus, including clinical isolates and 
a neuraminidase inhibitor-resistant strain (EC50 = 0.004 to 0.04 µg/ml). CV-N was 
inactive against rhinoviruses, human parainfluenza virus, respiratory syncytial 
virus, and enteric viruses, but was moderately active against some herpesvirus and 
hepatitis virus (bovine viral diarrhea virus) strains (50% effective concentration 
[EC50] = ~1 µg/ml) while inactive against others. CV-N may act by binding certain 
high mannose oligosaccharide structures such as oligomannose-8 and 
oligomannose-9, which may account, at least in part, for the spectrum of its antiviral 
activity (O'Keefe et al., 2003).  
A 20-amino-acid peptide (EB, for entry blocker) RRKKAAVALLPAVLLALLAP 
derived from the signal sequence of fibroblast growth factor 4, binds to the viral 
haemagglutinin, so inhibiting the attachment of virus to cellular receptors, 
preventing infection. EB peptide exhibited broad-spectrum antiviral activity against 
influenza viruses including the H5N1 subtype in vitro and in four- to six-week-old 
BALB/c mice (Jones et al., 2006a). Pretreatment of mice with EB provided 100% 
protection against numerous subtypes including the highly pathogenic H5N1 
viruses (Jones et al., 2006b). Other entry blocker peptides include a 16 amino acid 
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peptide sequence, Flufirvitide, derived from the fusion initiation region of the HA, 
which is currently in clinical trials. This has shown effective inhibition of influenza 
virus infection by blocking binding of HA to sialic acid. The peptide also appears 
to modulate the immune system of the host by inducing the production of anti-
inflammatory cytokines and chemokines, so increasing the activity of neutrophils, 
and improving phagocytosis of macrophages (Cederlund et al., 2011, Skalickova et 
al., 2015a).  
The human genome encodes a viral envelope targeting peptides, cathelicidins 
hCAP-18, which are between 12 and 80 amino acids long (Puig-Basagoiti et al., 
2016).  These cationic antimicrobial peptides are able to destroy the viral envelope 
and induce a number of host protective mechanisms, including chemokine and 
cytokine production, promotion of barrier repairs, T-cell polarization and enhance 
viral dsRNA signalling via Toll-Like Receptor 3 (TLR3) (Choi and Mookherjee, 
2012, Currie et al., 2016).  
Like the cathelicidins the defensins are host defence antimicrobial peptides. One of 
their activities is to target viral envelopes, including that of influenza virus (Wilson 
et al., 2013, Shah and Chang, 2012). As well as a direct action on the viral envelope,  
defensins stimulate the innate immune response (Mohan et al., 2013). In this study 
they were able to inhibit the synthesis of viral RNA and proteins and increase the 
activity of mucosal epithelia (Salvatore et al., 2007).  
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1.5.2.3 ‘FluPep’ 
 
It was discovered that influenza A virus, including the H1N1 subtype, was strongly 
susceptible to a peptide called FluPep (Nicol et al., 2012b). FluPep was originally 
identified as a sequence in Tkip (tyrosine kinase inhibitor peptide), thought to act 
as a mimic of the suppressor of cytokine signalling (SOCS) protein that binds to the 
autophosphorylation site of tyrosine kinases. SOCS is often indispensable to virus 
replication, as it inhibits the activation of STAT transcription factors, which 
regulate the intensity of inflammatory cytokine responses involved in protecting the 
host. In initial work with poxvirus, Tkip protected against acute poxvirus infection 
and chronic autoimmune damage in the nervous system (Ahmed et al., 2009) and 
so its activity against other viruses, particularly ‘flu virus was determined (Nicol et 
al., 2012b).  FluPep and derived sequences inhibited a variety of influenza A virus 
subtypes (including H1N1, H3N2 and H5N1) at nanomolar concentrations in cell 
models. In 5–6-week-old BALB/c mice inoculated intranasally with mouse-adapted 
A/WSN/33 virus, pre-treatment with FluPep resulted in 100% survival of the mice, 
with no symptoms and loss of weight (Nicol et al, 2012a). 
However, it transpired that this peptide derived from Tkip exerted its antiviral 
activity outside the cell, so independent of it blocking SOCS, which is actually 
inside the cell. Thus, the peptide was shown to prevent virus attachment to cells, by 
an ELISA type assay for virus (Nicol et al., 2012b). Using an ELISA with Flupep 
absorbed to the wells, HA was shown to bind the peptide and a minimal binding 
sequence of 6 amino acids was determined to be the core sequence responsible for 
this interaction. This peptide also inhibited virus infectivity, though with an IC50 in 
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the micromolar range. The conclusion was that FluPep’s anti-viral activity occurred 
by means of it binding HA protein, so preventing ‘flu virus binding to epithelial 
cells. However, there are some discrepancies in these data. The competition assay 
on the MDCK cells where peptide prevented virus binding does not show an 
obvious dose response. In addition, the concentrations of peptide required for the 
inhibition of virus binding and of virus infectivity in cells are different (Nicol et al., 
2012a). It is, therefore, not given that the mechanism proposed by these authors 
whereby FluPep inhibits ‘flu virus infectivity is indeed by binding HA. 
1.6 Aims of the project 
 
Although the FluPep has been shown to be effective in vitro and in vivo, peptides 
in general are not very stable in biological environments due to proteolysis, though 
this can be modulated by the incorporation of D-amino acids and/or non-amide 
bonds between amino acids (Nicol et al., 2012b). Peptides also often require organic 
solvents such as dimethyl sulfoxide (DMSO) to improve their solubility, which 
restricts their use in a clinical setting. Indeed, FluPep is extremely hydrophobic, 
which limits its solubility in water. Moreover, the mechanism of how peptides such 
as FluPep exert their antiviral activity is often poorly defined. This is partly due to 
a lack of high sensitivity probes that are readily quantifiable and easily conjugated 
to the peptide.  
The objective of this thesis is to synthesise conjugates of FluPep and gold 
nanoparticles. The incorporation of FluPep into a nanoparticle may improve its 
solubility. In addition, the number of FluPeps per nanoparticles can be controlled 
(Levy et al., 2006a). So the effect of valency on antiviral activity can be explored. 
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Most importantly, gold nanoparticles also provide a ready means to quantify 
FluPep-nanoparticle conjugates. The aims of this thesis are: 
A- To synthesise gold nanoparticle functionalised with FluPep and compare 
their antiviral activity to free peptide. 
B- To determine if plurifunctionalisation of gold nanoparticles with FluPep 
increases the antiviral activity of the peptide. 
C- To identify the mechanism of FluPep antiviral activity. 
D- To use information relating to the mechanism to design a more potent 
FluPep. 
This will be achieved by: 
1- Determine if nanoparticle ligand shell could be designed with reduced non-
specific interaction compared to the mix matrix ligand shell. 
2- Functionalising and purifying FluPep-gold nanoparticle conjugates and 
determining their stability. 
3- Characterise the anti-flu activity of FluPep-gold nanoparticle conjugates. 
4- Characterise the interactions of FluPep-gold nanoparticle conjugates with 
influenza virus and cells. 
5- Test in parallel the anti-viral activity of FluPep-silver nanoparticle 
conjugates. 
6- Design modified FluPep sequences with enhanced activity. 
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Chapter 2 
Gold nanoparticles passivation, functionalisation with FluPep and 
determination their antiviral activity 
 
2.1 Introduction 
 Gold nanoparticles may be passivated successfully with a mix matrix (70% 
CVVVTol: 30% HS-(CH4)11-EG4 both mole/mole) ligand shell (Sections 1.4.2, 
1.4.6). They are stable in a variety of in vitro tests, including DTT ligand exchange 
and can be functionalised in a manner that provides control over the number of 
functional ligands incorporated into the ligand shell. Moreover, mix matrix 
passivated nanoparticles have low non-specific binding to cells (Duchesne et al., 
2012), indicating that they would be suitable for experiments involving cultured 
mammalian cells. However, this is not the only ligand combination that is able to 
impart good stability to nanoparticles. 
Thus, in previous work other ligand mixtures that produce robust ligand shells on 
gold nanoparticles were identified. Some of the ones imparting stability in vitro 
tests that was at least as good as the mix matrix ligand shell included a mixture of 
HS-(CH4)11-EG4 with either the peptidols H-CAVLT-ol, H-CAVLTY-ol or H-
CFFFY-ol (Chen et al., 2012). In this chapter, different ligand shell combinations 
were examined to see if any perform better than the standard mix matrix and would, 
therefore, be useful for probing FluPep function. This work was also driven by the 
early observation (Section 3.2.2) that the standard mix matrix ligand shell was quite 
hydrophobic; that is, nanoparticle passivated with this ligand shell bound to 
hydrophobic interactions columns. Since hydrophobic interaction chromatography 
would be one means to purify nanoparticles functionalised with FluPep ligand, 
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which is itself hydrophobic, identifying a less hydrophobic ligand shell was 
important. The ligands tested included the following:  
1. CVT-ol 
2. A peptidol with a charged group at position 3 (K or D) 
3. A peptidol with a serine backbone (CSSSS-ol).  
4. A peptidol with polar group at position 3 (CVNVT-ol)  
5. A peptidol with a zwitterionic C- terminus (CVVVK-OH) 
6. Standard peptide, so with an acidic C-terminus. 
In addition various a combinations of the above were tested. The rational was as 
follows. Though counter intuitive from the point of view of ligand packing, 
peptidols such as (1) above, which are shorter than the eleven carbon alkane chain 
on the alkane thiol ethylene glycol ligand, were previously observed to impart 
greater stability of gold nanoparticles when part of a ligand mixture with HS-
(CH4)11-EG4 (Chen et al., 2012). The introduction of amino acids with charged or 
polar side chains (3-4 above) may result in the formation of salt bridges or extra H-
bonds between ligands and so increase ligand shell stability. Whereas a peptide will 
impart a negative charge to the nanoparticle and in all likelihood cause non-specific 
binding to positively charged molecules in a biological experiment (Duchesne et 
al., 2008a), it was of interest to examine the stability of such peptides mixed with 
the alkane thiol ethylene glycol ligand. Peptides with a zwitterionic C-terminus 
were also tested, since they may form a ligand shell with no net charge. Finally, 
evidence was acquired to demonstrate that nanoparticles with a mix matrix ligand 
shell could be functionalised with FluPep ligand and purified by cation-exchange 
chromatography. 
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2.2 Materials and Methods 
 
2.2.1 Buffers 
10 x PBS (pH 7.4) 
 1.4 M NaCl 
 27 mM KCl 
 81 mM Na2PO4 
 15 mM KH2PO4 
 1 M Tris-HCl  (pH 7.4) 
 121.14 g Tris Base 
 800 mL dH2O 
Silver nanoparticles preparation (pH 7.4) 
 10 x (100 mM NaNO3) 
 10x(20 mM HEPES) 
Enzyme preparation (pH 7.0) 
 100 mM sodium acetate  
  0.1 mM calcium acetate 
2.2.2 Peptides and nanoparticles 
Peptides (Table 2.1) were purchased from Peptide Protein Research (PPR Ltd, 
Hampshire, UK), with the exception of a small batch of FluPep, which was a gift 
of Prof. Tony Nash, University of Edinburgh.  The peptide, synthesized by the 
School of Chemistry, University of Edinburgh was the same as used in Niccol et 
al., 2012 and allowed direct comparison of the commercial peptide used for most 
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of the work in the thesis. The alkethiol ethylene glycol ligand, HS-EC11-EG4, was 
purchased from Prochimia (ProChimia Surface Sp. z o.o., Sopot, Poland). Gold 
nanoparticles of 9 nm diameter stabilized in citrate buffer were purchased from 
British Biocell (BBInternational Ltd, UK) and silver nanoparticles of diameter 10 
nm from nanoComposix Inc. (CA, USA). Nanosep filters 10 kDa cut off were from 
PALL (PALL Corp., Portsmouth, and Hants, UK). UV-Vis spectra (2 nm 
incremental steps) were measured using a SpectraMax Plus spectrophotometer 
(Molecular Devices, Wokingham, UK) and 384 well plates from Corning (Lowell, 
US) and the concentration of gold nanoparticles and of silver nanoparticles 
determined at 450 nm (Haiss et al., 2007) and 392 nm (Paramelle et al., 2014) 
respectively. 
2.3 Nanoparticle synthesis 
2.3.1 Mix Matrix Nanoparticle preparation (AuNPs or AgNPs) 
Mix matrix ligands 70:30 (mole:mole) CVVVT-ol: HS-(CH2)11-EG4-OH were 
prepared as described (Duchesne et al., 2008a) by first diluting  35 µL CVVVT-ol 
(4 mM DMSO:H2O) with 35 µL ddH2O and 6 µL HS-C11-EG4-OH (2 mM) with 6 
µL EtOH and 18 µL ddH2O. Adding the two solutions together yielded a 2 mM 
ligand solution of 70% (mole/mole) CVVVT-ol and 30% (mole/mole) HS-C11-EG4-
OH. The ligand mixture was added to 900 µL (gold or silver) nanoparticles and 
vortex mixed. Once mixed, 100 µL of x10 phosphate-buffered saline (PBS: 137 
mM NaCl, 3 mM KCl l, 8 mM Na2HPO4, 15 mM KH2PO4) with Tween-20 (0.1 % 
v/v) pH 7.4 was added to gold nanoparticles (Duchesne et al., 2008a) and 10 x (100 
mM NaNO3, 20 mM HEPES (Free et al., 2012)  with Tween-20 (0.1 % v/v)  pH 7.4 
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to silver nanoparticles (Free et al., 2012), vortex mixed and the (gold or silver) 
nanoparticles placed on a rotating wheel for 24 h at room temperature. 
Nanoparticles were concentrated 10 x using 10 kDa Nanosep centrifugal filters 
(PALL Corp., Portsmouth, Hants, UK). Samples were centrifuged for 7 min at 
10000 g (~12,000 x g) and the gold nanoparticles diluted with 1 x PBST (PBS 
0.05% (v/v) Tween-20) and silver nanoparticles with 1x (100 mM NaNO3, 20 mM 
HEPES). Other ligand shells (Chapter 3) were synthesised by the same method, by 
varying the ligand and the relative ratio of the ligands. 
2.3.2 Chromatography 
2.3.3 Gel filtration  
Sephadex G25 was used to group separate AuNPs or AgNPs from small (<1000 
Da) molecules and to buffer-exchange AuNPs or AgNPs. In general, AuNPs or 
AgNPs were applied in volume no greater than 3% of the column volume, e.g. 100 
µL AuNPs or AgNPs on to a 3 mL Sephadex G25 column. The column was 
equilibrated in the required buffer and run in the same buffer. Columns were 
calibrated with blue dextran (elutes in V0) and potassium dichromate (elutes in Vi). 
AuNPs or AgNPs were easily recovered in the void volume, since they are bright 
pink and yellow respectively. 
2.3.4 Purification of functionalised (AuNPs or AgNPs) 
FluPep functionalised gold nanoparticles should bind to carboxymethyl CM 
Sepharose as the net charge of the FluPep ligand sequence is +6 (Table 2.1). FluPep 
functionalised nanoparticles were eluted by increasing electrolyte concentrations 
(Table 2.2). Thus, the FluPep functionalised (AuNPs or AgNPs) ion-exchanged on 
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this chromatography support, which is, therefore, suitable for their purification. 
Gold nanoparticles were synthesised with a range of mole % of FluPep ligand. After 
application of the (AuNPs or AgNPs) to the column, the non-functionalised ones 
were collected in the flow through and the functionalised ones eluted with1 M NaCl 
2.5 mM NaH2PO4. Quantification of the gold nanoparticles by UV-Vis 
spectrophotometry then allowed the relation of bound and unbound (AuNPs or 
AgNPs) to the mole % of FluPep in the original ligand mixture to be analysed. The 
data indicate that at 0.03% mole %, 10 % of the AuNPs bound the column and thus 
most (~95 %) of these (AuNPs or AgNPs) will possess just a single FluPep ligand 
(Levy et al., 2006a) At higher mole % the number of FluPep ligands per 
nanoparticle will increase. It is interesting to note that all the (AuNPs or AgNPs) 
were not observed to bind to the CM Sepharose column at higher mole % of FluPep 
ligand, something that has been observed previously with other functional peptides 
(Nieves et al., 2014, Paramelle et al., 2015). Nonetheless, the simple purification of 
the functionalised (AuNPs or AgNPs) means that the effects on influenza virus 
infectivity of mono- versus plurifunctionalisation can be determined. Moreover, 
since it is known that (AuNPs or AgNPs) passivated with the mix matrix (70:30 
molar ratio of SH-(CH2)11EG4 and CVVVT-ol) have an average of 1200 peptidols 
per nanoparticle (Duchesne et al., 2008a), it is possible to estimate the average 
number of FluPep ligands grafted on the gold nanoparticles by simply using their 
mole % in the ligand mixture. 
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2.3.5 Ion-exchange, hydrophobic and affinity chromatography 
Ion-exchange, hydrophobic and affinity chromatography were performed on 
homemade micro columns of diethylaminoethyl (DEAE), carboxymethyl (CM), 
phenyland nickel- nitrilotriacetic acid (Ni-NTA) Separose and heparin agarose. The 
chromatography gel was packed into a white pipette tip (200µL) using half the filter 
as a frit at the bottom and equilibrated in the appropriate buffer (Table 2.2). Capped 
AuNPs or AgNPs were concentrated on a Nanosep filter and exchanged into the 
appropriate buffer. Then, the AuNPs or AgNPs were applied to the column, the 
unbound fraction was recovered. Columns were washed with the eluted with the 
appropriate buffer (Table 2.2). The concentration of AuNPs and AgNPs in the 
different fractions was determined by measuring absorbance at 450 nm (Haiss et 
al., 2007) and  410 nm (Paramelle et al., 2015), respectively. 
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Table 2.2 Chromatography buffers, pH 7.4 
Chromatography 
gel 
Equilibration 
buffer 
Washing 
buffer 
Elution buffer 
1 
Elutionbuffer 
2 
Diethylaminoethyl 
(DEAE) Sepharose 
1 x PBS 1 x PBS 1 M NaCl in 
2.5 mM  
NaH2PO4 
pH 7.4 
2 M NaCl 
5 mM 
NaH2PO4 
pH 7.4 
Carboxymethyl (CM) 
Sepharose 
1 x PBS 1 x PBS 1 M NaCl 
2.5 mM  
NaH2PO4 
pH 7.4 
2 M NaCl 
5 mM  
NaH2PO4 
pH 7.4 
Phenyl Sepharose 1 x PBS 1 x PBS H2O  
0.1%(v/v)  
Triton-X-100 
pH 7.4 
H2O  
0.1%(v/v) 
Triton-X-100 
pH 7.4 
Ni-NTA Sepharose 20 mM Tris-
Cl 
 
pH 7.4 
20 mM 
Tris-Cl 
 
pH 7.4 
1 M imidazole 
in 20 mM 
Tris-Cl 
pH 7.4 
10 mM EDTA 
in 20 mM 
Tris-Cl 
pH 7.4 
Heparin agarose 1 x PBS 1 x PBS 1M NaCl 
2.5 mM  
NaH2PO4 
pH 7.4 
2M NaCl 
5 mM  
NaH2PO4 
pH 7.4 
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2.3.6 Sample and buffer flow considerations for microcolumns 
Initially it proved difficult to bind functionalised AuNPs to ion exchange gels. It 
was subsequently found that this was due to the flow rate on the micro columns 
being too fast. Ideally such columns should be run under gravity flow, but they are 
too small for this. Therefore, samples and buffers must be loaded slowly using a 
pipette with a maximum flow rate ~ 100 µL/90s to ensure sufficient contact time 
between the nanoparticles and the column. 
2.4 Direct functionalization of AuNPs and AgNPs 
AuNPs and AgNPs were functionalised with antiviral peptides via two routes. 
Directly by using an antiviral peptide incorporating the standard mix matrix peptide 
sequence at the N- terminus. Indirectly by reaction of a thiol at the antiviral peptide 
N-terminus with a maleimide on the AuNPs ligand shell. The antiviral peptides are 
based on the published nomenclature (Nicol et al., 2012a). The sequence and 
nomenclature of the peptides used is described in (Table 2.1). 
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Table 2.1 Antiviral peptides names and their amino acid sequences. FP4 and 
FP2 sequences are from (Nicol et al., 2012a) 
Peptide 
name 
Amino acid sequence MW 
FluPep WLVFFVIFYFFRRRKK 2252 
RRKK FluPep RRKKWLVFFVIFYFFR 2252 
FluPep   
RRKK
WLVFFVIFYFFR 1684 
FP2 WLVFFVIAYFAR 1531 
FluPep ligand CVVVTAAAWLVFFVIFYFFRRRKK 2967 
RRKK FluPep 
ligand 
CVVVTAAARRKKWLVFFVIFYFFR 2967 
FluPep ligand  
RRKK 
CVVVTAAAWLVFFVIFYFFR 2398 
H6FluPep 
ligand 
CVVVTAAAHHHHHHWLVFFVIFYFFRRRKK 3790 
FluPep 
ligandH6 
CVVVTAAAWLVFFVIFYFFRRRKKHHHHHH 3790 
Super FluPep 1 CVVVTAAARRPKGRGKRRREKQRWLVFFVIFYFF 4345 
Super FluPep 2 CVVVTAAARGAPRRGQRTRRKNKWLVFFVIFYFFR 4218 
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2.4.1 Functionalization with FluPep ligands 
To functionalise AuNPs and AgNPs directly with FluPep and its variants (Table 
2.1) were included in the ligand mix. The ligand shell was prepared as stated 
previously (Section 2.2), but the initial ligand mixture included the functionalised 
peptide at the mole % indicated in the figure legends. Then AuNPs from the rotating 
wheel were concentrated to ~ 100 µL with 10 kDa Nanosep centrifugal filters, by 
centrifugation for 7 min 10000 g. The AuNPs were diluted to 500 µL and the 
centrifugation repeated. As the functional peptides have a higher molecular weight 
than the Vi cut off of  Sephadex G25, this process was repeated 6 to 7 times to 
remove excess functional peptide. The grafting number of CVVVT-ol peptides for 
2 mM Mix matrix capped 10 nm AuNPs is around 1200 per nanoparticle (Duchesne 
et al., 2008a). The proportion of functional peptide in solution is assumed equal to 
the proportion of functional peptide on the AuNPs (Levy et al., 2006b). So to 
prepare AuNPs with different average numbers of FluPep, the mole % of FluPep in 
the ligand mix was varied. 
2.4.2 Indirect Functionalization of AuNPs  
A considerable amount of work was done on indirect functionalisation of 
nanoparticles, due to the initial inability to get functionalised nanoparticles to bind 
to chromatography supports (cation-exchange and affinity). However, as this issue 
was related to flow rate (Section 2.2.4) it was abandoned. The method is reported 
here, since it may be of use in the future.  
Mix matrix ligand were prepared as stated previously (Section 2.2) and included 
with peptides possessing both azide and 6xH functions (CVVVTHHHHHHN3, 
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CVVVT N3 HHHHHH), and left on the rotating wheel overnight. As with the 
FluPep ligands, the molecular weight of these functionalised peptides (> 1000 Da) 
meant they could not be removed by gel filtration of G25. Instead, AuNPs were 
subjected to at least 5 cycles of concentration to 100 µL and diluted to 500 µL in a 
10 KDa cut-off Nanosep filter (7 min centrifugation at 10000 g).The AuNPs were 
then subjected to nickel- affinity chromatography (Section 2.3) and their 
concentration determined. This was also used to demonstrate successful 
functionalization. The azide functionalised AuNPs were then reacted with a 
maleimide functionalised cyclooctyne (DIBO-Mal).  Samples were left overnight 
in dark on a rotating wheel to yield maleimide functionalised gold nanoparticles. 
The resulting  maleimide AuNPs were reacted with molecules containing a thiol 
group, FGF2 was used as a positive control (Nieves et al., 2014). Then AuNPs were 
coupled to FluPep ligand.  
Maleimide has a double bond which reacts with thiols to form a covalent thioether 
linkage. This is known as thiol-Michael addition. FGF2 was added in a 35-fold 
molar excess to increase the reaction yield. In the case of reaction with FluPep, it 
was important to remove any excess, unreacted FluPep, which might confound 
subsequent measurements of antiviral activity of AuNPs. Consequently, after 
reaction with FluPep, the reaction mixture was subjected to 6 to 7 cycles of 
concentration and dilution from 100 µL to 500 µL in 10 kDa cut-off Nanosep filters. 
2.5 UV-Visible spectrophotometry and nanoparticle quantification 
Absorption spectra of AuNPs and AgNPs were recorded using a Spectra Max 
spectrophotometer (Molecular Devices, Wokingham, UK), between 450 nm and 
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700 nm for gold nanoparticles and 410 nm to 600 for silver nanoparticles with 2 nm 
incremental steps. 
2.6 Dithiothreitol (DTT) ligand exchange  
2.6.1 Ligand exchange assay 
A one molar DTT stock solution was prepared. The stock solution was further 
diluted to give concentrations ranging from 0.05 to 500 mM. Purified ligand capped 
AuNPs or AgNP 57µL, 33 µL 10x PBS and 10 µL DTT solutions) at different 
concentrations (or milliQ water when the required concentration of DTT was 0 
mM) were added to a 384 well plate. A blank well, which only contained 100 µL 
of milliQ water, was used as reference. All samples were in assayed in duplicate. 
2.6.2 Calculation of Aggregation Parameter (AP) 
The surface plasmon absorption peak of 8.8 nm diameter gold nanoparticles is at 
520 nm. When gold nanoparticles are aggregated, their surface plasmons couple 
causing a red shift in their plasmon absorbance to nearly 650 nm. The aggregation 
parameter (AP) was defined as (A 650 nm – A ref 650 nm)/ (A520 nm – A ref 520), where A 
650 nm and A520 nm are the absorbance of gold nanoparticles at 650 nm and 520 nm, 
respectively, and Aref650nm and Aref520 are the absorbance of water at 650 nm and 520 
nm, respectively (Chen et al., 2012). For comparison of results, this primary 
stability parameter was normalised by dividing the AP value of control ligand 
capped AuNPs measured in milli Q water where [DTT] = 0. 
For silver nanoparticles diameter ~10 nm with a ligand shell the surface plasmon 
absorption peak is at 410 nm. Consequently, the AP for silver nanoparticle was 
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defined as (A 600 nm-A ref 600 nm)/ (A410 nm-A ref 410), where A 600 nm and A 410 nm are the 
absorbance of Ag nanoparticles at 600 nm and 410 nm, respectively and A ref 600 nm 
and A ref 410 are the absorbance of water at 600 nm and 410 nm, respectively. 
2.7 Tissue culture 
2.7.1 Cell culture  
Madin-Darby canine kidney epithelial cells (MDCK) were grown in Dulbecco’s 
Modified Eagle’s Medium supplemented with 5% (v/v) bovine serum, 1% (v/v) of 
200 mM L-Glutamine, 1% (v/v) 100 U/mL penicillin and 1% (v/v) 100 µg/mL 
streptomycin and incubated at 37°C under 5% (v/v) CO2 atmosphere. Cells were 
passaged with 0.05% (v/v) trypsin along with the chelating agent, 1x Versene-
EDTA (Gibco, life technologies, UK). 
2.7.2 Cell freezing and thawing 
The cells were released from the cell dish by trypsin digestion (Section 2.6.1) and 
9 mL cell culture medium was added. The cells were counted, placed in a 20 mL 
universal tube and collected by centrifugation at 800 g for 5 minutes. The 
supernatant was discarded and the cell pellet was resuspended in freezing medium 
(14.5 mL Dulbecco’s modified Eagle’s medium (DMEM, Life technologies), 1.5 
mL dimethyl sulfoxide and 4 mL FCS to obtain the desired cell concentration 
(1~1.5 x 106 cells/mL). The cells (1 mL) in freezing medium were placed in 1.5 mL 
cryotubes and transferred to a -80oC freezer. The frozen cells were stored in a -
140oC freezer. The cells taken out from freezer were thawed at 37oC in a water bath. 
Then, the cells were transferred into a universal tube and 20 mL thawing medium 
(16 mL DMEM medium and 4 mL FCS) was slowly added. The cells in the thawing 
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medium were collected by centrifugation at 800 g for 5 minutes and 10 mL cell 
culture medium was added to resuspend cells, which were then placed into a 10 cm 
dish and transferred to the 37 oC incubator. 
2.7.3 Cell counting 
There are two methods for cell counting, both of which were used, depending on 
availability.  
 Coulter counter method, detached cells (0.5 mL) were diluted to 20 mL with 
coulter Isoton II diluent (Beckman Coulter). The cells were counted in a 
Coulter Electronics particle counter. Cells from each dish were counted 
three times. 
 Hemocytometer: 
  Using a pipette, take 100 μL of trypan blue-treated cell suspension and 
apply to the hemocytometer.  Very gently fill both chambers underneath the 
coverslip, allowing the cell suspension to be drawn out by capillary action.  
 Using a microscope, focus on the grid lines of the hemocytometer with a 
10X objective. 
 
 Using a hand tally counter, count the live, unstained cells (live cells do not 
take up trypan blue) in one set of 16 squares. When counting, employ a 
system whereby cells are only counted when they are within a square or on 
the right-hand or bottom boundary line. Following the same guidelines, 
dead cells stained with trypan blue can be also be counted for a viability 
estimate if required. 
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 Move the hemocytometer to the next set of 16 corner squares and carry on 
counting until all four sets of 16 corner squares are counted. 
2.8 Influenza virus preparation 
2.8.1 Preparation of influenza virus stock 
To infect a T25 flask of MDCK cells, cells were grown to 90% confluence, which 
corresponds to 7 x 106 cells. Then, the cell monolayer was washed with 2 x 5 mL 
PBS. Then, virus was added to the cells at a multiplicity of infection (MOI) (Section 
1.3.1) of 0.001 in 2 mL DMEM, made up by adding 7 µL virus stock to 1993 µL 
DMEM. Cells were incubated with virus for 1 h at 37 0C on a rocking platform or 
flasks were manually rocked every 10 mins.  A stock of 2.5 µg/mL N-acetyl trypsin 
was prepared by adding 125 uL from the original stock (100 µg/mL) to 4875 uL 
DMEM. Virus containing medium was removed and the cell monolayer washed 
with 2 x 5 Ml DMEM. The N-acetyl trypsin in DMEM was added to the flask and 
cells were incubated 24 – 48 h at 370C until the cytopathic effect (CPE) had 
developed to a point where the cells were lifting from the flask surface. Medium 
was removed and centrifuged for 5 min at 2500 g to remove cell debris and this 
viral stock was stored at -800C.    
2.8.2 Determination of influenza virus titre by plaque assay 
Serial dilution of the virus was prepared by pipetting 990 µL of DMEM (containing 
Pen/Strep and L-Glutamine) in a 5 mL bijoux and 10 µL of stock virus to give a 
100-fold dilution followed by serial 10-fold dilutions. This was repeated down to 
10-8. Virus (400 µL) from each bijoux was added to duplicate wells, and the number 
of plaques determined (Section 2.7.3). 
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2.8.3 Anti-viral activity of AuNPs incorporated with FluPep 
The purified nanoparticles functionalised with the appropriate FluPep at different 
mole % (Section 2.3) were diluted in PBS as appropriate and mixed with virus. The 
mixture of virus and AuNPs was then added to the cells (Section 2.7.5). 
2.8.4 Influenza virus plaque assay 
Two days prior to infection, six well plates were set up with 0.5 x 106 MDCK cells 
per well. When the cells were confluent, medium was removed and wells were 
washed with PBS twice prior to infection. The monolayers of MDCK cells were 
then infected with a dilution of ‘flu virus stock (A/WSN/33 H1N1 subtype, Section 
2.7.1) required to obtain around 100 plaques per well.  
2.8.5 Infection with flu viruses 
Serial dilutions of the virus were prepared by pipetting 990 µL serum free DMEM 
(containing Pen/Strep and L-Glutamine) in a bijoux with 10 µL of stock virus to 
give a first 10-2 dilution followed by serial 10-fold dilutions. This was repeated 
down to 10-8. 400 µL from each bijoux was added to the corresponding wells in 
duplicates. Plates were then placed in the 37 oC incubator and rock every 10 minutes 
for 1 hr. 
2.8.6 Gel agarose overlay  
 Low melting agarose (2% w/v) was melted in sterile distilled water and kept at 55 
0C in a water bath prior to use. To make the overlay medium, 50 mL 10 x MEM 
medium was mixed with 10 µL of a 10 mg/mL stock of N-acetyl trypsin bovine 
pancreas type V-S was added to give a final concentration of 2 µg/mL. This was 
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then divided into two 25 mL volumes and kept at 37 0C. After 1 h of infection with 
virus, the medium was removed from the culture dishes. Then, 25 mL of the 2 % 
(w/v) agarose was quickly added to one of the 25 mL aliquots of 2x MEM medium. 
This was mixed and 2 mL added to each well, left for 15 minutes to set, and then 
plates were inverted and placed back in the incubator for 3 days. 
2.8.7 Fixing and staining of cells 
After approximately three days post-infection, cells were fixed with 4 mL 10% (v/v) 
neutral buffered formalin (Leica Biosystems Peterbrough Ltd, Bretton 
Peterborough, Cambridgeshire for 1 hr. Then the 10% (v/v) neutral buffered 
formalin was removed, the agarose overlay was discarded and plates were stained 
with 0.1% (w/v) toluidine blue in water or 20 minutes, washed with water and left 
to dry before counting plaques. 
 2.8.8 Determination of IC50 
A dose-response curve describes the relationship between increasing the 
concentration of the compound and the change in response that is measured in the 
biological system. In this Thesis compounds are peptides and nanoparticles and the 
response is the number of plaques caused by ‘flu virus in MDCK cells. In the case 
of inhibitors, the concentration at which half the biological response is inhibited is 
the IC50. This provides a convenient way to compare different experiments with 
different compounds. IC50 was calculated using Prism and a. step-by-step example 
is given to guide Prism users through constructing sigmoidal curves from dose–
response data. The steps in this example are outlined here: 
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 Enter data – Create a data table for dose-response data.  
 Transform X values to log form – Alter the number format of the X values.  
 Normalize the Y values – Express Y values from different data sets on a 
common scale.  
 Nonlinear regression – Use an equation defined in Prism to determine 
specific parameter values for your data. 
 Compare the curves statistically – Use Prism to determine whether two 
curves are statistically different.  
 Review the graph – Check that the data and the analysis agree. 
 Review the results – View and interpret the results of the analysis. 
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2.9 Results 
 
2.9.1 Resistance of mix matrix nanoparticles to DTT ligand exchange 
Standard mix matrix nanoparticles with 70% CVVVT-ol and 30% HS-(CH2)11EG4 
(both mole/mole) were synthesized (Section 2.2.1). After purification of the 
nanoparticles from excess ligands on Sephadex G25, they were subjected to a DTT-
ligand exchange stability test (Section 2.5.1). The normalised aggregation 
parameter of the mix matrix didn’t change up to 10 mM DTT, even after 24 h 
incubation. However, at 5 mM DTT after 48 h there was some evidence for ligand 
exchange, as the aggregation parameter was above 1.0 and at 10 mM DTT the 
ligand shell was clearly compromised at this time (Fig. 3.1) Therefore, these 
nanoparticles were similar in terms of their resistance to ligand-exchange to those 
made previously by others (Chen et al., 2012). 
 
Fig. 2.1. Stability of mix matrix gold nanoparticles to DTT ligand exchange 
Time and dose-dependence of DTT ligand exchange for mix matrix gold 
nanoparticles. The molar ratios of the ligands are indicated in the legend. Results 
are the mean ± SD (n=3). 
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As noted in (Section 3.1), there is evidence that combinations of ligands other than 
the standard mix matrix may be more stable, at least with respect to ligand exchange 
(Duchesne et al., 2008a, Chen et al., 2012). To explore this, a selection of different 
peptidols were used in combination with the alkane thiol ethylene glycol HS-
(CH2)11EG4, as well as some peptides on their own. However, since Flupep ligand 
was considered to have the potential to alter the chromatography of nanoparticles, 
the interaction of Flupep ligand functionalised nanoparticles with different 
chromatography matrices was first determined.  
2.9.2 Functionalisation of gold nanoparticles with FluPep and their interaction 
with chromatography matrices 
The mix matrix ligand shell of 70:30 (mole/mole) peptidol and alkanethiol ethylene 
glycol assembled on gold nanoparticles has well characterised stability with respect 
to ligand exchange and non-specific binding (Duchesne et al., 2008a, Chen et al., 
2012).  In all cases the nanoparticles capped by the standard mix matrix ligand shell 
did not bind to either CM Sepharose or DEAE Sepharose in 20 mM Tris-Cl, pH 7.2 
(Fig 3.2). This is consistent with previously published data (Duchesne et al., 2008a) 
and indicates that these nanoparticles do not have a non-specific interaction with 
Sepharose, DEAE or CM groups. However, when gold nanoparticles with this 
ligand shell were applied to a phenyl Sepharose column they all bound (Fig. 3.2C). 
This indicates that the mix matrix ligand shell results in a fairly hydrophobic 
nanoparticle. Indeed, attempts at eluting the mix matrix nanoparticles from the 
column with 1 % (v/v) Triton-X-100 were unsuccessful. 
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Fig. 2.2. CM, DEAE and phenyl Sepharose HIC column chromatography of 
purified gold nanoparticles with a mix matrix ligand shell. Homemade mini 
columns were prepared (Section 2.2.5) and equilibrated in 20 mM Tris HCl 
(pH7.2). Nanoparticles, in some cases functionalised with FluPep ligand (Section 
2.3) were applied to the column and if bound, elution was attempted with a suitable 
buffer. (A) Mix matrix gold nanoparticles applied to DEAE Sepharose. (B) Mix 
matrix gold nanoparticles applied to CM Sepharose. (C) Mix matrix gold 
nanoparticles applied to phenyl Sepharose. Mix matrix gold nanoparticles 
functionalised with 0.1% (D), 3% (E) and 5 % (F) FluPep ligand (all mole/mole) 
were applied to DEAE Sepharose. (G) Mix matrix gold nanoparticles functionalised 
with 0.1% (G), 3% (H) and 5% (I) FluPep ligand (all mole/mole) were applied to 
CM Sepharose. (J) Mix matrix gold nanoparticles functionalised with 0.1% (J), 3% 
(K) and 5% (L) gold nanoparticles- FluPep ligand applied to a phenyl Sepharose 
column. The arrow indicates the reddish/pink band where nanoparticles have bound 
to the column. 
 
Gold nanoparticles were then functionalised with different mole % of FluPep ligand 
and purified from excess ligand using size-exclusion chromatography on Sephadex 
G25 and filtration on a 10 kDa cut off filter (Section 2.2.4). FluPep ligand 
functionalised nanoparticles did not bind to DEAE Sepharose (Figs 2.2 D-E), so 
FluPep ligand in itself does not bind to Sepharose or DEAE.  FluPep ligand when 
incorporated into a ligand shell will have a net charge of +6. Not surprisingly, when 
purified FluPep ligand functionalised gold nanoparticles were applied to a CM 
Sepharose they bound (Figs 2.2 G-I).  FluPep ligand is quite hydrophobic and gold 
nanoparticles functionalised with it bound to phenyl Sepharose (Figs 2.2 J-L). 
However, the underlying hydrophobicity of the mix matrix ligand shell (Fig. 2.2C) 
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means that hydrophobic interaction chromatography cannot be used to separate 
FluPep ligand functionalised gold nanoparticles from non-functionalised ones. 
2.9.3 Stability of gold nanoparticles functionalised with different peptidols 
2.9.3.1 Overview 
Different peptidols were combined with the alkane thiol ethylene glycol (Table 2.3) 
to test various hypotheses regarding how the stability of the standard mix matrix 
nanoparticles might be improved. Another motivation was the observation that mix 
matrix nanoparticles are quite hydrophobic and bind strongly to phenyl Sepharose 
(Fig. 3.2). This property does not lead to substantial non-specific binding on cells 
(Duchesne et al., 2012). However, it precludes advantage being taken of the 
hydrophobicity of FluPep for the purification of FluPep ligand functionalised 
nanoparticles (Fig. 2.2). Thus, reducing the hydrophobicity of the ligand shell 
would allow the use of hydrophobic interaction chromatography for the purification 
of the functionalised nanoparticles.  
CVT-ol was used because it has been reported that shortening the peptidol enhances 
stability (Chen et al., 2012). This is counterintuitive, since the pentapeptidol 
CVVVT-ol is roughly the same length as the alkane unit of the alkane thiol ethylene 
glycol. Then, a series of peptidols with charged or polar groups in the stem between 
the cysteine and the C-terminal threoninol were used, to see if the supplementary 
H-bonding capacity might increase the stability of the ligand shell. Finally, 
peptidols alone, without the alkane thiol ethylene glycol, and a peptide with a 
zwitterionic C-terminus were tested, as these might provide high stability, but not 
interact non-specifically with charged macromolecules. 
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Table 2.3. Ligand shell types and the sequences of the peptidol and peptide ligands 
 
2.9.3.2 CVT-ol 
Published data indicated that shortening the peptidol would enhance the stability of 
the nanoparticles, so CVT-ol was used in a ligand mixture as 70 % CVT-ol : 30 % 
HS-(CH2)11EG4 (both mole/mole) to passivate  gold nanoparticles. The stability of 
the nanoparticles passivated with this ligand shell against DTT ligand exchange was 
determined. The results showed that the normalised aggregation parameter was 
unchanged up to 25 mM DTT after 24 h. However, at 5 mM after 48 h, the 
Ligand shell type Ligand shell sequence 
Short peptidol CVT-ol 
charged group position 3 (K or 
D) 
CVKVTol, CVDVTol 
serine backbone CSSSS-ol 
polar group at position 3 CVNVT-ol 
zwitter ionic C- terminus CVVVK-OH 
Mix of all above CVNVTol+CVDVTol 
CVNVTol+CVKVTol 
CVNVTol+CSSSSol 
CVDVTol+CVKVTol 
peptides with a terminal 
carboxylic acid 
CALNN-OH 
peptidols with an amine CVVVK-ol 
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normalised aggregation parameter started to rise above 1, and at 10 mM after 48 h 
the normalised aggregation parameter showed clearly that the nanoparticles had 
aggregated and so had undergone substantial ligand exchange (Fig 2.2 A). The 
proportion of CVT-ol peptidol in the Mix matrix was varied from the standard 
(70:30, 50:50 and 30:70) and compared to HS-EC11-EG4. The normalised 
aggregation parameter is shown for the 48 h time point. The normalised aggregation 
parameter for 50:50 (mole/mole) varied similarly to the 70:30 (mole/mole) mixture 
(Figs 2.3 A, B). However, the 30:70 (mole/mole) mixture of CVTol and HS-EC11-
EG4 was more stable since at 48 h the aggregation parameter remained at 1 up to 
10 mM DTT and only increased at 25 mM DTT (Fig 2.3 B). This is consistent with 
the high stability of the HS-EC11-EG4 ligand shell (Fig. 2.3 B).  
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Fig. 2.3. Stability of gold nanoparticles capped with CVT-ol and HS-EC11-EG4 
to DTT ligand exchange (A) Time and concentration dependence of DTT ligand 
exchange for gold nanoparticles with a ligand shell of 70% CVT-ol: 30% HS-EC11-
EG4 (both mole/mole). (B) Concentration-dependence of DTT ligand exchange of 
nanoparticles capped with different mole% of CVT-ol and HS-EC11-EG4. The molar 
ratios of the ligands are indicated in the legend. Results are the mean ± SD (n=3). 
 
2.9.3.3 Effect of a charged amino acid side chain at position 3 in the peptidol 
The effect of either charged amino acids K or D at position 3 were investigated by 
synthesising nanoparticle ligand shells with different mole % of CVDVTol and 
CVKVTol and the alkane thiol ethylene glycol ligand (70:30, 50:50 and 30:70). 
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The results shown that after 24 h the aggregation parameter for CVDVTol and 
CVKVTol 70:30 and 50:50 was unchanged up to 10 mM DTT, while at 25 mM 
DTT this increased to ~ 4.6 for CVDVTol and ~4 CVKVTol, indicating 
nanoparticle aggregation. However, for 30:70  nanoparticles with either CVDVTol 
or CVKVTol the aggregation parameter unchanged until 25 mM and at 50 mM the 
aggregation parameter reached about 4.6 (Fig 2.4 A).  
 
Fig. 2.4. Stability of mix matrix gold nanoparticles to DTT ligand exchange A 
Time and dose-dependence of DTT ligand exchange for mix matrix gold 
nanoparticles for CVDVTol and CVKVTol ligand shell after 24 h. B after 48 h. The 
molar ratios of the ligands are indicated in the legend. Results are the mean ± SD 
(n=3). 
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However, after 48 h the relative stability of the different formulations of the ligand 
shells changed for CVKVTol. Thus, for ligand shells comprising CVDVTol and the 
alkane thiol ethylene glycol, the rank order of stability remained the same as at 24 
h: increasing the proportion of alkane thiol ethylene glycol to 70% (mole/mole) 
increased the resistance of the nanoparticles to DTT ligand exchange. However, for 
ligand shells with CVKVTol the nanoparticles with 70 % (mole/mole) alkane thiol 
ethylene glycol were less stable than those with a lesser mole % of this ligand in 
the mixture (Fig 2.4 B). Compared to the standard mix matrix (Fig. 2.1), 
incorporating a charged amino acid at position 3 either had no effect on the stability 
of the nanoparticles to ligand exchange or it increased it by a factor of around two. 
This suggests that increasing the H-bonding capacity of the peptidol in the ligand 
shell may increase the stability of that ligand shell to ligand-exchange. 
2.9.3.4 Effect of polar amino acids  
The effect of polar amino acids S and N were investigated by synthesising ligand 
shells with different mole % of CVNVTol and CSSSSol (70:30, 50:50 and 30:70) 
and alkane thiol ethylene glycol. It was expected that these would also be able to 
form additional H-bonds within the ligand shell. Interestingly, ligand shells with 
these peptides were either less resistant to ligand exchange with DTT than the 
standard mix matrix (CVNVT-ol, 70 % mole/mole) or similar Fig. 2.5). Thus, it 
would appear that incorporating a basic or acidic amino acid in the middle of the 
peptidol (Fig. 2.4) is more effective than an amide or using an entirely polar peptidol 
(Fig. 3.4). 
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Fig. 2.5. Stability of gold nanoparticles capped with mixtures of polar peptidols 
and alkane thiol ethylene glycol ligands to DTT ligand exchange (A) Ligand 
exchange after 24 h incubation with different concentrations of DTT for gold 
nanoparticles capped with CVNVTol or CSSSSol and alkane thiol ethylene glycol 
ligands after 24 h and (B) after 48 h. The molar ratios of the ligands are indicated 
in the legend. Results are the mean ± SD (n=3). 
2.9.3.5 Effect of combining different peptidols 
The effect of combining of different peptidols which might enhance mix matrix 
stability was investigated by synthesising ligand shells form mixtures with different 
mole % of peptidols with a polar or charged amino acid at position 3:  
CVNVTol+CVDVTol and CVNVTol+CVKVTol with the alkane thiol ethylene 
glycol ligand at rations of 70:30, 50:50 and 30:70. It would appear that the presence 
of the asparagine at position 3 has a greater impact on the resistance of the 
 ` 
72 
 
nanoparticles to ligand exchange than either of the two charged residues (Fig. 2.6). 
That is the stability against DTT ligand exchange of these nanoparticles resembles 
most that of the nanoparticles with a ligand shell comprising CVNVTol and the 
alkane thiol ethylene glycol (Figs 2.6A, B). 
When the peptidols CSSSS-ol and CVNVT-ol were incorporated into mixed ligand 
shells they did not enhance the stability of the nanoparticles in ligand exchange tests 
(Figs 2.6 C). Thus, the incorporation of polar residues into the peptidol at best did 
not improve the resistance of the nanoparticle ligand shell to exchange with DTT, 
but in some cases reduced stability, with respect to the standard mix matrix ligand 
shell (Fig. 2.1)    
The two peptidols with a charged residue were also combined, on the grounds that 
these may form a salt bridge in the ligand shell. Again these pairs were used with 
the alkane thiol ethylene glycol at different molar ratios of total peptidol (70:30, 
50:50 and 30:70). These combinations were at least as resistant to ligand exchange 
with DTT (Figs 2.6 C, D) as the mix matrix ligand shell (Fig. 2.1) and in some cases 
more stable, but they did not impart greater stability that when used alone with the 
alkane thiol ethylene glycol (Fig. 2.4). 
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Fig. 2.6. Stability of combining different peptidols mix matrix gold 
nanoparticles to DTT ligand exchange A Time and dose-dependence of DTT 
ligand exchange for of polar amino acids peptidols + charged amino acids 
CVNVTol+CVDVTol and CVNVTol+CVKVTol mix matrix gold nanoparticles 
after 24 h. B after 48 h. C.  Time and dose-dependence of DTT ligand exchange for 
polar and charged amino acids CVNVTol+CSSSSol and CVDVTol+CVKVTol 
after 24 h. D after 48 h.  The molar ratios of the ligands are indicated in the legend. 
Results are the mean ± SD (n=3). 
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2.9.3.6 Effect of charge at the C-terminus 
The introduction of charge at the C-terminus of the peptide would in principle 
reduce the hydrophobicity of the ligand shell, particularly if this was sufficiently 
stable to reduce and even omit the alkane thiol ethylene glycol, which will 
contribute to the hydrophobicity of the ligand shell. However, this is known to 
reduce the stability of the nanoparticles to ligand exchange (Chen et al., 2012, 
Duchesne et al., 2008a). The effect of charge at the C-terminus was investigated by 
synthesising ligand shells of CVVVKOH (C-terminal zwitterion) or CVVVKol (C-
terminal amine) with the alkane thiol ethylene glycol at molar rations of 70:30, 
50:50 and 30:70. Although little aggregation was apparent at 24 h (Fig. 3.7 A), at 
48 h the 70:30 molar ratio ligand shells were as susceptible to ligand exchange as 
the control mix matrix (Figs 2.1 and 2.7 B).  
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Fig. 2.7. Stability of charge at the C-terminus mix matrix gold nanoparticles 
to DTT ligand exchange A time and dose-dependence of DTT ligand exchange for 
mix matrix gold nanoparticles for CVVVKOH and CVVVKol ligand shell after 24 
h. B after 48 h. The molar ratios of the ligands are indicated in the legend. Results 
are the mean ± SD (n=3). 
Further experiments were performed with the peptide that had a C-terminal 
zwitterion, (CVVVK-OH, which was compared to a peptide with a terminal 
carboxylic acid (CALNN-OH). These were in some experiments mixed with the 
alkane thiol ethylene glycol. Neither CVVVK-OH nor CALNN-OH alone was able 
to prevent DDT mediated ligand exchange after 1 h (Fig. 2.8A). The relative 
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instability of the CALNN ligand shell in this assay has been noted previously(Chen 
et al., 2012) and the zwitterion terminated peptide was no more stable. Addition of 
even a small mole % of the alkane thiol ethylene glycol increased the resistance of 
the ligand shell to ligand exchange (Figs 2.8A-C). However, where their stability 
was greater than the standard mix matrix ligand shell (Fig. 2.1) this can be attributed 
by an increased mole % of the alkane thiol ethylene glycol ligand.  
Fig. 2.8. Stability of A zwitterion of (CVVVK-OH), peptides with a terminal 
carboxylic acid (CALNN-OH) mix matrix gold nanoparticles to DTT ligand 
exchange A Time and dose-dependence of DTT ligand exchange for mix matrix 
gold nanoparticles for CVVVKOH and CALNN ligand shell after 1h.  B 24 h. C 
after 48 h. The molar ratios of the ligands are indicated in the legend. Results are 
the mean ± SD (n=3) 
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2.9.4 Discussion  
 
The planned work with ‘flu virus (Chapters 3 and 4) will entail incubating live cells 
in culture medium with nanoparticles for around three days, since this is the time 
required for the formation of plaques (Section 2.7.4). Previous work with 
functionalised mix matrix nanoparticles has only involved much shorter contact 
time of the nanoparticle with the culture medium and the cell (Duchesne et al., 2012, 
Nieves et al., 2015)). Resistance of the nanoparticle ligand shell to ligand exchange 
by small thiols will be very important, since cell culture medium contains ~ 1 mM 
cysteine, which though less effective than DTT, does cause ligand exchange (Chen 
et al., 2012), and this may be more pronounced over three days in the presence of 
the many other medium components. Consequently, ligand shells that were not as 
resistant as the mix matrix one were considered to be too high risk to use. Moreover, 
since the mix matrix ligand shell is well established for using nanoparticles as 
probes with cells, it was decided that a substantial improvement in resistance to 
DTT ligand exchange (~10-fold) would be necessary for the ligand shell to be 
changed with confidence. 
Mix matrix gold nanoparticles were synthesized that had the same resistance to 
ligand exchange (Fig. 2.1) and absence of binding to Sephadex, Sepharose, 
carboxylic acids and amines (Fig. 2.2) as in previous work (Chen et al., 2012). 
However, these nanoparticles were observed to be very hydrophobic (Fig. 2.2), 
which was surprising, since they had been shown to exhibit little non-specific 
binding to cells (Duchesne et al., 2012, Nieves et al., 2015). However, it should be 
noted that hydrophobicity had never been examined before. As there were 
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indications in previous work that there may be more stable ligand shells, attempts 
were  made to build on these data to design a more stable ligand shell, and also to 
determine whether a less hydrophobic, but equally stable one could be identified. 
The results were mixed. Some combinations of ligands were a little more resistant 
to ligand exchange, but the difference compared to the mix matrix was not 
considered to be large enough to pursue. This is because of the demonstration by 
others that the mix matrix ligand shell performs well in the context of living cells 
(Duchesne et al., 2012, Nieves et al., 2015). Changing the ligand shell on the 
grounds of an incremental increase in vitro stability was thought to be too high a 
risk. The ligand shells with a terminal charge, including those synthesised with 
zwitterionic ligands were considered to have reduced the stability of the 
nanoparticle to too great an extent to be useful in the planned work with ‘flu virus.  
On a more positive note, FluPep ligand functionalised nanoparticles were shown to 
bind to CM-Sepharose, but not DEAE-Sepharose. Since the control nanoparticles 
did not do so and mix matrix nanoparticles are stable in high electrolyte 
concentrations (Duchesne et al., 2012), these data mean that FluPep ligand 
functionalised nanoparticles should be easily purified from non-functional ones by 
cation-exchange chromatography. The principle of purification of functionalised 
nanoparticles by ion-exchange chromatography is demonstrated by the successful 
of purification of mix matrix nanoparticles functionalised with an acidic peptide on 
DEAE Sepharose (Paramelle et al., 2015). Therefore, the purification of FluPep 
ligand nanoparticles on CM-Sepharose was considered to be the method of choice 
for this step. 
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2.9.5 Conclusion   
Gold nanoparticles were passivated successfully with a ligand shell called mix 
matrix, composed of 70% of CVVVTol:30% HS-EC11-EG4 (both mole/mole), 
which provided protection against non-specific binding to DEAE and CM 
Sepharose, Sephadex, and stability against electrolyte induced aggregation. 
However, nanoparticles passivated with the mix matrix bound to phenyl Sepharose 
indicating a high degree of hydrophobicity. Many attempts were made to reduce the 
hydrophobicity of the ligand shell. The results identified ligand mixtures that in 
some instances enhanced stability a little, but without a major effect on the 
hydrophobicity. Thus, it was decided that these ligand shell were not, from an 
experimental point of view, substantially better than the original mix matrix. 
Consequently, the remainder of the work in this thesis used the mix matrix ligand 
shell to passivated gold and silver nanoparticles. Gold nanoparticles were 
functionalised with different mole % of FluPep. FluPep functionalisation did not 
alter the stability of the nanoparticles, but did allow the nanoparticles to bind to CM 
Sepharose in an electrolyte-dependent manner, due to the RRKK C-terminal 
sequence on FluPep. 
Aplaque assay demonstrated that the gold nanoparticles functionalised with FluPep 
inhibited ‘flu virus infectivity. Thus FluPep conjugated to gold nanoparticles 
retained its antiviral activities. 
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Chapter 3  
 
3.1 Introduction 
FluPep WLVFFVIFYFFRRRKK is potentially a new treatment for ‘flu virus 
infection; it was demonstrated by (Nicol et al., 2012b) that influenza A virus, 
including the H1N1 subtype, was strongly susceptible to inhibition by FluPep in 
cell and animal models (Section 1.5.2.3 ). This was promising, but there remains 
important questions regarding the mechanism of action of FluPep. To elucidate this 
question requires a sensitive probe to be attached to FluPep. Gold and silver 
nanoparticles were used due to their optical properties (Sections 1.4.2 and 1.4.5), 
which means these have the highest extinction coefficient and can be detected by 
UV-Vis spectroscopy at very low concentration. Moreover, photothermal 
microscopy, an optical technique, and transmission electron microscopy enable 
single nanoparticle detection, the latter at the subcellular scale, should this be 
required. The high density of these noble metal nanoparticles also enables easy 
separation. In Chapter 2 it was established that the mix matrix ligand shell of 70 % 
peptidol and 30 % (both mole/mole) is suitable for the synthesis of FluPep 
functionalised gold nanoparticles. In this chapter, the synthesis and purification of 
FluPep ligand functionalised gold and silver nanoparticles is described. The 
stability of the nanoparticle-FluPep conjugates in vitro has been determined and 
their anti-viral activity established. This work lays the foundation for the 
subsequent analysis of the mechanism of action of FluPep and the design of more 
effective peptides in Chapter 4.   
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3.2 Enhanced inhibition of influenza virus infection by peptide-nanoparticle 
conjugates 
Section 3.2 is based on a preprint ref. https://www.biorxiv.org/content/early/2018/05/17/324939 
3.2.1 Materials & methods 
3.2.1.1 Materials 
3.2.1.2 Peptides and nanoparticles 
Peptides FluPep WLVFFVIFYFFRRRKK, FluPep ligand 
CVVVTAAAWLVFFVIFYFFRRRKK and the ligand shell matrix peptidol 
CVVVT-ol were purchased from Peptide Protein Research (PPR Ltd, Hampshire, 
UK). The alkethiol ethylene glycol ligand, HS-EC11-EG4, was purchased from 
Prochimia (ProChimia Surface Sp. z o.o., Sopot, Poland). Gold nanoparticles of 9 
nm diameter stabilized in citrate buffer were purchased from British Biocell 
(BBInternational Ltd, UK) and silver nanoparticles of ~10 nm diameter from 
nanoComposix Inc. (CA, USA). Nanosep filters 10 kDa cut off were from PALL 
(PALL Corp., Portsmouth, and Hants, UK). UV-Vis spectra (2 nm incremental 
steps) were measured using a SpectraMax Plus spectrophotometer (Molecular 
Devices, Wokingham, UK) and 384 well plates from Corning (Lowell, US) and the 
concentration of gold nanoparticles and of silver nanoparticles determined at 450 
nm (Haiss et al., 2007) and 392 nm (Paramelle et al., 2014), respectively. 
3.2.2 Nanoparticle synthesis 
3.2.2.1 Synthesis of FluPep functionalised nanoparticles  
Mix matrix ligands 70:30 (mole:mole) CVVVT-ol: HS-(CH2)11-EG4-OH were 
prepared as described (Duchesne et al., 2008a) by first diluting  35 µL CVVVT-ol 
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(4 mM DMSO:H2O) with 35 µL ddH2O and 6 µL HS-C11-EG4-OH (2 mM) with 6 
µL EtOH and 18 µL ddH2O. Adding the two solutions together yielded a 2 mM 
ligand solution of 70% (mole/mole) CVVVT-ol and 30% (mole/mole) HS-C11-EG4-
OH. The ligand mixture was added to 900 µL (gold or silver) nanoparticles and 
vortex-mixed. Once mixed, 100 µL of 10 x phosphate-buffered saline (PBS: 137 
mM NaCl, 3 mM KCl l, 8 mM Na2HPO4, 15 mM KH2PO4) with Tween-20 (0.1 % 
v/v) pH 7.4 was added to gold nanoparticles (Duchesne et al., 2008a) and 10 x (100 
mM NaNO3, 20 mM HEPES (Free et al., 2012)  with Tween-20 (0.1 % v/v)  pH 7.4 
to silver nanoparticles (Free et al., 2012), vortex mixed and the (gold or silver) 
nanoparticles placed on a rotating wheel for 24 h. Nanoparticles were concentrated 
10-fold using 10 kDa Nanosep centrifugal filters (PALL Corp., Portsmouth, Hants, 
UK). Samples were then centrifuged for 7 min at 10000 rpm (~12,000 x g) and the 
gold nanoparticles diluted with 1 x PBST (PBS 0.05% (v/v) Tween-20) and silver 
nanoparticles with 1x (100 mM NaNO3, 20 mM HEPES). The nanoparticles were 
then further separated from excess ligands by applying them (100 µL) to a 5 mL 
Sephadex G25 gel filtration column with PBS as a mobile phase.  
To functionalise the nanoparticles with FluPep ligand, this was incorporated into 
the initial ligand mix at the mole % indicated in the figure legends. However, the 
separation of free FluPep ligand (Mw 2967 Da) required, in addition to the final 
gel-filtration on Sephadex G25, six washes, each wash involving a 10-fold dilution 
of the nanoparticles on a 10 kDa cut off Nanosep filter. 
The concentration of FluPep ligand in a nanoparticle preparation was estimated in 
two ways: for low mole % of FluPep ligand, where the majority of the nanoparticles 
are determined to be functionalised with a single FluPep ligand, the nanoparticle 
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concentration was used as a proxy for FluPep ligand concentration, at higher mole 
% FluPep ligand, the number of  peptidols incorporated into a 70:30 (mole/mole) 
mix matrix ligand shell of 8.8 nm gold nanoparticles (measured previously, 1200 
peptidols, Duchense et al., 2008) was then multiplied by the mole % of FluPep 
ligand and by 1200. This latter estimate will deviate from actual concentration by 
the fraction of non-functionalised nanoparticles, since the functionalised 
nanoparticles are purified from the latter.  
3.2.2.2 Ion-exchange chromatography 
Ion-exchange chromatography were performed on homemade mini columns of 
diethylaminoethyl (DEAE) and carboxymethyl (CM) Sepharose (GE Healthcare 
Bio-Sciences AB, Sweden). The chromatography gel slurry was packed into a white 
pipette tip (200 µL) using half the filter as a frit and equilibrated in PBS. Capped 
nanoparticles were concentrated and exchanged into the appropriate buffer using a 
a 10 kDa cut off Nanosep centrifugal filter. The nanoparticles were then applied to 
the column, the unbound fraction was recovered. Columns were washed with PBS 
and eluted with 1 M NaCl and then 2 M NaCl in 8 mM Na2HPO4, 15 mM KH2PO4, 
pH 7.4.  
3.2.2.3 Calculation of the aggregation parameter (AP) 
The surface plasmon absorption peak of 8.8 nm diameter gold nanoparticles is at 
520 nm. When gold nanoparticles are aggregated, their surface plasmons couple 
causing a red shift in their plasmon absorbance to approximately 650 nm. The 
aggregation parameter (AP) was defined as (A 650 nm-Aref 650nm)/ (A 520nm-Aref 520), 
where A650nm and A520nm are the absorbance of gold nanoparticles at 650 nm and 
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520 nm, respectively, and Aref650nm and Aref520 are the absorbance of water at 650 nm 
and 520 nm, respectively (Chen et al., 2012). For comparison of results, this primary 
stability parameter was normalised by dividing the AP value of control ligand 
capped gold nanoparticles measured in milli Q water where [DTT] = 0. 
For silver nanoparticles diameter of approximately 10 nm, the surface plasmon 
absorption peak with a mix matrix ligand shell is at 410 nm. The AP for silver 
nanoparticle was defined as (A 600 nm-A ref 600nm)/ (A 410 nm-A ref 410), where A600nm 
and A410nm are the absorbance of Ag nanoparticles at 600 nm and 410 nm, 
respectively and Aref 600nm and Aref 410 are the absorbance of water at 600 nm and 410 
nm, respectively. 
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3.2.3 Results and Discussion  
3.2.3.1 Stability of FluPep functionalised gold nanoparticles 
The mix matrix ligand shell of 70:30 mole/mole peptidol and alkanethiol ethylene 
glycol assembled on gold nanoparticles has well characterised stability with respect 
to ligand exchange and non-specific binding (Duchesne et al., 2008a, Chen et al., 
2012), but the effect of incorporating the FluPep amino acid sequence at the C- 
terminus of the CVVVT matrix sequence is unknown. Since the molecular weight 
of FluPep ligand (2967 Da) is greater than that required for group separation on 
Sephadex G25 (1000 Da) additional purification by means of washes on a 10 kDa 
cut off Nanosep filter were included to ensure removal of any free FluPep ligand. 
When up to 5% (mole/mole) FluPep ligand was incorporated in the ligand matrix, 
the gold nanoparticles still eluted in the void volume of the Sephadex G25 column, 
so did not bind non-specifically to this chromatography matrix and their UV-Vis 
spectrum in PBS was indistinguishable from that of control mix matrix gold 
nanoparticles (Fig. 3.1A). This indicates that the FluPep sequence did not reduce 
the stability of the gold nanoparticles under these standard conditions. A more 
stressful test is ligand exchange with small thiols (Chen et al., 2012, Duchesne et 
al., 2008a, Schulz et al., 2016, Schulz et al., 2013). Ligand-exchange results in a 
ligand shell that is unable to prevent electrolyte-induced aggregation of the 
nanoparticles, demonstrated by a decrease in the plasmon absorption at 520 nm. 
Gold nanoparticles with a ligand shell incorporating 5% (mole/mole) FluPep ligand 
had a very similar resistance to ligand exchange with DTT as the control mix matrix 
protected gold nanoparticles. Thus, their aggregation parameter was unchanged up 
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to 5 mM DTT, even after 48 h incubation (Figs 3.1 B, C). At 10 mM DTT after 48 
h there was some evidence for ligand exchange, as the aggregation parameter was 
above 1.0 and at 25 mM DTT the ligand shell was clearly compromised. 
Nanoparticles incorporating lesser amounts of FluPep ligand (0.1% to 3 % 
mole/mole) were no less stable (Figs S1A-F). Consequently, the incorporation up 
to 5% (mole/mole) FluPep ligand in the ligand mixture did not reduce the stability 
of the gold nanoparticles with respect to ligand exchange and such nanoparticles 
could be used in cell culture medium. 
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Fig. 3.1.  Stability of gold nanoparticles to DTT ligand exchange (A) UV-Vis 
spectra of mix matrix capped gold nanoparticles and mix matrix capped gold 
nanoparticles incorporating 5% (mole/mole) Flu|Pep ligand in PBS. Time and dose-
dependence of DTT ligand exchange for (B) mix matrix gold nanoparticles and for 
gold nanoparticles with a ligand shell incorporating 5% (mole/mole) FluPep ligand. 
Results in (b) and (C) are the mean ± SD (n=3). 
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3.2.3.2 Purification of functionalised gold nanoparticles 
 
To functionalise the nanoparticles, the peptide FluPep ligand was included in the 
ligand mix, its mole % in relation to the matrix ligand reflects its grafting density 
on the gold nanoparticles (Levy et al., 2006a, Duchesne et al., 2008a, Duchesne et 
al., 2012, Free et al., 2012, Paramelle et al., 2015, Nieves et al., 2014). This can be 
determined by chromatography targeting specifically the grafted function, which 
also provides a means to purify the functionalised gold nanoparticles from those not 
functionalised, when the mole % of the functional ligand is low. Thus, when 10% 
of the functionalised gold nanoparticles bind to the chromatography column, most 
of these (95 %) will possess just one grafted functional ligand (Levy et al., 2006a, 
Duchesne et al., 2008a). Since FluPep ligand, like FluPep, has a net charge at pH 
7.4 of +6, cation-exchange chromatography was used to purify functionalised gold 
nanoparticles. Parallel chromatography was performed on the anion-exchanger 
DEAE-Sepharose to control for possible non-specific binding of FluPep ligand to 
Sepharose. 
Mix matrix gold nanoparticles did not to bind to either CM Sepharose or DEAE 
Sepharose (Fig. S2), as described previously (Duchesne et al., 2008a). Similarly, 
when FluPep ligand was incorporated in the ligand shell there was no binding to 
DEAE Sepharose, indicating an absence of non-specific interactions with the 
chromatography resin (Fig. S2). In contrast, the FluPep functionalised gold 
nanoparticles bound to CM Sepharose and were eluted by increasing electrolyte 
concentrations (Fig. 3.2). Thus, the FluPep functionalised gold nanoparticles ion-
exchanged on this chromatography support, which is, therefore, suitable for their 
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purification. Gold nanoparticles were synthesised with a range of mole % of FluPep 
ligand. After application of the gold nanoparticles to the column, the non-
functionalised gold nanoparticles were collected in the flow through and the 
functionalised ones eluted. Quantification of the gold nanoparticles by UV-Vis 
spectrophotometry then allowed the relation of bound and unbound gold 
nanoparticles to the mole % of FluPep in the original ligand mixture to be analysed. 
The data indicate that at 0.03 mole %, 10 % of the gold nanoparticles bound the 
column and thus most (~95 %) of these gold nanoparticles will possess just a single 
FluPep ligand (Levy et al., 2006a). At higher mole % the number of FluPep ligands 
per nanoparticle will increase. It is interesting to note that not all gold nanoparticles 
were observed to bind to the CM Sepharose column at higher mole % of FluPep 
ligand, something that has been observed previously with other functional peptides 
(Nieves et al., 2014, Paramelle et al., 2015).  
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Fig. 3.2.  Purification of FluPep ligand functionalised gold nanoparticles by 
CM-Sepharose cation-exchange chromatography. Gold nanoparticles 
functionalised with different mole % FluPep ligand were subjected to 
chromatography on CM-Sepharose. Top, images of columns after loading and 
washing with PBS. Bottom, quantification by absorption at 450 nm (Haiss et al., 
2007) of unbound (through and PBS wash fractions) and bound (eluted with 2 M 
NaCl) fractions. Results are the mean ± SD (n=3). 
 
3.2.3.3 Anti-flu activity of FluPep and FluPep ligand 
The MDCK are susceptible to both influenza type A and B viruses and are routinely 
used to measure ‘flu virus infectivity. The principle is that following virus binding, 
virus will infect a cell, reproduce and lyse that cell; released virus then infects 
neighbouring cells, the overlay preventing long-range diffusion of virus. After three 
days, the area of lysed cells is visualised as a plaque that does not stain with 
toluidine blue. In control (no virus) and vehicle (DMSO) treated cells, the cell 
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monolayer in the well was evenly stained (Fig. S3). In the presence of virus, there 
were substantial areas where cells had lysed and there was no staining. Virus titre 
was adjusted so that the cleared lysed cell areas corresponded to individual plaques, 
i.e., clear circles that could be distinguished from one another and so counted 
(corresponding to ~100 plaques/well). In the presence of FluPep there was a 
reduction in the number of plaques and this was concentration-dependent (Fig 3.4, 
A). Counting plaques in multiple experiments allowed the determination of the 
dose-response and the IC50. In these experiments the IC50 of the original FluPep 
sequence was found to be of the order of 140 pM (Fig. 3.3). This is less potent than 
described in the original publication, where an IC50 of 14 pM was measured. The 
source of this discrepancy is unknown, but more than likely relate to differences in 
cells such as passage number, and/or virus preparations. The FluPep ligand, used to 
functionalise gold nanoparticles was slightly less potent, with an IC50 of around 210 
pM, suggesting that the N-terminal extension CVVVTAA reduced the antiviral 
activity somewhat (Fig 3.3 and Table 3.1). 
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Fig. 3.3: Determination of the half maximal inhibitory concentration (IC50) of 
FluPep and and FluPep ligand in a plaque assay. Results, demonstrated that 
FluPep IC50 less than FluPep ligand, this might be due to the incorporation of the 
CVVVTAAA- extension.Results are the mean ±SD (n=3). 
 
Table 3.1: (IC50) of FluPep and FluPep ligand. 
FluPep    IC50 nM 
FluPep 0.14 
FluPep ligand   2.1 
3.2.3.4 Anti-flu activity of FluPep functionalised gold nanoparticles 
The addition of control mix matrix passivated nanoparticles had no detrimental 
effect on viral infectivity, since their addition to the cells did not change the number 
of plaques (Fig. 3.4A). However, when purified mix matrix capped gold 
nanoparticles functionalised with 5 % (mole/mole) FluPep ligand were added, there 
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was a marked decrease in the number of plaques, i.e. reduced virus infectivity (Fig. 
3.4A). Thus, FluPep ligand antiviral activity was maintained when it was 
conjugated to gold nanoparticles. 
For gold nanoparticles functionalised with 0.03% (mole/mole) FluPep ligand, the 
number of plaques started to decrease at 20 pM gold nanoparticles and reached a 
minimum of approximately two to eight plaques at 200 pM (Fig. 3.4B). As the 
grafting density of FluPep ligand was increased, so did the antiviral activity, to 
reach a maximum at 5 % (mole/mole) FluPep (Fig. 3.4B). This is reflected by the 
decreased IC50, which shows a 4.5-fold greater potency of nanoparticles 
functionalised with 5 % (mole/mole) FluPep ligand, when compared to 
nanoparticles functionalised with just 0.03 % (mole/mol) FluPep ligand (Table 3.2). 
The nanoparticles were always purified by cation-exchange chromatography (Fig. 
3.2), so in all cases nanoparticles had at least one FluPep ligand. When most 
nanoparticles have just a single FluPep ligand (0.03 % and 0.1 % mole/mole, Fig. 
3.2), the nanoparticle concentration is a reasonable proxy for FluPep ligand 
concentration. Taken together, these data indicate that the potency of FluPep ligand 
on the nanoparticles is greater than that of free FluPep and of the native FluPep 
peptide (Tables 3.1 and 3.2). 
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Fig. 3.4. Effect of gold nanoparticles functionalised with FluPep ligand on 
influenza virus plaque formation. (A) Number of plaques observed in the 
presence of mix matrix control gold nanoparticles and gold nanoparticles 
functionalised with 5 % (mole/mole) FluPep ligand. (B) Dependence of inhibition 
of plaque formation on the concentration of gold nanoparticles and the % 
(mole/mole) of FluPep ligand. Results and the mean ±SD (n=3). Error bars may be 
smaller than the symbol 
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Table 3.2: (IC50) of different mole% of FluPep ligand with respect to gold 
nanoparticle concentration.      
Mole % FluPep ligand   IC50 nM 
0.03 0.073 
0.1 0.068 
0.3 0.058 
1 0.023 
3 0.016 
5 0.015 
3.2.3.5 Stability of FluPep functionalised silver nanoparticles 
 
Silver has well-established anti-microbial properties. It was of interest to determine 
whether FluPep functionalised silver nanoparticles possessed a similar anti-flu 
activity to their gold counterparts. The mix matrix ligand shell has been shown to 
impart good stability to silver nanoparticles (Free et al., 2012). First, the effect of 
incorporating FluPep into the ligand shell on nanoparticle stability was measured. 
As for gold nanoparticles, up to 5% (mole/mole) FluPep ligand incorporated into 
the ligand matrix had no discernible effect on the handling and purification of the 
silver nanoparticles: the silver nanoparticles did not bind non-specifically to 
Sephadex G25, as they eluted in the void volume and their UV-Vis spectrum in 
PBS was indistinguishable from that of control mix matrix silver nanoparticles (Fig. 
3.5A). When challenged by a small thiol, DTT, the silver nanoparticles passivated 
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by the mix matrix ligand shell were somewhat more prone to ligand exchange than 
their gold counterparts. Thus, after 3 h and 6 h in 50 mM DTT a small increase in 
aggregation parameter was apparent (Fig. 3.5B). After 24 h and 48 h, the 
aggregation parameter started to rise at 3 mM DTT, which was most pronounced at 
48 h. Importantly, the inclusion of 5% (mole/mole) FluPep ligand in their ligand 
shell did not change the stability of the silver nanoparticles with respect to DTT-
mediated ligand exchange (Fig. 3.5C). 
Purification of the FluPep functionalised silver nanoparticles was achieved by 
cation-exchange chromatography on CM-Sepharose. As the percentage of FluPep 
incroprated into the ligand shell increased, so did the percentage of nanoparticles 
bound to CM-Sepharose (Fig. 3.6). This suggests that the mole % FluPep ligand in 
the initial mixture of ligands added to the nanoparticles reflects its incorporation 
into the ligand shell (Levy et al., 2006a, Duchesne et al., 2008a). Thus, as for gold 
nanoparticles, when 10 % of the total nanoparticle preparation bound to the CM-
Sepharose column, ~95% of the bound nanoparticles will possess a single FluPep 
ligand (Levy et al., 2006a); at higher mole % of FluPep ligand and increasing 
proportion of the silver nanoparticles will incorporate more than one FluPep ligand. 
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Fig. 3.5. Stability of silver nanoparticles to DTT ligand exchange. (A) UV-Vis 
spectra of mix matrix capped silver nanoparticles and mix matrix capped silver 
nanoparticles incorporating 5% (mole/mole) Flu|Pep ligand in PBS. Time and dose-
dependence of DTT ligand exchange for (B) mix matrix silver nanoparticles and 
(C) silver nanoparticles incorporating different mole % FluPep ligand. Results are 
the mean ± SD (n=3). 
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Fig. 3.6. Purification of FluPep ligand functionalised silver nanoparticles by 
CM-Sepharose cation-exchange chromatography. Silver nanoparticles 
functionalised with different mole % FluPep ligand were subjected to 
chromatography on CM-Sepharose. Top, images of columns after loading and 
washing with PBS. Bottom, quantification of unbound (through and PBS wash 
fractions) and bound (eluted with 2 M NaCl) fractions. Results are the mean ± SD 
(n=3). 
 
3.2.3.6 Anti-flu activity of FluPep ligand incorporated to silver nanoparticles 
Control mix matrix passivated silver nanoparticles had no effect on viral infectivity 
(Fig. 7). It is the silver (Ag+) ions that exert anti-microbial activity (Hsueh et al., 
2015). Thus, this result indicates that there is not a substantial release of Ag+ ions 
from the silver nanoparticles during the experiment. This concurs well with our data 
(Fig. 3.5) and previously reported observations (Free et al., 2012) demonstrating 
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that the mix matrix ligand shell imparts good stability to the silver nanoparticles. 
Incorporation of FluPep ligand into the mix matrix ligand shell caused a marked 
reduction in number of plaques (Fig. 3.7). As the mole % of FluPep ligand in the 
ligand shell increased, so did the antiviral activity of these particles (Fig. 3.7 and 
Table 3.4). Around 10% of silver nanoparticles functionalised with 0.03 % 
(mole/mole) FluPep ligand bind to the CM-Sepharose column, indicating that the 
majority of these will carry just a single FluPep ligand (Fig. 3.6), so the nanoparticle 
concentration will equate to the FluPep ligand concentration. These nanoparticles 
are as potent as free FluPep and more potent than free FluPep ligand (Tables 3.1 
and 3.3). However, FluPep ligand functionalised silver nanoparticles were less 
effective at inhibiting influenza virus infectivity than the corresponding gold 
nanoparticles (Tables 2 and 4). At higher mole % FluPep ligand (≥0.1 % 
mole/mole) many, if not all nanoparticles, will be functionalised with two or more 
FluPep ligands. As for gold nanoparticles, the nanoparticle concentration will no 
longer equate to the FluPep ligand concentration.  
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Fig. 3.7.  Determination of the half maximal inhibitory concentration (IC50) of 
silver nanoparticles functionalised with FluPep ligand. Dependence of 
inhibition of plaque formation on the concentration of silver nanoparticles and the 
% (mole/mole) of FluPep ligand. Results and the mean ±SD (n=3). 
 
Table 3.3: (IC50) of silver nanoparticles functionalised with different mole % 
FluPep ligand. 
Mole % FluPep ligand   IC50 nM 
0.03 0.14 
0.1 0.077 
0.3 0.056 
1 0.019 
3 0.016 
5 0.015 
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3.2.4 Conclusion 
Influenza viruses pose a substantial danger to global health, because of 
susceptibility of these viruses to rapid mutations in their genomes, ease of 
transmission via the respiratory route, and availability of animal reservoirs.  
Currently, the preventative and remedial therapies against these viruses are 
inadequate. In the current study, we have functionalised nanoparticles with FluPep, 
a peptide demonstrated to inhibit influenza A virus subtypes, including H1N1, 
H3N2 and H5N1(Nicol et al., 2012b). Monofunctionalised nanoparticles-FluPep 
were more active that free peptide. These data highlight that a nanoparticle 
formulation of such peptide inhibitors of ‘flu virus may be particularly effective. 
Purification of the functionalised nanoparticles by cation-exchange 
chromatography indicated that the FluPep ligand sequence was exposed to solvent, 
rather than associated with the mix matrix ligand shell, a conclusion supported by 
the observation that the gold and silver nanoparticle FluPep ligand conjugates 
possessed antiviral activity. At low stoichiometries of FluPep ligand: nanoparticle 
conjugation, the potency of the FluPep ligand is enhanced compared to that of the 
free peptide. The FluPep amino acid sequence is hydrophobic and its solubilisation 
requires dimethyl sulfoxide (DMSO). Although a useful solvent, its use in therapies 
is problematic due to DMSO potential adverse reactions in some individuals such 
as a sensation of burning, vesiculation, dryness of skin and local allergic reactions 
(Cavaletti et al., 2000, Delatorre et al., 1981, Worthley and Schott, 1969).  Thus, 
conjugation to nanoparticles may provide a means to deliver effectively and safely 
FluPep ligand with enhanced activity in a solvent-free formulation. Though the mix 
matrix ligand shell prevents the dissolution of the silver, its modification will reduce 
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its effectiveness (Free et al., 2012). Thus, it will be possible to design silver 
nanoparticles that act through FluPep ligand and released Ag+ ions. The pulmonary 
route to deliver drugs against respiratory infections is well established, therefore, 
delivery of functionalised nanoparticles against ‘flu viruses is highly feasible.  In 
conclusion, nanoparticle formation of FluPep ligand or analogous peptides offers a 
route to new treatments for ‘flu and other respiratory pathogens.  
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3.2.5 Supplementary information 
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108 
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Fig. S1.  Stability of gold nanoparticles functionalised with FluPep ligand. Gold 
nanoparticles incorporating different % (mole/mole) FluPep ligand in their ligand 
shell were incubated in varying concentrations of DTT for different times and the 
normalised aggregation parameter was calculated. A 70:30 CVVVT-ol HS-
(CH2)11-EG4-OH mix matrix gold nanoparticles. B 0.1% (mole/mole) FluPep 
ligand functionalised gold nanoparticles. C 0.3% (mole/mole) FluPep ligand 
functionalised Gold nanoparticles. D 1 %( mole/mole) FluPep ligand functionalised 
gold nanoparticles. E 3% (mole/mole) FluPep ligand functionalised gold 
nanoparticles. F 5 % (mole/mole) FluPep ligand functionalised gold nanoparticles. 
Results are the mean ± SD (n=3). 
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Fig. S 2. CM-Sepharose and DEAE-Sepharose chromatography of gold 
nanoparticles. Gold nanoparticles were applied to mini columns of CM- and 
DEAE-Sepharose, as described in Materials and Methods in 20 mM Tris HCl  
(pH7.2) and the column washed with PBS. (A) Mix matrix gold nanoparticles 
applied to DEAE Sepharose. (B) Mix matrix gold nanoparticles applied to CM 
Sepharose. (C) Mix matrix gold nanoparticles functionalised with 0.3% 
(mole/mole) FluPep ligand applied to DEAE Sepharose (D) Mix matrix gold 
nanoparticles functionalised with 3% (mole/mole) FluPep ligand applied to DEAE 
Sepharose. (E) Mix matrix gold nanoparticles functionalised with 5% (mole/mole) 
FluPep ligand applied to DEAE Sepharose. In all cases the nanoparticles failed to 
bind to the ion-exchange column. This demonstrates that mix matrix passivated 
nanoparticles do not bind to CM- or DEAE-Sepharose and that when these 
nanoparticles are functionalised with FluPep ligand, they fail to bind to DEAE-
Sepharose.  
 
Fig. S 3:  Example of a plaque assay. A confluent monolayer of MDCK cells was 
infected with influenza virus at varying dilutions and covered with an agarose 
overlay, to prevent the virus infection from spreading indiscriminately, as described 
in Materials and Methods. Virus plaques are the cleared circles, e.g., arrow. A viral 
plaque is formed when a virus infects a cell within the fixed cell monolayer. The 
virus infected cell will lyse and spread the infection to adjacent cells where the 
infection-to-lysis cycle is repeated. Here, the ability of FluPep to inhibit replication 
of WSN virus (~100 plaques per well in control) was determined. Assays were 
carried out with virus in the presence of vehicle (DMSO, 1.5% final concentration), 
or virus in the presence of increasing concentrations of FluPep. Concentrations of 
FluPep are shown. 
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Fig. S 4: Stability of silver nanoparticles functionalised with FluPep ligand. 
Silver nanoparticles incorporating different % mole/mole FluPep ligand in their 
ligand shell were incubated in varying concentrations of DTT for different times 
and the normalised aggregation parameter was calculated. A 70:30 CVVVT-ol HS-
(CH2)11-EG4-OH mix matrix silver nanoparticles. B 0.1% (mole/mole) FluPep 
ligand functionalised silver nanoparticles. C 0.3% (mole/mole) FluPep ligand 
functionalised silver nanoparticles. D 1 % (mole/mole) FluPep ligand 
functionalised silver nanoparticles. E 3% (mole/mole) FluPep ligand functionalised 
silver nanoparticles. F 5 % (mole/mole) FluPep ligand functionalised silver 
nanoparticles. Results are the mean ± SD (n=3). 
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3.3 Positive control for gold nanoparticles functionalisation 
 
FluPep and FluPep ligand are effective at very low concentrations (Table 3.1). 
There is a high concentration of Flupep ligand in the ligand mixture (Section 2.3.1). 
Therefore, it was important to demonstrate that the purification of FlupPep ligand 
functionalised nanoparticles from free ligand (Section 2.2.4) not incorporated into 
the ligand shell was effective. Gold nanoparticles with 5% (mole/mole) FluPep 
ligand and in parallel a mock reaction control of 5% (mole/mole) FluPep ligand 
mixed with the standard mix matrix 70% CVVVTol: 30% HS-(CH2)11EG4 in the 
absence of gold nanoparticles were prepared. These were subjected to the standard 
purification procedure (Section 2.2.4). Then the antiviral activity of the retentate 
was measured. In the case of the FluPep ligand functionalised nanoparticles, the 
antiviral activity of the retentate was considerable, as expected (Fig. 3.3). However, 
for the mock reaction control, the number of plaque remained nearly the same as 
the viral control untreated with FluPep ligand which is about ~ 87 plaques (Fig. 
3.3). The ligand only mixture was not subjected to Sephadex G25 chromatography, 
which will remove some of the Flupep ligand. Thus, any residual activity in this 
sample represents the upper limit for a contribution to the inhibitory activity in the 
nanoparticle sample form free FluPep ligand. These results demonstrate that the 
antiviral activity observed with FluPep functionalised nanoparticles is indeed due 
to Flupep ligand conjugated to the nanoparticles rather than free FluPep ligand 
carried over from the ligand hell synthesis step. 
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Fig. 3.3: Measurement of the effectiveness of the separation of free Flupep 
ligand from gold nanoparticles. Gold nanoparticles were functionalised with 5% 
(mol/mole) FluPep ligand and a mock functionalisation, containing ligands but no 
nanoparticles were subjected to purification by centrifugation on a 10 kDa nanosep 
filter. The antiviral activity of the retentates was measured. Results are the mean 
±SD of three measurements. 
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3.4 Discussion 
 
It was demonstrated by (Nicol et al., 2012b), that FluPep inhibited influenza virus 
infectivity in cell and animal models (Section 1.5.2.3). In this chapter gold and 
silver nanoparticles were functionalised with Flupep ligand and some of their 
properties measured. As described in this section, the incorporation of up to 5% 
mole/mole Flupep ligand in the nanoparticles does not affect their stability, 
measured by non-specific interaction with Sephadex and Sepharose, DEAE and 
ligand exchange with DTT. When incorporated into the nanoparticle ligand shell. 
FluPep ligand retains its anti-viral activity.  
The nanoparticle probe appears to have no effect on viral infectivity. Thus, the 
observation that nanoparticles functionalised with FluPep retain the antiviral 
activity of the peptide means that such nanoparticle can be used to probe the 
mechanism of action of FluPep. This opens the way to use a similar approach for 
other antiviral peptides. As noted in (Section 1.5.2.3) for Flupep the experiments 
that led to the conclusion that it interact with HA are not entirely convincing. This 
relates to a simple problem: how to detect a peptide at low concentration in a 
biological system. Nanoparticles provide one means to achieve this (Section 1.4). 
Consequently, the work in this chapter provides a strategy to the wider community 
engaged in the identification and functional analysis of peptides that inhibit virus 
infectivity, some of which were described in (Sections 1.5.1 and 1.5.2.1). 
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3.5 Conclusion  
Gold and silver nanoparticles were passivated with mix matrix and functionalised 
with FluPep. Purification and stability assays demonstrated that FluPep didn’t alter 
the stability of the gold and silver gold nanoparticles. However, silver nanoparticles 
were somewhat less stable than gold ones. Only nanoparticles functionalised with 
FluPep showed antiviral activity. Moreover, conjugation to nanoparticles enhanced 
considerably the antiviral activity of FluPep.  
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Chapter 4  
 
4.1 Introduction 
In Chapter 3, the successful incorporation of FluPep into the ligand shell of gold 
and silver nanoparticles was demonstrated and these nanoparticles possessed strong 
antiviral activity. There remains an important question relating to FluPep: what is 
the mechanism of its antiviral action? Knowing its molecular targets would allow 
hypotheses to be tested and potentially the design of novel peptides with even 
greater antiviral activity.  Gold nanoparticles can be detected with high sensitivity 
by a variety of means, due to their plasmon resonance (Section 1.4.2). In this chapter 
advantage is taken of detection of the gold nanoparticles by UV-Vis spectrometry 
to establish what the target of FluPep may be: virus, cell surface molecule or both. 
In this way the association of the gold nanoparticle-peptide conjugates with cells 
was measured directly, by UV-Vis spectrophotometry, and indirectly as the 
antiviral activity with the plaque assay. This is complemented by selective 
treatments of cells to identify the classes of molecules that FluPep binds to. Finally, 
the importance of the association of FluPep with extracellular anionic 
polysaccharides was tested by using peptides with a FluPep sequence and a variety 
of extensions, designed to increase interactions with extracellular matrix 
polysaccharides.  
4.2  
An anti-‘flu peptide that interacts with sulfated glycosaminoglycans 
Section 3.2 is a manuscript in preparation 
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4.2.1 Materials & methods 
4.2.1.1 Materials 
4.2.1.2 Peptides and gold nanoparticles 
Peptides FluPep WLVFFVIFYFFRRRKK, FluPep ligand 
CVVVTAAAWLVFFVIFYFFRRRKK, super FluPep 1 
CVVVTAAARRPKGRGKRRREKQRWLVFFVIFYFFR, super FluPep 2 
CVVVTAAARGAPRRGQRTRRKNKWLVFFVIFYFFR, CVVVTAAARRKK, 
and the ligand shell matrix peptidol CVVVT-ol were purchased from Peptide 
Protein Research (PPR Ltd, Hampshire, UK) (Table 4.1). The alkethiol ethylene 
glycol ligand, HS-EC11-EG4, was purchased from Prochimia (ProChimia Surface 
Sp. z o.o., Sopot, Poland). Gold nanoparticles of  9 nm diameter stabilized in citrate 
buffer were purchased from British Biocell (BBInternational Ltd, UK). Nanosep 
filters 10 kDa cut off were from PALL (PALL Corp., Portsmouth, Hants, UK). UV-
Vis spectra (2 nm incremental steps) were measured using a SpectraMax Plus 
spectrophotometer (Molecular Devices, Wokingham, UK) and 384 well plates from 
Corning (Lowell, US) and the concentration of gold nanoparticles was determined 
at 450 nm (Haiss et al., 2007). 
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Table 4.1. Peptide names, amino acid sequences and their molecular weight  
Peptide name Amino acid sequence 
MW   
(Da) 
FluPep NH2WLVFFVIFYFFRRRKK-OH 2252 
RRKKFluPep NH2RRKKWLVFFVIFYFFR-OH 2252 
FluPep RRKK NH2WLVFFVIFYFFR-OH 1684 
FluPep ligand NH2CVVVTAAAWLVFFVIFYFFRRRKK-OH 2967 
RRKK FluPep 
ligand 
NH2CVVVTAAARRKKWLVFFVIFYFFR-OH 2967 
FluPep 
ligandRRKK 
NH2CVVVTAAAWLVFFVIFYFFR-OH 2398 
Super FluPep1 NH2CVVVTAAARRPKGRGKRRREKQRWLVFFVIFYFFR-OH 4345 
Super FluPep2 NH2CVVVTAAARGAPRRGQRTRRKNKWLVFFVIFYFFR-OH 4218 
 
4.2.2 Synthesis of FluPep functionalised nanoparticles  
Mix matrix ligands 70:30 (mole:mole) CVVVT-ol: HS-(CH2)11-EG4-OH were 
prepared as described (Duchesne et al., 2008a) by first diluting  35 µL CVVVT-ol 
(4 mM DMSO:H2O) with 35 µL ddH2O and 6 µL HS-C11-EG4-OH (2 mM) with 6 
µL EtOH and 18 µL ddH2O. Adding the two solutions together yielded a 2 mM 
ligand solution of 70% (mole/mole) CVVVT-ol and 30% (mole/mole) HS-C11-EG4-
OH. The ligand mixture was added to 900 µL gold nanoparticles and vortex mixed. 
Once mixed, 100 µL of x10 phosphate-buffered saline (PBS: 137 mM NaCl, 3 mM 
KCl l, 8 mM Na2HPO4, 15 mM KH2PO4) with Tween-20 (0.1 % v/v) pH 7.4 was 
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added to gold nanoparticles (Duchesne et al., 2008a) vortex mixed and the gold 
nanoparticles placed on a rotating wheel for 24 h. Nanoparticles were concentrated 
10 x using 10 kDa Nanosep centrifugal filters (PALL Corp., Portsmouth, Hants, 
UK). Samples were centrifuged for 7 min at 10000 rpm (~12,000 x g) and the gold 
nanoparticles diluted with 1 x PBST (PBS 0.05% (v/v) Tween-20). The 
nanoparticles were then further separated from excess ligands by applying them 
(100 µL) to a 5 mL Sephadex G25 gel filtration column with PBS as a mobile phase.  
To functionalise the nanoparticles with functional peptide ligands such as FluPep 
ligand, these were incorporated into the initial ligand mix at the mole % indicated 
in the figure legends. However, the separation of these ligands (Mw > 1000 Da) 
required in addition to gel-filtration on Sephadex G25 six washes, each involving a 
10-fold dilution of the nanoparticles on a 10 kDa cut off Nanosep filter. 
The concentration of functional peptide ligand in a nanoparticle preparation was 
estimated in two ways. For low mole % of functional peptide ligand, where the 
majority of the nanoparticles are determined to be grafted with a single functional 
ligand, the nanoparticle concentration was used as a proxy for functional ligand 
concentration. At higher mole % functional ligand, the number of  peptidols 
incorporated into a 70:30 (mole/mole) mix matrix ligand shell of 8.8 nm gold 
nanoparticles (measured previously, 1200 peptidols, Duchense et al., 2008) was 
then multiplied by the mole % of functional ligand and by 1200. Since the 
functionalised nanoparticles are purified, this latter estimate will not reflect that 
actual concentration.  However, the error can be estimated from the fraction of 
nanoparticles functionalised.  
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4.2.2.1 Purification of functionalised gold nanoparticles 
Ion-exchange, and heparin affinity chromatography were performed on homemade 
micro columns of diethylaminoethyl (DEAE), carboxymethyl (CM) and heparin 
agarose. The chromatography gel was packed into a white pipette tip (200µL) using 
half the filter as a frit at the bottle and equilibrated PBS. Capped GNPs were 
concentrated by Nanosep and exchanged into PBS. Then, the GNPs were applied 
to the column, the unbound fraction was recovered. Columns were washed with 
PBS and eluted stepwise with 1 M NaCl and 2 M NaCl in1x PBS pH 7.2. The 
concentration of GNPs in the different fractions was determined by measuring 
absorbance at 450 nm (Haiss et al., 2007). Quantification of the gold nanoparticles 
then allowed the relation of bound and unbound gold nanoparticles to the mole % 
of functional ligand in the original ligand mixture to be analysed. The data indicate 
that at 0.03% (mole/mole) functional ligand, 10 % of the gold nanoparticles bound 
the column and thus most (~95 %) of these gold nanoparticles will possess just a 
single functional ligand, as determined previously (Levy et al., 2006a). At higher 
mole % the number of functional ligands per nanoparticle will increase. Thus, the 
purification of the functionalised gold nanoparticles means that the effects on 
influenza virus infectivity of mono- versus plurifunctionalisation can be 
determined.  
4.2.2.2 Separation of influenza virus from gold nanoparticles by filtration  
WSN/H1N1 virus stock (10 µL) was mixed with 10 µL gold nanoparticles and left 
for one hour on a rocking platform at 37 °C and then 980 µL phosphate-buffered 
saline (PBS) was added. The mixture of influenza virus and gold nanoparticles were 
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centrifuged on a nanosep filter of 100 kDa cut off (PALL Corporation, 600 south 
Wanger Road. Ann Arbor ,Michigan) with approximate pore size of ~ 10 nm for 
one minute at 10000 g. Following resuspension of the residual ~100 µL retentate in 
PBS, this was repeated 4-5 times.  The concentration of gold nanoparticles in the 
retentate and filtrate was measured at 450 nm (Haiss et al., 2007). 
4.2.2.3 Pretreatment of MDCK cells with peptides and functionalised gold 
nanoparticles  
The medium from confluent monolayers of MDCK cells was removed and 10 µL 
of different gold nanoparticles functionalised with different mole % of FluPep 
ligand or free peptide mixed with 440 µL of DMEM was added and incubated at 37 
0C for one hour. After removing this solution the cell monolayers were washed with 
different solutions as indicated in the figure legends.  Then a viral plaque assay was 
performed to determine the degree to which the antiviral activity of the gold 
nanoparticles functionalised with different mole % of FluPep ligand or free peptide 
was retained.  
4.2.3 Measurement of association of nanoparticles with virus and cells 
4.2.3.1 Filtration method to separate virus and nanoparticles  
WSN/H1N1 virus stock (10 µL) was mixed with 10 µL of ~10 nm gold or silver 
nanoparticles functionalised with a defined mole % of FluPep ligand in a 1.5 mL 
Eppendorf tube and then 300 µL PBS was added. After one hour in a tissue culture 
incubator (37 °C) a further700 µL PBS was added and the mixture placed in a 100 
kDa cut off nanosep filter unit (PALL), which has an approximate pore size of ~ 10 
nm. Following centrifugation for one minute at 10000 g, the ~100 µL retentate (care 
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being taken not to centrifuge to dryness) was diluted with 700 µL PBS and the 
process repeated 4-5. The final retentate and filtrate were then subjected to analysis 
by UV-Vis spectroscopy to quantify nanoparticles (Section 2.5) and SDS-PAGE to 
identify proteins.  
4.2.3.2 Association of nanoparticles with cells  
MDCK cells were cultured in six well plates as for the viral plaque assay (Section 
2.8.4). Cell monolayers then incubated for one hour at 37 0C with gold 
nanoparticles, as described in the figure legends. In some experiments a competitor 
was included with the nanoparticles. Then the culture medium was removed and 
the cell monolayers were washed twice with 3 mL PBS to remove any residual free 
nanoparticles.  Various washes and extracts from the cells, detailed in the figure 
legends, were collected and the nanoparticle content quantified by measuring the 
absorption at 520 nm. 
In some experiments peptides or nanoparticles after the washes with PBS or with 
PBS and 2 M NaCl the activity of virus was measured by the plaque assay (Section 
2.8.4)  
4.2.3.3 Treatment of MDCK cells with glycosidases 
Following fixation (Section 2.8.7) the fixed cells were washed with PBS three times 
and then incubated with 2 mL PBS containing 25 mM Glycine to block any 
remaining partially active fixative. The blocking medium was discarded after 15 
min and cells were washed with 3x PBS to remove any remaining blocking medium. 
Cells were then incubated with the following enzymes: 
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(i) To degrade heparan sulfate 400 µL heparinase II and III (100 µL heparinase II 
and 200 µL heparinise and 100 µL of  100 mM sodium acetate and 0.1 mM calcium 
acetate, pH 7.0; gift from Dr. Edwin Yates, University of Liverpool). 
(ii) To degrade chondroitin sulfate (including dermatan sulfate) 1 mL 
chondroitinase ABC (Sigma-Aldrich; 1.25 mU in PBS with x mg/mL bovine serum 
albumin) was added to the cells. The inclusion of bovine serum albumin is essential 
with these enzymes, as they contain traces of protease; the bovine serum albumin 
ensures cell proteins are not degraded. 
(iii) To degrade sialic acid, neuraminidase 200 µL neuraminidase + 800 µL of 50 
mM sodium acetate 4 mM CaCl2 100 µg/mL BSA, pH 7.4 
In all cases, cells were incubated with the enzymes overnight at 37 0C.  
4.2.4 SDS-PAGE and silver staining  
4.2.4.1 SDS-PAGE 
To prepare samples for SDS-PAGE, sample (30 μL) was mixed with 10 μL 4x SDS-
PAGE loading buffer (50 % (v/v) glycerol, 10 % (w/v) SDS, 25 % (v/v) 2-
mercaptoethanol in 0.3 M Tris-Cl, pH 6.8 and coloured with bromophenol blue), 
and then heated at 95°C for 10 min. Ten μL of the samples along with 10 μL SDS-
PAGE markers (SDS7-1VL, Sigma) were loaded onto a 12 % (w/v) SDS-
polyacrylamide gel (Table 2.3) and the gels were run at 30 mA (per gel), 200 V for 
50 min with running buffer (50 mM Tris-Cl, 192 mM glycine and 0.1 % (w/v) SDS). 
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Table 4.2: SDS-PAGE Gel preparation 
           SDS-PAGE Resolving Gel 
(ingredients for 12 % gel – 2 gels)                                      Total 10 mL 
Acrylamide/ bis-acrylamide stock (30 %, w/v) 4.0 mL 
Tris-HCl (3 M), pH 8.85 2.5 mL 
DD- Water 3.5 mL 
10 % Sodium dodecyl sulfate (SDS) w/v 100 μL 
TEMED(N, N, N’, N’, Tetramethylethylene diamine) 10 μL 
Ammonium persulphate 50 mg/mL (freshly made) 100 μL 
 
            SDS-PAGE Stacking Gel 
       (ingredients for 12 % gel – 2 gels)                                      Total 5 mL 
Acrylamide/ bis-acrylamide stock (30 %, w/v) 650 μL 
Tris-Cl (1.25 M), pH 6.8 500 μL 
DD- Water 3.5 mL 
10 % Sodium dodecyl sulfate (SDS) w/v 50 μL 
TEMED (N, N, N’, N’, Tetramethylethylene diamine) 10 μL 
Ammonium persulphate 50 mg/mL (freshly made) 50 μL 
 
4.2.4.2 Coomassie Staining and Destaining 
The gels were incubated in Coomassie stain (50 % (v/v) methanol v/v, 10 % (v/v) 
acetic acid, 0.25 % (w/v) CBB R-250)(ThermoFisher, UK) for 60 min, then soaked 
in de-staining buffer (40 % (v/v) methanol, 10 % (v/v) acetic acid) until the bands 
became clear. 
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4.2.4.3 Silver staining 
After electrophoresis, the gels were soaked in fixative (40 % (v/v) ethanol, 10 % 
(v/v) acetic acid) for 1 hour following by soaking twice in 10 % (v/v) ethanol (5 
min/each) and washing in RO water three times, each for 5 min. 
Following incubation in 0.2 % (w/v) silver nitrate for 30 min, the gels were washed 
with water for 15 s and then dipped in freshly made developer solution (2.5 % (w/v) 
Na2CO3, 0.03 % (v/v) formaldehyde) until the solution went brown. New developer 
was then used to further stain the gel until bands were stained to the required 
intensity. Stop solution (1 % v/v acetic acid) was used to stop the reaction between 
silver and formaldehyde. The gels were then washed with water six times for 5 min 
each. Freshly made reducer (0.6 % w/v sodium thiosulphate, 0.3 % w/v potassium 
ferricyanide, 0.1 % w/v sodium carbonate) was used to remove the excess silver 
and clear the background. The gels were then quickly washed with a large volume 
of water and followed by five washes with water (5 min/each). When required, gels 
were re-stained to increase the sensitivity of detection, starting by the addition of 
0.2 % (v/v) silver nitrate for 30 min. 
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4.2.5 Results and Discussion 
4.2.5.1 Binding of nanoparticle-FluPep ligand conjugates to virus  
FluPep may interact with the influenza virus envelope, components of the cell 
surface or both. Initial experiments aimed to determine which of these was the 
physical target of FluPep was. Advantage was taken of the exceptionally high 
extinction coefficient of the gold nanoparticles, which allows sensitive detection by 
UV-Vis spectrophotometry (Haiss et al., 2007) and the difference in size between 
the nanoparticle-FluPep ligand conjugate (diameter ~10 nm) and the virus 
(diameter ~100 nm). Virus and FluPep ligand -conjugated gold nanoparticles were 
incubated at 37 °C for 30 min, as in a plaque assay (section 3). The gold 
nanoparticles were then separated from virus with a centrifugal filter with a cut-off 
of 10 nm. The results demonstrated that the gold nanoparticle-FluPep ligand 
conjugate was recovered in the filtrate and not in the retentate. (Fig.4.1A). The 
presence of virus was determined by detection of viral protein. SDS-PAGE 
demonstrates that the retentate, but not the filtrate, contains bands corresponding to 
the expected size of HA protein (Fig. 4.1B). These data demonstrate that the FluPep 
ligand does not interact directly with the virus, since virus and FluPep 
functionalised nanoparticles are effectively separated by the filtration step. 
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Fig. 4.1. Measurement of binding of FluPep functionalised nanoparticles to 
virus by filtration. (A) Following incubation of FluPep functionalised 
nanoparticles, the mixture was subjected to filtration on a 100 kDa cut-off 
centrifugal filter (Materials and Methods). The absorbance in the retentate and the 
filtrate was measured to determine the presence of nanoparticles. Results are the 
mean ± SD (n=3). (B) SDS-PAGE of the fractions from (A), the bands 
corresponding to major viral proteins are only present in the retentate and indicated 
by arrows.  
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4.2.5.2 Binding of nanoparticle-FluPep ligand conjugates to cells 
 
To determine if the gold-nanoparticle-FluPep ligand conjugate bound to cells, these 
were incubated at 37°C for 30 min with the conjugate in the same conditions as for 
a plaque assay (Chapter 3). Following incubation, the nanoparticles released by 
various treatments were quantified. The PBS wash fractions contained virtually no 
detectable gold nanoparticles, indicating that there were no gold nanoparticles 
loosely associated with the cell surface. The absorbance of cells collected by 
scraping could not be read directly, due to scattering by cell clumps, so instead, 
cells were released by trypsin treatment. After trypsinisation the cells were found 
to contain a large amount of gold nanoparticles functionalised with either 3% 
(mole/mole) or 5% (mole/mole) FluPep ligand (Fig. 4.2A). The recovery of 
nanoparticles functionalised with 3% (mole/mole) and 5% (mole/mole) FluPep 
ligand 0.53 and 0.54, respectively in the cells represents ~60% of the gold 
nanoparticle FluPep ligand conjugate added. This demonstrates that not only are 
the FluPep ligand conjugated gold nanoparticles associated with the cells, but that 
their binding site(s) has a high capacity and reasonably fast kinetics. To determine 
whether the interaction of the gold nanoparticle-FluPep ligand conjugate with its 
cellular target(s) involved ionic bonding, cells were washed with PBS and then with 
2 M NaCl. The results showed that NaCl released 32% of the gold nanoparticles 
added to the cells, which is a little over half of the amount of the total cell-associated 
FluPep ligand -conjugated nanoparticles (Fig. 4.2B).  
Thus, around half of the cell bound gold nanoparticle-FluPep ligand conjugate are 
associated with an anionic component. The remainder may also be associated with 
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such components, but may have other interactions (H-bonding, van der Walls 
bonding) preventing release by high concentrations of electrolytes or have been 
internalised, so no longer accessible to the 2 M NaCl.  
To determine whether internalisation of the FluPep ligand -nanoparticle conjugates 
was occurring the experiment was repeated, but at 4°C. Initially the effect of 
temperature on the level of binding was determined, since reactions are slower at 
4°C. At the lower temperature, the PBS wash still failed to remove bound gold 
nanoparticle-FluPep ligand conjugate, a little more gold nanoparticle-FluPep ligand 
conjugate was recovered in the 2 M NaCl wash as the absorption of this wash was 
~ 0.36. Following trypsinization, the absorption of 3% (mole/mole) or 5% 
(mole/mole) FluPep ligand was 0.64  and 0.67  respectively, which corresponded 
to ~ 69% of the  FluPep ligand-gold nanoparticles originally added to the cells. This 
is slightly more than at 37°C (~ 56%) (Fig.4.2C). This indicates that at the lower 
temperature binding will have reached near maximal levels within the 30 min 
incubation. Next, following trypsinisation, the cells were mixed with fetal calf 
serum (FCS) to block trypsin and centrifuged to allow quantification of FluPep 
ligand-nanoparticles associated with trypsin-sensitive molecules on the cell surface 
and those that have been internalised. The results showed that the PBS wash did not 
remove any detectable bound gold nanoparticles-FluPep ligand conjugates. 
However, the supernatant of the trypsinised cells incubated with 3% and 5% 
(mole/mole) gold nanoparticles FluPep ligand at 37°C had an absorption of 0.06 
and 0.08, respectively, while the corresponding supernatant of the cells incubated 
with 3% and 5% (mole/mole) gold nanoparticles FluPep ligand at 4°C had a higher 
absorption of 0.11 and 0.17, respectively (Fig. 4.2E). In contrast, the absorption of 
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the pellet of the cells incubated with 3% and 5% (mole/mole) gold nanoparticles 
FluPep ligand at 37°C was 0.22 and 0.42, respectively, while the absorption of the 
pellet of the cells incubated with 3% and 5% (mole/mole) gold nanoparticles FluPep 
ligand at 4°C was 0.13 and 0.2 respectively (Fig. 4.2F).  
Thus, at 37 °C, most of the FluPep ligand-nanoparticle conjugate is associated with 
a trypsin resistant compartment; at 4 °C, this fraction decreases by around 40 % to 
50 %. One interpretation of these data is that the FluPep ligand-nanoparticle 
conjugate is internalised. However, the fraction of FluPep ligand nanoparticles 
released by washing the cells with 2 M NaCl is less than that associated with the 
trypsin-sensitive compartment. The former will release FluPep ligand nanoparticle 
conjugates associated with anionic components on the cell surface. The difference 
between the two fractions may be due to steric hindrance by the nanoparticle, or of 
the protein it is associated with, preventing trypsin from cleaving the proteins.  
It appears that the nanoparticle-FluPep ligand conjugate binds to extracellular 
components, at least some of which are anionic, and does not readily dissociate into 
the bulk medium. This is reminiscent of how growth factors, and other protein 
ligands involved in paracrine signalling interact with sulfated glycosaminoglycans 
of the extracellular and pericellular matrix (Duchesne et al., 2012, Sun et al., 2016). 
To determine if FluPep ligand might interact with sulfated glycosaminoglycans 
competitions were performed.  FluPep ligand itself at 100 µM reduced the binding 
of gold nanoparticle-FluPep ligand conjugates by ~ 80%, whereas heparin at 100 
µM reduced the binding by 90% (Fig. 4.2D). The strong, but incomplete 
competition by FluPep ligand and heparin may reflect the multivalency of the gold 
nanoparticle-FluPep ligand conjugate, the very high capacity of its cell binding sites 
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or interactions with multiple and distinct cellular components. Nevertheless, these 
data demonstrate the specificity of the interaction of the FluPep ligand-nanoparticle 
conjugate and that it binds to anionic cellular components, which can be competed 
with heparin. 
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Fig. 4.2. Association of gold nanoparticles-FluPep ligand with MDCK cells. A. 
MDCK cells were treated with mix matrix gold nanoparticles, different mole % of 
gold nanoparticles -FluPep ligand and MDCK cells only, then incubated for one 
hour at 37 0C, thereafter unbound mix matrix gold nanoparticles and gold 
nanoparticle-FluPep ligand conjugates were removed and the cells washed with 1x 
PBS. The cells were then trypsinised to facilitate measurement of the absorbtion of 
the nanoparticles at 520 nm. B. Cells were washed with 1x PBS and then with 2 M 
NaCl, these fractions were collected and absorption measured at 520 nm. C. The 
previous steps were done in sequence in the cold room with fixed cells; washed 
with PBS, 2 M NaCl then trypsinised. D. competitions by including 100 µL heparin 
(100 µM) or free FluPep (100 µM). E and F measuring the contribution of 
internalisation to the association of nanoparticles funciotnalised by FluPep ligand 
to the cells. Binding of the nanoparticles functionalised with FluPep was performed 
at 37 °C or 4 °C. Following a wash with PBS, cells were trypsinised and centrifuged 
for 1 min at 10000 g and the absorbance of the nanoparticles at 520 nm measured. 
Results are the mean ± SD (n=3). 
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The gold nanoparticle-FluPep ligand conjugate has previously been shown to bind 
to CM-Sepharose, which is used to purify these nanoparticles (Chapter 3). Since 
the nanoparticle-FluPep ligand conjugates bound to cellular anionic components, it 
was of interest to determine if they would also bind to a heparin affinity matrix. The 
results showed that gold nanoparticles FluPep ligand conjugates, regardless of the 
mole/mole % functionalisation bound to a heparin affinity column. This binding 
was due to the FluPep ligand, since as the mole % of FluPep ligand increased, so 
did the percentage of gold nanoparticles binding to the column (Fig. 3). Moreover, 
as the mole % of FluPep ligand increased, so did the concentration of NaCl required 
for elution (Fig. 4.3). 
 
Fig. 4.3. Binding of gold nanoparticles functionalised with FluPep ligand to 
heparin affinity columns. (A) Image of columns following loading of gold 
nanoparticles functionalised with different mole % FluPep ligand and washing the 
columns with PBS. The pink colour represents bound nanoparticles. (B) 
Quantification of the % of nanoparticles unbound and eluted with 2 M NaCl from 
heparin affinity columns in terms of the mole % of FluPep ligand in the ligand 
mixture used to functionalise the nanoparticles. Results are the mean ± SD (n=3). 
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4.2.5.3 Binding of gold nanoparticle-FluPep ligand conjugates to fixed and 
enzyme-treated MDCK cells 
 To define better the anionic component(s) on the cells the gold nanoparticle-FluPep 
ligand conjugates interact with, cells were subjected to various enzyme treatments 
prior to measuring binding of the nanoparticles. To avoid the effect of the 
continuous biosynthesis of such molecules by cells and any acute effects due to the 
stimulation of a cell signalling pathways, fixed cells were employed. First the 
effects of fixation on the binding of the gold nanoparticle-FluPep ligand conjugates 
were determined. Following fixation, the amount of bound gold nanoparticle-
FluPep ligand conjugate was determined for fixed and live cells. MDCK cells were 
incubated with 10 µL nanoparticles functionalized with 5% (mole/mole) FluPep 
ligand in 440 µL PBS for 1 hour at 37 0C and then washed with PBS. Trypsinisation 
with 500 µL trypsin for 15 mins was used as before to enable quantification of cell-
associated nanoparticles. The results demonstrated that fixation did not affect the 
amount of FluPep ligand functionalised gold nanoparticles bound to the cells (Fig. 
4.4). 
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Fig. 4.4. Comparison of binding of FluPep functionalised nanoparticles to live 
and fixed MDCK cells. Cells (live and fixed were incubated with mix matrix gold 
nanoparticles, some functionalised with FluPep ligand, and the cell-associated 
nanoparticles quantified in a PBS wash and the trypsinised cells. Results are the 
mean ± SD of 3 experiments. 
A series of enzyme digestion experiments with neuraminidase (sialidase), 
heparinase and chondroitinase ABC were then used to determine what FluPep 
ligand was binding to in the pericellular matrix of MDCK cells. Following 24 h 
digestion of fixed cells, they were incubated with gold nanoparticles functionalised 
with 3% and 5% (both mole/mole) FluPep ligand 1 hour at 37 0C. Cell-associated 
gold nanoparticles were quantified by measuring the absorption at 520 nm of 
trypsinised cells. In untreated cells, the absorption of the trypsinate was between 
0.47 and 0.52. In neuraminidase treated wells the absorption was reduced to 0.13-
0.14, a ~70% decrease (Fig. 4.5A). Similarly, treatment of the cells with heparinase 
reduced the amount of bound FluPep ligand functionalised gold nanoparticles by ~ 
80%, whereas chondroitinase ABC digestion had no effect on the absorption at 520 
nm of the trypsinate (Fig. 4.5B). These data demonstrate that the FluPep ligand 
functionalised gold nanoparticles bind to sialic acid-containing glycans and to 
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heparan sulfate, the latter being consistent with the in vitro binding of the 
nanoparticles to a heparin-affinity column (Fig. 4.3). It is interesting to note the 
selectivity of FluPep ligand binding, since no chondroitinase ABC sensitive 
interaction was detected; it is important to note that the inclusion of BSA with the 
chondroitinase was important to block the small amount of contaminating protease 
that is often in commercially sourced enzymes. Neuraminidase and heparinase, 
reduced, but did not abolish the binding of the FluPep ligand-functionalised gold 
nanoparticles. However, when cells were digested with both enzymes the amount 
of bound FluPep ligand functionalisd gold nanoparticles was reduced by ~96% (Fig. 
4.5C). These data indicate that sialic acid containing glycans and heparan sulfate 
represent the major binding sites of FluPep ligand on cells. Thus, it is likely that it 
is through these interactions that FluPep ligand exerts its effect, directly or 
indirectly. 
In the original work, RRKK was added to either the N or C termini of the peptide 
derived from the sequence of TKIP, in order to improve solubility in aqueous 
solution (Nicol et al., 2012). We reasoned that this basic tract of amino acids may 
be responsible, at least in part, for the interaction of FluPep ligand-conjugated 
nanoparticles with anionic polysaccharides. To test this idea, gold nanoparticles 
were functionalised with FluPep ligand and with FluPep ligand lacking this basic 
tract of amino acids (FluPepRRKK). A considerable amount of the FluPep ligand 
functionalised nanoparticles bound the cells (absorption at 520 nm of 0.55) and 80% 
of this binding was sensitive to neuraminidase (Fig. 4.5D). However, less gold 
nanoparticles functionalised with FluPepRRKK bound to the cells and 
neuraminidase treatment only reduced this by 43% (Fig. 4.5D). Thus, the TKIP 
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sequence itself does engage with these anionic polysaccharides, but the enhanced 
binding of FluPep ligand observed when it contains the RRKK C-terminal sequence 
is likely due to this enhancing the interaction of the original Tkip-derived peptide 
with sialylated glycans and in all likelihood heparan sulfate. The basic tract is less 
likely to impart any degree of selectivity. Consequently, the lack of effect of 
chondroitinase ABC digestion may reflect the selectivity of the TKIP sequence for 
sialic acid and heparan sulfate, with the C-terminal basic tract enhancing binding to 
these, but unable to override the selectivity. 
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 Fig. 4.5. Sensitivity of binding of FluPep functionalised nanoparticles to 
degradation of cellular polysaccharides.  Fixed MDCK cells were subjected to 
digestion with neuraminidase or heparinases andthen incubated with FluPep 
functionalised nanoparticles. Cells were then washed with PBS and then trypsinised 
to enable quantification of the nanoparticles by their absorption at 520 nm. A. 
Neuraminidase. B heparinase and chondroitinase ABC digestions. C sequential 
digestion with heparinase and neuraminidase. Treated with enzyme(s) (+) and non-
treated (+) D Investigating the effect of RRKK on TKIP ability to engage to 
anaionic extracellular compounds cells were pre-treated with FluPep ligand and 
with FluPep lacking RRKK then treated with neuraminidase.  
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4.2.5.4 Anti-viral activity of cell bound gold nanoparticle-FluPep ligand 
conjugates 
Over half of the gold nanoparticle-FluPep ligand conjugate added to cells were 
bound. Moreover, the C-terminal sequence, RRKK not only enhanced cell binding 
(Fig. 4.5D), but was also shown to increase the anti-viral activity of the Tkip peptide 
(Nicol et al., 2012b). Consequently, it seems likely that cells can be loaded with 
gold nanoparticle-FluPep ligand conjugate, and washed and be protected from viral 
infection by the pool of cell-associated gold nanoparticle-FluPep ligand conjugates. 
In a control experiment, cells were washed with 2 M NaCl and then infected with 
virus. This showed that the 2 M NaCl wash has no effect on viral infectivity, and 
so on cell viability (Fig. 4.6A). Moreover, the dose response to free FluPep peptide 
was identical whether the cells had been washed beforehand with 2 M NaCl or not 
(Fig. 4.6A). Cells were then incubated with gold nanoparticle-FluPep ligand 
conjugates functionalised with different mole % FluPep ligand, washed with PBS 
and then subjected to a plaque assay. The results demonstrate that the gold 
nanoparticle-FluPep ligand conjugate that remains bound to the cells after the PBS 
wash (Fig. 4.6B) is capable of inhibiting the infectivity of influenza virus (Fig. 
4.6B). The IC50 is around 734-220 pM, higher than determined previously for the 
gold nanoparticle-FluPep ligand conjugate without washing (Table 2 chapter 3), 
presumably due to removal of virus loosely associated with the cells o in the 
medium residue left after aspiration. When the cells are washed with 2 M NaCl after 
the incubation with nanoparticle-FluPep ligand conjugate, there was very little 
inhibition of viral infectivity apparent (Fig. 4.6C). Thus, the fraction of 
nanoparticle-FluPep ligand conjugate that can be removed from the cells with 2 M 
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NaCl and so which is interacting with anionic components of the cell surface seems 
responsible for much of the anti-viral activity. Analogous experiments with 
heparinases and sialidase were not possible, since these would also affect the ability 
of the virus to bind and infect cells, so confounding the analysis. 
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Fig. 4.6. Anti-viral activity of cell bound gold nanoparticle-FluPep ligand 
conjugates. MDCK cells were pre-treated with nanoparticles functionalised with 
different mole % of FluPep ligand one hour before virus treatment. Cells were, 
where applicable, washed with the indicated solutions and then infected with ‘flu 
virus and a plaque assay performed. A. Comparison of the anti-viral effect of 
FluPep ligand on cells washed with PBS or 2 M NaCl to determine if the short 
exposure to a hyper osmolar solution affected cell viability and so viral infectivity. 
Cells were washed with the respective solution and then incubated with FluPep 
ligand and virus and plaques measured. B, C cells were incubated with 
nanoparticles functoinalised with different mole % FluPep and then washed with 
PBS (B) or 2 M NaCl (C), after which cells were infected with ‘flu virus and the 
number of playes determined. Results are the mean ± SD (n=3). 
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4.2.5.5 Antiviral activity of FluPep, FluPep ligand and gold nanoparticles -
FluPep ligand conjugates with respect to RRKK  
We next determined the contribution of the RRKK sequence to antiviral activity of 
the peptides alone, of the peptide ligands (so incorporating the N-terminal sequence 
required for nanoparticle functionalisation) and of FluPep ligand-nanoparticle 
conjugates (Table 4.1). With the peptides alone, FluPep had the greatest antiviral 
activity, while RRKKFluPep (so with the basic tract at the N-terminus, rather than 
the usual C-terminal position) possessed a slightly lower antiviral activity and 
finally FluPepRRKK had the lowest antiviral activity (Fig. 4.7A Table 4.3). The 
antiviral activity of the corresponding the ligands was lower, in agreement with 
previous data that show that the N-terminal sequence CVVVTAA reduces antiviral 
activity (Chapter 3), and the rank order of potency of the peptides was slightly 
different: the postion of the RRKK sequence (N- or C-terminal to the TKIP 
sequence) has little effect, though the absence of this basic tract again reduced the 
anti-viral activity of the peptides (Fig. 4.7B, Table 4.3). The four basic residues on 
their own were without effect (Fig. 4.7B). 
When gold nanoparticles were functionalised with these peptides, the position of 
the basic tetrapeptide, RRKK, made little difference to the antiviral activity of the 
nanoparticles (Figs 4.7C). However, as found for the free peptides, the absence of 
this basic sequence reduced the potency of the functionalised nanoparticles 
considerably (Fig. 4.7C and Table 4.6). Thus, gold nanoparticles functionalised 
with FluPep RRKK, possessed IC50 values, of 59 pM (5% mole/mole) and 278 
pM (0.3% mole/mole) (Fig. 4.7C), which are considerably higher than found for 
FluPep ligand (Table 4.6). 
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Table 4.3: (IC50) of different free FluPep in a plaque assay. Results are the mean 
±SD (n=3). 
 
 
Table 4.6: IC50 of different mole% of gold nanoparticles-FluPep, RRKK 
FluPep and FluPep  RRKK with respect to gold nanoparticles. Results are 
the mean ±SD (n=3). 
 
 
 
 
 
 
 
 
 
Peptide IC50  (nM) 
FluPep 0.14 
RRKK FluPep 1.52 
FluPep RRKK 2.57 
FluPep ligand  2.13 
RRKK FluPep ligand 3 
FluPep ligand RRKK 3.2 
Super FluPep 1 0.9 
Super FluPep 2 0.09 
Peptide 
mole% 
FluPep ligand 
IC50 nM 
RRKK FluPep 
IC50 nM 
FluPep RRKK 
IC50 nM 
0.03% 0.072 0.126 0.27 
0.1% 0.068 0.075 0.21 
0.3% 0.058 0.060 0.16 
1% 0.023 0.032 0.088 
3% 0.016 0.018 0.068 
5% 0.015 0.018 0.059 
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Fig. 4.7. Influence of the RRKK sequence on the antiviral activity of FluPep 
ligand. (A) A comparison of the antiviral activity of TKIP peptides lacking the 
RRKK sequence (FluPep) or with this sequence at the C-terminus (FluPep) or the 
N-terminus. (B) A comparison of the same peptides in (A), but in the form of 
nanoparticle ligands, so with CVVVTAAA at the N-terminus. In addition, the 
antiviral activity of a peptide without the TKIP sequence, so just RRKK, was 
measured. (C) A comparison of the antiviral activity of gold nanoparticles 
functionalised with different mole % of the peptide ligands in (B). Results are the 
mean ± SD (n=3). 
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4.2.5.6 FluPep ligand with protein-derived heparin binding sites 
FluPep ligand -functionalised gold nanoparticles bound to both sialic acid and 
heparan sulfate on cells and to heparin-affinity columns (Figs. 4.5A, B). Moreover, 
a variety of chemically modified heparin derivatives, some with very weak 
anticoagulant activity, have been shown to inhibit ‘flu virus H5N1 entry into cells 
using a pseudo virus type assay (Skidmore et al., 2015). Selectivity of the virus for 
particular sulfation patterns in heparin that would be more commo0n in cellular 
heparin sulfate was demonstrated by virtue of 6-O desulfated heparin possessing 
much less inhibitory activity that heparin itself, whereas 2-O desulfated heparin was 
considerably more active. There is a considerable amount of published data on 
protein structures and sequences that bind to heparin and heparan sulfate (Ori et al., 
2008, Ghezzi et al., 2017). We reasoned that incorporating such sequences in place 
of the RRKK sequence might enhance the activity of the FluPep ligand further, by 
providing a more selective and higher affinity interaction with heparan sulfate. 
Indeed, such an approach has been used to increase the binding to heparan sulfate 
and activity of growth factors (Martino et al., 2014). Two sequences were chosen. 
One was derived from placental growth factor2 (PLGF2), and corresponds to a 
sequence used to enhance growth factor heparan sulfate binding (Martino et al., 
2014) and the other from the cannonical heparan binding site of fibroblast growth 
factor7 (FGF7) (Xu et al., 2012) and are termed “super FluPep 1” and ‘super FluPep 
2”, respectively (Table 4.1). Nanoparticles functionalised with either of these 
peptides were as stable as ones functionalised with FluPep, in terms of their 
resistance to ligand exchange (Fig. S 1-2. The relative affinity for heparin of gold 
nanoparticles functionalised with 0.1 % (mole/mole) FluPep ligand, Super FluPep 
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1,2 was determined in terms of the concentration of NaCl required for elution from 
a heparin affinity column. Elution of FluPep ligand functionalised nanoparticles is 
apparent at 0.6 M NaCl and 1 M NaCl (Fig. 4.8). In contrast, both super FluPep 1 
2 functionalised nanoparticle required 1.5 M to 2 M NaCl for elution, demonstrating 
that these had a stronger electrostatic interaction with the polysaccharide (Fig. 4.8).  
 
Fig. 4.8. Comparison of concentration of NaCl required to elute gold 
nanoparticles functionalised with FluPep, super Flupep1 and super Flupep2 
from heparin affinity columns. The nanoparticles functionalised with the 
respective FluPep ligand were applied to a heparin affinity column, which was then 
eluted with increasing concentrations of NaCl. Nanoparticles were quantified by 
their absorption at 450 nm. Results are the mean ± SD (n=2). 
4.2.5.7 Antiviral activity of super FluPep 1 and 2 
The antiviral activity of the super FluPep 1 and 2 peptides (Table 4.1) alone and 
conjugated to gold nanoparticles was measured. Both peptides inhibited viral 
infectivity in a concentration-dependent manner and were more effective than 
FluPep ligand (Fig. 4.9). Thus IC50 of the super FluPep 1 and 2 ligands was 900 and 
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90 pM, respectively. As noted previously (Chapter 3) the FluPep ligand is less 
potent than FluPep, likely due to the N-terminal CVVVTAA sequence necessary 
for incorporation into nanoparticle ligand shells. Thus, addition of the heparin 
binding sequences derived from PLGF and FGF7 rendered the FluPep ligand 
peptide as potent as the FluPep peptide.  
 
Fig. 4.9. Anti-viral activity of TKIP peptides carrying various basic sequence 
extensions. Virus infection of a monolayer of MDCK cells was performed in the 
presence of FluPep, FluPep ligand, with the N-terminal extension necessary for 
conjugation to gold nanoparticles, and two peptides where the RRKK sequence of 
FluPep is replaced by a known heparin-binding sequence, Super FluPep 1 and Super 
FluPep2. Results are the mean ±SD (n=3). Error bars may be smaller than the 
symbol 
The antiviral activity of nanoparticles functionalised with different mole % of super 
FluPep 1 and 2 was measured. The number of viral plaques was reduced as the 
concentration of gold nanoparticles functionalised with either super FluPep 1 ligand 
or Super FluPep 2 ligand increased (Figs 4.10 A, B). Thus, for gold nanoparticles 
functionalised with 0.03% (mole/mole) Super FluPep 1 and 2, the number of 
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plaques started to decrease at 20 pM gold nanoparticles and reached a minimum of 
around 13-17 plaques at 200 pM (Figs 4.10. A, B). As the grafting density of Super 
FluPep ligands was increased, so did the antiviral activity, to reach a maximum at 
5 % (mole/mole) super FluPep1,2 (Figs 4.10. A, B). This is reflected by the 
decreased IC50, which shows a 5-fold greater potency of nanoparticles 
functionalised with 5 % (mole/mole) super FluPep1 and super FluPep2  ligand 
compared to nanoparticles functionalised with just 0.03 % (mole/mole) of these 
ligands (Tables 4.4 and 4.5). It is noteworthy that the antiviral activity of super 
FluPep1 and 2 conjugated to gold nanoparticles is greater than that of the free 
peptides (Tables 4.4 and 4.5). 
 
Table 4.4: (IC50) of different mole % of super FluPep 1 with respect to gold 
nanoparticles. Results are the mean ±SD (n=3). 
Mole % super FluPep1                     IC50 nM 
0.03 0.060 
0.10 0.058 
0.30 0.027 
1 0.018 
3 0.013 
5 0.012 
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Table 4.5: (IC50) of different mole% of super FluPep 2 with respect to gold 
nanoparticles. Results are the mean ±SD (n=3). 
Mole % super FluPep 2  IC50 nM 
0.03 0.063 
0.1 0.057 
0.3 0.028 
1 0.01 
3 0.013 
5 0.013 
 
However, the data also demonstrate that free FluPep and FluPep ligand are less 
active than nanoparticles grafted with a single FluPep ligand. This was suggested 
to be due to FluPep weakly self-associating, perhaps due to its hydrophobicity (with 
FluPep ligand being more hydrophobic than FluPep), while the monomeric species 
is the most active with respect to inhibiting influenza virus infectivity (Chapter 3). 
Such self-association might be greater for a nanoparticle surface with several 
grafted functional ligands. The association of functional peptides grafted into a 
peptide ligand shell on nanoparticles has been observed directly previously 
(Duchesne et al., 2008b). Alternatively, the targets for FluPep may be separated by 
a distance similar or greater than their average physical separation on nanoparticle 
surface, resulting in only some of the grafted FluPep ligands on the nanoparticle 
surface being able to exert an antiviral activity.  
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The IC50 values for Super FluPep 1 and 2 were compared to those of the other 
peptides and it is clear that the addition of the heparin-biding sequences for PLGF 
and FGF7 enhanced the antiviral activity of the peptide and peptide-nanoparticle 
conjugates considerably (Fig. 4.10. C) (Table 4.3). Thus, enhancing the interaction 
of FluPep with extracellular/pericellular matrix appears to be a valid strategy for 
enhancing its inhibition of infectivity in at least the MDCK model. 
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Fig. 4.10. Anti-viral activity of gold nanoparticles functionalised with super 
FluPep 1 and super FluPep 2. MDCK monolayers were incubated with influenza 
virus and nanoparticles functionalised with different mole % of super FluPep 1 and 
super FluPep 2, following which the number of plaques was determined. 
Dependence of inhibition of plaque formation on the concentration of gold 
nanoparticles and the % (mole/mole) of super FluPep 1 ligand (A) and super FluPep 
ligand 2 (B). (C) Comparison of IC50 values for nanoparticles functionalised with 
super FluPep ligand 1 and 2 and FluPep ligand variants. Results are the mean ±SD 
(n=3). 
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4.2.6 Conclusion 
The FluPep ligand, when conjugated to nanoparticles binds to cells, rather than 
virus. Cell binding is likely to be key to the mechanism of FluPep’s antiviral 
activity, since enhancing cell binding enhances the antiviral activity of the peptide. 
Interestingly, cell binding is relatively selective, since FluPep ligand binding was 
sensitive to neuraminidase and heparinase, but not chondroitinase ABC treatment, 
despite chondroitin sulfates possessing a high charge density. Thus, while the 
RRKK basic tract enhanced the activity of FluPep ligand, this is likely to be relative 
non-elective in terms of its interactions with sulfated polysaccharides; the 
selectivity is, therefore likely to reside within the TKIP-derived sequence and may 
involve a combination of ionic bonding and H-bonding, the latter through the 
amides of the peptide bond. In terms of the mode of action of FluPep ligand, its 
glycan selectivity is consistent with the documented importance of sialic acid 
binding in infectivity and the anti-viral activity of heparin compounds (Bateman et 
al., 2008),(Hosoya et al., 1991). This indicates that engineering an even more 
effective FluPep, by analogy with the engineering of more potent growth factors 
(Martino et al., 2014) depends on increasing the interaction of the peptides with 
some of the charged glycans of the pericellular matrix of cells. Given the very 
substantial literature on the structures in proteins responsible for binding heparan 
sulfate (Ori et al., 2008, Ghezzi et al., 2017), it should be possible to design FluPep 
type sequences with even more potent anti-viral activity. 
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4.2.7.1 Purification of superFluPep functionalised AuNPs 
Since FluPep ligand and the two super FluPep ligands will carry a net positive 
charge at neutral pH, cation-exchange chromatography was used to purify 
functionalised gold nanoparticles. As for FluPep (Chapter 3), super FluPep 1 and 2 
functionalised gold nanoparticles bound to CM Sepharose and were eluted by 
increasing electrolyte concentrations (Fig. SI 1). To functionalise the nanoparticles, 
functional ligands, are included in the ligand mix, and their mole % in relation to 
the matrix ligand reflects their grafting density on the gold nanoparticles (Levy, 
2006, Duchesne et al., 2008a, Duchesne et al., 2012) (Free et al., 2012, Paramelle 
et al., 2015, Nieves et al., 2014, Levy et al., 2006a). Gold nanoparticles with a range 
of mole % of ligands were synthesized and applied to a CM-Sepharose column and 
those that were functionalised eluted with 1.5-2 M NaCl. Quantification of the gold 
nanoparticles by UV-Vis spectrophotometry then allowed the relation of bound and 
unbound GNPs to the mole % of FluPep in the original ligand mixture to be 
analysed. The data indicate that at 0.03% mole % ligand, ~10% of the nanoparticles 
bound the column and thus most (~95 %) of these gold nanoparticles will possess 
just a single functional ligand (Levy, 2006). At higher mole % the number of ligands 
per nanoparticle will increase. 
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Fig. S 1. Purification of super FluPep ligand functionalised gold nanoparticles 
by CM-Sepharose cation-exchange chromatography. Gold nanoparticles 
functionalised with different mole % super FluPep ligand were subjected to 
chromatography on CM-Sepharose. Top, images of columns after loading and 
washing with PBS. Bottom, quantification of unbound (through and PBS wash 
fractions) and bound (eluted with 2 M NaCl) fractions. Results are the mean ± SD 
(n=3). 
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4.2.7.2 Stability of super FluPep 1 and 2 functionalised gold nanoparticles 
Gold nanoparticles with a ligand shell incorporating 5% (mole/mole) super FluPep 
1 and 2 ligand had a very similar resistance to ligand exchange with DTT as the 
control mix matrix protected gold nanoparticles. Thus, their aggregation parameter 
was unchanged up to 10 mM DTT, even after 48 h incubation (Figs. S2,B, C). At 
25 mM DTT after 48 h there was some evidence for ligand exchange, as the 
aggregation parameter was above 1.0 and the ligand shell was clearly compromised 
(Figs S3, S4, A-F). Consequently, the incorporation up to 5% (mole/mole) FluPep 
ligand in the ligand mixture did not reduce the stability of the gold nanoparticles 
with respect to ligand exchange. 
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Fig. S 2. Stability of gold nanoparticles to DTT ligand exchange (A) UV-Vis 
spectra of mix matrix capped gold nanoparticles and mix matrix capped gold 
nanoparticles incorporating 5% (mole/mole) super FluPep ligand 1 and 2 in PBS. 
(B)Time and dose-dependence of DTT ligand exchange for (C) mix matrix gold 
nanoparticles with a ligand shell incorporating 5% (mole/mole) super FluPep 
ligand1. Results in (b) and (C) are the mean ± SD (n=3) 
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Fig. S 3. DTT Stability test of gold nanoparticles functionalised with super 
FluPep 1. Gold nanoparticles were incubated with varying concentrations of DTT 
for different time intervals, UV-Vis spectrum and the normalised aggregation 
parameter was calculated. A 70:30 CVVVT-ol HS-(CH
2
)
11
-EG
4
-OH mix matrix 
Gold nanoparticles. B 0.1%(mole/mole) FluPep functionalised Gold nanoparticles. 
C 0.3% (mole/mole) FluPep functionalised Gold nanoparticles. D 1 %( mole/mole) 
FluPep functionalised Gold nanoparticles. E 3% (mole/mole) FluPep functionalised 
Gold nanoparticles. F 5 % (mole/mole) FluPep functionalised Gold nanoparticles. 
Results are the mean ± SD (n=3). 
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Fig. S 4: Stability of gold nanoparticles functionalised with super FluPep 2. 
Gold nanoparticles were incubated with varying concentrations of DTT for different 
times intervals, UV-Vis spectrum and the normalised aggregation parameter was 
calculated. A 70:30 CVVVT-ol HS-(CH
2
)
11
-EG
4
-OH mix matrix Gold 
nanoparticles. B 0.1%(mole/mole) FluPep functionalised Gold nanoparticles. C 
0.3% (mole/mole) FluPep functionalised Gold nanoparticles. D 1 %( mole/mole) 
FluPep functionalised Gold nanoparticles. E 3% (mole/mole) FluPep functionalised 
Gold nanoparticles. F 5 % (mole/mole) FluPep functionalised Gold nanoparticles. 
Results are the mean ± SD (n=3) 
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4.3 Discussion 
 
It was demonstrated in the current work that gold nanoparticles-FluPep ligand 
conjugates didn’t bind to the virus. In contrast, these nanoparticles associated with 
cells. The majority of the cell-associated FluPep ligand functionalised nanoparticles 
were bound to heparan sulfate and sialic acids; these interactions were additive, in 
that digestion of cells with both heparinases and neuraminidase reduced binding of 
nanoparticles to a greater extent than digestion with either alone. It was interesting 
to observe that chondroitinase ABC digestion had not effect on the interaction of 
FluPep conjugated nanoparticles with MDCK cells. Since these cells produce 
chondroitin sulfate proteoglycans and these are found in their pericellular matrix 
(Borges et al., 2005), these data indicate that FluPep is somehow selective for sialic 
acid and heparan sulfate. 
The interactions with sialic acid and heparan sulfate are linked to the mechanism of 
action of FluPep. For example, the FluPep functionalised nanoparticles bound to 
the cell were able to protect the cell from subsequent viral infection. The affinity of 
FluPep for heparin, so in all likelihood heparan sulfate, was increased by replacing 
the RRKK C-terminal sequence with those from protein heparin binding sites. This 
was shown to increase the anti-viral activity of the peptides and nanoparticle 
conjugates produced with these peptides.  The IC50 values for the peptides and the 
peptide-nanoparticle conjugates are generally in the mid to high pM-nM. The 
affinity for sialic acid and heparan sulfate is unlikely to be equivalent. For example, 
heparin-binding proteins generally have affinities in the mid to high nM range for 
heparin/heparan sulfate (Ori et al., 2008), whereas the various FluPep peptides will 
present a relatively unstructured set of basic side chains for binding. Moreover, the 
number of binding sites on these polysaccharides is extremely high, for example in 
fibroblasts it is of the order of one million heparan sulfate binding sites for FGF2 
(Duchesne et al., 2012). These considerations suggest that direct competition for 
viral binding sites may not be the underlying mechanism for the anti-viral action of 
FluPep. However, there are two mitigating considerations that suggest direct 
competition cannot be completely ruled out at this stage. One is that a large amount 
of the peptide/nanoparticle binds to the cell pericellular matrix, so its effective 
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concentration in this small volume will be much higher. From this perspective direct 
competition might still be a valid mechanism. The other is that not all sialic acids 
and heparan sulfates are equivalent: sialic acid can occur on different structures and 
the underlying glycans for N-glycans, can have different numbers of branches; 
heparan sulfate itself is very polydisperse with a vast array of sulfation patterns 
produced by cells (Ori et al., 2008). In addition, it is not evident that for virus 
internalisation that binding sites on, e.g.., sialic acid, are the receptor. That is not all 
glycoproteins with sialic acids are likely to be able to trigger virus internalisation. 
There is thus the possibility that FluPep selectively binds to the 
polysaccharide/protein unit that represents the receptor for internalisation. The 
alternative is that FluPep activates a cell surface receptor that in turn activates a 
cellular anti-viral response. These ideas are explored in more detail in the following 
chapter. 
4.4 Conclusion 
After the successful functionalisation of gold nanoparticles with FluPep ligand and 
investigating their potential antiviral activity, the next step of work moved to 
investigate the possible FluPep ligand mechanism of action. It was believed by the 
group of Edinburgh University (Nicol et al., 2012) that the FluPep mechanism by 
interacting with viral hemagglutinin. However, FluPep ligand didn’t interact with 
hemagglutinin. Based on initial work, gold nanoparticles-FluPep ligand conjugates 
were bound to heparin column, this means gold nanoparticles-FluPep ligand 
conjugates bind to carbohydrates and possibly one of the extracellular anionic 
sulfated GAGs. Pretreatment of MDCK cells with gold nanoparticles-FluPep ligand 
conjugates showed that the hypothesis is true since the pretreatment significantly 
reduced the viral activity. Enzyme degradation assay with heparinises, 
neuraminidase and chondroitinase ABC demonstrated that FluPep ligand binding 
sites are heparan sulfate and sialic acids but not chondroitin sulfate, these data 
indicate that FluPep is somehow selective for sialic acid and heparan sulfate. New 
designed FluPep with an extensions from protein to replace RRKK with heparin 
binding sites called super FluPep 1, 2. Their antiviral activity were significantly 
high as their mechanism of action by increasing the local concentration in the 
pericellular matrix. 
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Chapter 5 
General Discussion 
5.1 Overview 
Peptides as therapeutics have gained traction ever since the FDA approved 
Enfuvirtidie against HIV (Cooper and Lange, 2004). A number of peptides have 
been discovered to possess antiviral activity in cell and animal models (Section 1.5) 
The initial work on FluPep (Nicol et al., 2012b) demonstrated that it effectively 
inhibited viral activity in cell and animal models (Section 1.5). Importantly, the 
latter work demonstrated that nasal delivery was sufficient. This means that a future 
drug based on FluPep would be simple to administer via a standard nebuliser. ‘Flu 
remains a major health concern; the occurrence of epidemics and pandemics is 
certain, what is uncertain is when and what will be the virus strain responsible. 
Vaccines are unable, within the current economic model to cover all the population 
and they are not always fully effective and have a long lead time. Therefore, the 
development of drugs that prevent ‘flu infection is a high priority (Section 1.2.3).  
Thus, FluPep is a potential lead to a drug that prevents ‘flu infection.  
There are major gaps in our understanding of how FluPep exerts its antiviral activity 
(Section 1.5). The synthesis of a FluPep with a probe that can be detected with high 
sensitivity is one key step if the mode of action of FluPep is to be established. In 
this thesis noble metal nanoparticles were chosen as the probes. This is because 
they can be detected optically with high sensitivity, and at the limit at the single 
nanoparticle level (Section 1.4.3). Radioactive peptides would also be very 
sensitive, but would limit analysis to cultured cells, would present longer time 
delays between experiment and acquisition of measurement data, and restrictions 
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on their use could limit the range of possible experiments. Fluorescent labels may 
have a greater impact on the physicochemical properties of the peptide, because 
unlike noble metal nanoparticles their interaction with molecules in the 
environment is not physically separated from their optical detection (Section 1.4.6). 
Moreover, the complete optical stability of noble metal nanoparticles, e.g., no 
photobleaching, and their high density relative to biological molecules means they 
can be used to purify an associated functional peptide from a biological system. 
This first aim of the thesis was to establish whether FluPep ligand functionalised 
nanoparticles retained any antiviral activity. Considerable effort was put into 
redesigning nanoparticle ligand shells, which were found to be sufficiently 
hydrophobic to bind strongly to hydrophobic interaction chromatography matrices.  
Beyond demonstrating that the mix matrix ligand shell was rather hydrophobic, this 
work did not yield a new, non-hydrophobic ligand shell that imparted good stability 
to the nanoparticles (Chapter 2). However, the successful functionalisation of 
nanoparticles with FluPep ligand and the purification route of these nanoparticles 
from non-functionalised ones on CM-Sepharose was demonstrated (Section 2.9.2), 
essential steps for the analysis of the antiviral activity of the functionalised 
nanoparticles. 
FluPep ligand functionalised gold and silver nanoparticles were found to possess 
antiviral activity (Chapter 3). The observation that silver nanoparticles 
functionalised with FluPep ligand possessed anti-viral activity illustrates the 
potential to design a future entity with two active substances: the anti-viral peptide 
and silver, as the latter is demonstrated to have anti-bacterial and antiviral activity 
in its own right. 
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A first question regarding the mechanism of action of FluPep ligand was whether it 
bound to virus or cells, or both. The experimental data (Chapter 4) demonstrate that 
FluPep ligand functionalised nanoparticles interacted solely with cells. A series of 
experiments were designed to establish the classes of molecules FluPep ligand 
interact with. These were found to comprise sialic acid and heparan sulfate, but not 
chondroitin sulfate, demonstrating an unexpected degree of selectivity on the part 
of the peptide. These discoveries led to a hypothesis: that binding to pericellular 
matrix would enhance the activity of FluPep ligand. This was tested using 
sequences of amino acids known to bind heparan sulfate and designing two new 
version of FluPep ligand, super FluPep 1 and super FluPep2. Both showed 
enhanced antiviral activity, demonstrating that this strategy, at least in the context 
of a cell based assay, will increase the antiviral activity of the peptide. 
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5.2 Future work 
The experimental results presented in this thesis lay the foundation for future work 
that aims to establish fully the mechanism of action of FluPep ligand in cultured 
cells and in animal models, and the engineering of FluPep derived peptides that 
provide long-lasting protection against ‘flu infection. Should this future work be 
successful, this would pave the way for clinical trials. 
The current evidence suggests that FluPep ligand may exert its antiviral activity by 
preventing the virus from either binding or delivering its genome to the cell’s 
cytosol. An alternative mechanism would be the delivery of the peptide to the 
cytosol. This seems unlikely due to the likelihood of proteolysis in endosomes and 
the cytosol, the absence of any negative effect of the nanoparticle on the antiviral 
activity of FluPep and of the addition of substantial sequences of amino acids in 
super FluPep 1 and super FluPep2. To provide direct evidence for an extracellular 
mode of action the presence of virus in the cells needs to be measured, along with 
the longevity of the protection of cells from infection by FluPep. Virus in cells can 
be determined using RT-PCR to measure viral RNA. By performing the 
measurements over days-weeks, the presence of any virus in the cells long after 
intracellular FluPep would be degraded will provide the necessary evidence. In 
addition, the by adding FluPep at different times after virus infection has been 
initiated may show whether it prevents spread of the infection (so acts outside the 
cells) or prevents replication of  existing virus in already infected cells (so acts in 
cells). 
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FluPep’s likely inhibition of virus infectivity by preventing its interaction with its 
receptors seems unlikely to be based on direct competition within the framework of 
current model for virus binding (Section 1.1.4). Only very modest concentrations 
of FluPep are required activity and given the consequent low IC50 of FluPep direct 
competition cannot account for the anti-viral activity of the peptide. The number of 
sialic acid and heparan sulfate binding sites on a cell is high (for example, over 106 
heparan sulfate binding sites per cell for FGF2, which binds a fairly common 
sequence of saccharides (Duchesne et al., 2012) that it is difficult to see how FluPep 
at pM concentrations could block these. However, it should be noted that the actual 
receptors responsible for ‘flu virus endocytosis are not well defined beyond the 
level of the glycan (Air, 2014). Viral HA binds to sialic acid and this is deemed by 
the field to be how the virus triggers its internalisation into endosomes (Section 
1.1.4). Sialic acid is a common terminal sugar on N- and O-glycans, so is present 
on most glycoprotein; most cell surface proteins are glycoproteins (Varki, 2008). It 
is not clear why binding to any of these will trigger a signalling response inside the 
cell that will cause internalisation. It seems more likely that only binding to a subset 
of these cell-surface glycoproteins will cause internalisation and thus all sialic acid 
containing glycoproteins may not be equivalent from the virus’ perspective.  
Moreover, it is not obvious whether the observed inhibition of virus infectivity by 
heparins (Skidmore et al., 2015) is due to inhibition of virus binding to heparan 
sulfate or to sialic acid. Thus, it may be that our understanding of the molecular 
targets of ‘flu virus on the cell surface is insufficient. In this respect, a paper 
demonstrating that inhibition of the fibroblast growth factor receptor kinase 
prevented viral infectivity (Liu et al., 2015) is suggestive. Like all receptor tyrosine 
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kinases, fibroblast growth factor receptors are N-glycosylated and the latter are 
documented to be sialylated (Duchesne et al., 2006).  Thus, internalisation of the 
virus may requires glycans (sialic acid and/or heparan sulfate) associated with 
particular cell surface receptors. The remaining glycan binding sites would then act 
as a reservoir, preventing the virus from leaving the vicinity of the cell and in vivo 
being swept away by the mucocilary escalator of the respiratory tract. This would 
allow a re-interpretation of the concept of ‘balance’ between HS and NA (Byrd-
elotis et al., 2017), whereby NA activity cleaving sialic acids would enable HA to 
‘explore’ the array of glycoproteins on the cell surface and in time enable the virus 
HA to bind sialic acids associated with a true receptor, that is a glycoprotein capable 
of triggering endocytosis. In this case, FluPep may exert its activity by binding both 
the protein and the glycan partner, so it possesses a dual receptor system. By 
analogy with the many natural dual receptor systems, including that of the fibroblast 
growth factors, affinity for each individual receptors is likely relatively low, but 
combined is high. The interaction with a high capacity binding site such as heparan 
sulfate ensures a pool of pericellularly located peptide at high local concentration. 
Thus, to define the mechanism of action of FluPep, it is also necessary to define the 
receptors of ‘flu virus at the cell surface. One obvious route to achieve this is mass 
spectrometry. Protection and labelling approaches, as used to define heparin 
binding sites in proteins, (Ori et al., 2009) would at the least uncover the basic 
residues in the viral proteins responsible for interaction with anionic species on the 
cell surface; they might also identify basic residues in cellular proteins involved 
directly or indirectly in virus binding. Label transfer reactions such at APEX fusion 
proteins (Martell et al., 2012) would be more challenging, as they would involve 
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insertion of APEX into viral envelope proteins. Should such viruses remain 
infective, they could then be used to biotinylated molecules within `20 nm of the 
virus. Analogous experiments would be performed with FluPep. This work would 
establish the binding sites and receptors for both virus and FluPep. Genetic 
disruption with e.g., SiRNA, would enable validation of receptor candidates and 
from there mechanism of action of FluPep. 
In vivo work would have three aims.  
First would be to determine the extent to which the observation in vitro that heparin-
binding peptide sequences enhance antiviral activity. Should this be the case, then 
this work would pave the way to the design of more effective peptides.  
Second is the pharmacokinetics (so the fate of FluPep) in the respiratory tract. This 
would include the extent of its access to different parts of the respiratory tract, its 
lifetime and its route of clearance. Nanoparticle-FluPep conjugates might be useful 
for at least the first phase of work, since they can readily be detected. N-terminal 
biotinylation of FluPep is unlikely to affect its activity, since FluPep ligand and 
FluPep nanoparticle conjugates possess antiviral activity.  The biotinylated FluPep 
could then be recovered by affinity chromatography and analysed by mass 
spectrometry from different parts of the respiratory tract over time. An isotope 
labelled FluPep (using heavy arginine) would allow administration of light then 
heavy FluPep and their ratios measured over time by mass spectrometry to provide 
quantitative data on the clearance of FluPep. Since the FluPep would be delivered 
nasally, it is likely the the amounts that eventually reach the body might be very 
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low, and to establish whether this is the case would be an important objective, since 
it would reduce the potential for harmful side-effects. 
Third would be the extension of the lifetime of FluPep, since increasing FluPep 
lifetime would reduce the frequency of its administration. With peptides, this is 
generally achieved by the incorporation of some D amino acids into the sequence 
or the incorporation of an unnatural peptide bon, e.g., isopeptide bond.  
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